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I am merely a reflection of my family, friends, mentors, and students. I have 
become who I am today by emulating those that I admire the most. Throughout life I 
have been gifted incredible relationships with truly inspiring people. The following 
section is about those people—the ones that really made all of this possible. 
I would like to begin by extending my gratitude to Dr. Sara Sawyer. I wandered 
into your lab with very little knowledge of biology and absolutely zero experience with a 
pipette. I was incredibly fortunate to find a mentor that invested so much time in my 
scientific apprenticeship. Thank you so much for challenging me, aggressively promoting 
my career, and never giving up on me, even when I make outrageous statements about 
wanting to go to law school. I hold you in the highest regard as a professor, a scientist, a 
mentor, a colleague, and most importantly, a friend. It has been a great honor to be a part 
of your burgeoning laboratory, and I hope it continues to grow in Colorado.  
Working towards a Ph.D. in molecular biology is a bit like being dragged through 
mud for six years straight. I could not have done it without my lab mates being there to 
pull me through the especially murky parts. Dr. Ann Demogines, you were there with me 
from the beginning and have always been my main scientific confidant. You always kept 
me on track with my wild ideas and taught me how to focus my efforts on the bench to 
maximize my productivity. It has been a privilege to see you become a mother, although 
you gave me far more baby information than a man of my age can handle. Thank you for 
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making lab a fun place where I could express my ideas and ask as many questions as I 
wanted… I know I tend to have a lot.  
Susan Rozmiarek, our fearless lab manager, where would the Sawyer Lab be 
without you? It is scary to even imagine that scenario. Thank you for keeping everything 
so organized for us and being so hospitable during our laboratory parties. You know how 
jealous I am of your beautiful home and it is so very kind of you to willingly share it with 
all of us. I would just like to reiterate in writing that I fully intend to recruit you away 
from whatever lab you are working in at the time that I start my own laboratory. I sure 
hope you will accept my offer. Dr. Paul Rowley, the man with infinite enthusiasm that 
brings his twin babies to pubs and hurls their dirty diapers at my face, I thank you for all 
of our wonderful conversations about the nuclear pore and how mesmerizingly beautiful 
of a machine it is. I will always cherish our first year at Cold Spring Harbor when we 
lived it up ‘Craigie’ style. Dr. Dianne Lou, my fellow graduate student, you and I can 
relate on so many levels with our experiences during grad school. Thank you for teaching 
me so many experimental techniques, you really are a great mentor and you had a whole 
troop of successful undergraduates to show for that. To the junior members of the lab 
(Alex Stabell, Maryska Kaczmarek, and Dr. Zhao Shan), I hope that I have been as 
helpful in your training as those I have mentioned above. You all have the potential to be 
great scientists, and I cannot wait to see what you accomplish in the near future. Here’s to 
Freddie Fridays, and to working overtime all the time, because deep in our hearts we 
know we love it.  
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I could not have been luckier when the TRIM25 project was dropped into my lap. 
I remember Sara calling me into her office and saying, “Well, get ready to become a flu 
biologist.” Putting the project itself aside, the reason I was so lucky is because it was 
through this project that I forged a relationship with Drs. Robert Krug and Ligang Zhou. I 
was welcomed into the Krug Lab with open arms and infinite resources. It felt like my 
second home. Dr. Krug, thank you for keeping your door open for me. You did not only 
listen to my ideas, but you carefully considered them and made me feel like a colleague. 
We really hit a home run with TRIM25, and it would not have been remotely possible 
without you. Ligang, the secret weapon of the TRIM25 project, I thank you infinitely for 
your patience in teaching me how to culture and study influenza virus. Our project was so 
confusing for so long, and I know you share the excitement I feel at having figured out 
the mystery.  
I would like to thank all of my remaining committee members: Drs. Jaquelin 
Dudley, James Bull, and Lauren Ehrlich. You all kept your doors open for me and were 
willing to discuss absolutely anything related to science or the graduate school 
experience. It was during my committee meeting this past April that I realized I had to 
stay in science. It was recommended that I give up my favorite project in order to 
graduate earlier. It is hard to explain how that made me feel, but I just knew I could not 
do it. It was then that I realized my obsession and that I would spend the rest of my life in 
science. Thank you all for providing the forum for me to grow professionally.  
I had the unique opportunity to be a part of the Woods Hole course on Molecular 
Evolution for three years in a row. Thank you Dr. David Hillis for nominating me as a 
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teaching assistant for this course. It was a magical and reinvigorating experience and I 
hope I can return to this course in the future. I would also like to thank Dr. Conor 
Meehan, a fellow teaching assistant from this course, for quickly becoming one of my 
best friends. I am saddened that we do not see each other more and it is likely that we will 
not connect again at Woods Hole, but who knows, maybe one day we’ll get that super lab 
we always talk about. It will be called Meyerson Lab, non-negotiable.  
To all of the students I have had in classes and as tutees, you gave me more 
insight than you will ever know. You challenged me to obtain a master’s knowledge of 
subject matter and always kept me on my toes with your questions and general concerns 
about academic life. I hope you all find the satisfaction in learning that I have, it is 
without a doubt the finest pleasure in life.  
To all of my friends outside of science, especially my high school friends from 
Humble, you made this whole experience real. Perspective is everything in science, and 
you all provided me with exactly that. I will forever treasure all the late nights in the 
studios, playing music and celebrating our togetherness. I am so lucky to have had the 
same friends for so long, I will miss you all incredibly as I begin the next stage of my 
career in Colorado.   
My mother and father have invested more in me than anyone else on this planet. 
They taught me about life and how to enjoy it, and in doing so projected me into a world 
where I see no boundaries. They always made me feel like I was in complete control of 
my future, and never judged my ambitions or pushed me away from things I was 
passionate about. I whole-heartedly thank you both for supporting me throughout my 
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endeavors. To my brother, sister, and all of my extended family, I have a tremendous 
amount of pride for where I came from. Thank you all for being invested in my 
education, your support is taken with gratitude.  
And finally, I give my eternal appreciation to my fiancée, Lauren Zeni. You have 
supported and loved me unconditionally throughout this entire process, which I know 
was no easy task. I am so lucky to have found someone that is accepting of who I am and 
who I want to be. We share the same vision for our future, and I could not be more 
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Viruses exert a tremendous evolutionary pressure on their hosts. By hijacking 
cellular machinery and resources, viruses have been wildly successful at infecting and 
propagating throughout all domains of life. In the following dissertation, the interactions 
between primates and some of the viruses that infect them are examined through an 
evolutionary lens. I begin by introducing the long-standing battle between mammals and 
viruses that has raged on for hundreds of millions of years. I propose a theoretical 
framework to understand how slowly evolving mammals are able to keep pace with 
rapidly evolving viruses, and how we might use this framework to monitor future virus 
outbreaks.  
The core of my analyses stems from an evolutionary concept known as the host-
virus arms race. This tug-of-war for survival between hosts and viruses leaves an imprint 
in the DNA of each organism involved that can be detected using statistical analyses. In 
 xii 
Chapter 2, I describe these analyses in great detail and perform many tests to ensure that 
they are being used and applied appropriately. 
The remainder of my studies focuses on detecting novel signatures of positive 
selection in primate genes that are likely caused by ancient host-virus arms races. I 
characterize the evolutionary history of several primate genes that have been implicated 
in viral life cycles and provide functional evidence that viruses drove their rapid 
divergence. In doing so I make three important discoveries. First, I characterize a genetic 
variant of CD4, the cellular receptor for HIV-1, in an owl monkey species that could 
make them a viable HIV-1 model system. Second, I show that gorilla-specific mutations 
in RANBP2, a gatekeeper of the cell nucleus, can inhibit HIV-1 infection. And finally, 
evolutionary signatures in TRIM25, a component of the innate immune system, revealed 
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Chapter 1* 
Two-stepping through time: mammals and viruses 
 Recent studies have identified ancient virus genomes preserved as fossils within 
diverse animal genomes. These fossils have led to the revelation that a broad range of 
mammalian virus families are older and more ubiquitous than previously appreciated. 
Long-term interactions between viruses and their hosts often develop into genetic arms 
races, where both parties continually jockey for evolutionary dominance. It is difficult to 
imagine how mammalian hosts have kept pace in the evolutionary race against rapidly 
evolving viruses over large expanses of time, given their much slower evolutionary rates. 
However, recent data has begun to reveal the evolutionary strategy of slowly-evolving 
hosts. We review these data, and suggest a modified arms race model where the 
evolutionary possibilities of viruses are relatively constrained. Such a model could allow 






                                                
* Dr. Sara L. Sawyer helped to formulate the ideas put forth in this chapter. This work 
was published in Trends in Microbiology [127]. Permission to adapt the contents of the 
publication was acquired from Dr. Sawyer and the publishing company.  
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The microscopic and sub-microscopic parasites can evolve so much more 
rapidly than their hosts that the latter have little chance of evolving 
complete immunity to them… The most that the average species can 
achieve is to dodge its minute enemies by constantly producing new 
genotypes.     -- J.B.S. Haldane, 1949 (1) 
 
Ancient relationships between mammals and their viruses  
Recent studies have unearthed a treasure trove of prehistoric virus ‘fossils,’ viral 
genomes or genome segments frozen millions of years ago as integrated copies in the 
genomes of diverse animal hosts (see (2) and references therein). The fact that these 
integrated viral fossils can be easily recognized as belonging to modern virus families is 
stunning, given the fact that modern exogenous viruses have replicated and evolved for 
many millions of years since these viral fossils were captured (2). Despite high rates of 
mutation, the evolution of virus sequence is clearly constrained. This constraint comes 
partially from intrinsic selective forces that limit virus evolution, such as selection for 
modulation of pathogenicity to the host, and the structural constraints of the virus itself. 
Other major constraints on virus evolution come from the diverse immune strategies 
imposed by hosts. Cumulatively, these constraints act together to limit all aspects of virus 
evolution, from the swarm of variants produced in a single host to the evolution of 
expanded host range. These newly identified fossils indicate that constraint on virus 
evolution may be far greater than has previously been appreciated. 
The discovery of these fossils also confirms that mammals have evolved to their 
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current form within a landscape full of diverse viral threats, a situation that has 
dramatically influenced their own evolution. Although constrained in many ways, viruses 
still evolve much more quickly than the hosts that they infect. The response time for 
evolutionary adaptation by viruses can be nearly instantaneous, whereas mammals 
reproduce on the scale of years or decades. The dominant force enabling mammals to 
counteract the extreme genetic diversity of the viruses that they face is generally thought 
to be the adaptive immune system. Adaptive immunity employs gene rearrangements 
performed during the lifetime of an individual host, creating a nearly infinite spectrum of 
receptors and antibodies that evens the playing field between the host and rapidly 
evolving viral pathogens. But the first line of defense in fighting infection, and one that is 
thought to be successful against the vast majority of pathogens encountered, is the hard-
wired innate immune system. Innate immunity is executed by genes that must function 
strictly in the form in which they were inherited. The human genome has approximately 
1,000 genes dedicated to defense or immunity, most of which cannot diversify in the 
course of a single host lifetime (3). Somehow all of these genes must remain honed 
against their viral targets even though they are trapped in a slowly evolving mammalian 
genome (4). In recent years, molecular evidence has emerged, largely from the HIV field, 
that describes how hosts respond to infection over evolutionary time. Although the 
strategy of viruses is to rapidly adapt to new challenges, the strategy of hosts is, by 




Host immune complexity dramatically limits the escape options available to viruses 
Genes involved in immunity and defense become effective against their viral 
targets by natural selection over many generations, with individuals encoding less 
effective alleles dying from infection with bias (5). Once effective immunity alleles 
become common, viruses are expected to counter-evolve, thereby placing selective 
pressure back on the host species. These dynamics create an ever-escalating genetic 
‘arms race’ between host and virus that results in the rapid evolution of both (6). Genetic 
arms races have been shown to play out predominantly through host and virus proteins 
that interact directly. For instance, host major histocompatibility complex (MHC) genes 
encode receptors that present peptides at the cell surface for recognition by T cells. MHC 
class I genes have been acutely selected for alleles that effectively present viral peptides 
and, as a result, MHC genes are highly divergent between and within species (4). Viruses, 
in turn, evolve under selection for mutations that prohibit presentation of viral peptides 
by these receptors. In the past ten years, an entire landscape of membrane-bound or 
cytosolic viral sensors have been discovered to act in innate immunity (7-10). These 
include a large number of constitutively expressed proteins called ‘restriction factors’ that 
recognize viruses and inhibit their replication directly (11). In primates, these proteins 
include tetherin/BST-2 and members of the APOBEC3 and tri-partite motif (TRIM) 
families (12-14). For example, the TRIM5α protein interacts with the capsid core of 
retroviruses as they enter the cytoplasm of an infected cell (Figure 1-1A). Different 
primate orthologs of TRIM5α have recognition specificity for different retroviral capsids, 
and infection is only blocked when interaction occurs (15). Physical interactions, such as  
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Figure 1-1: Evolutionary arms races involve interacting host and virus proteins. (A) 
A schematic of the HIV/SIV lifecycle is shown, illustrating some of the instances where 
virus proteins (V, red) are known to interact with host proteins (H, blue). In some cases 
these interactions involve host cofactors (squares and cell surface receptors) that are 
hijacked by the virus for replication. Hosts also encode antiviral restriction factors (pie 
shapes) that inhibit viral replication through various mechanisms. For instance, TRIM5α 
interferes with capsid cores, APOBEC3G hypermutates viral genomes, and tetherin 
inhibits virus budding. (B) The cellular receptor, CD4, is used to illustrate a hypothetical 
arms race scenario. Interaction of the viral spike glycoprotein with CD4 results in virus 
entry into the cell. Over time, any mutation in CD4 that reduces the strength of this 
interaction will be preferred by natural selection acting on the host population. Selective 
pressure will then be placed on the virus population for a mutation in the glycoprotein 
that re-establishes interaction with CD4. This back-and-forth interplay will result in the 
rapid fixation of mutations that alter both protein sequences.  
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the one between TRIM5α and capsid, are fertile ground for arms race dynamics (16, 17). 
In many cases, viruses also encode proteins that antagonize host immunity pathways (10, 
13), and these physical interactions can also be subject to arms races (18-20).  
Genetic arms races are fundamentally dialogues of call and response between host 
and viral genomes. However, since arms races unfold over evolutionary time scales, how 
do hosts actually compete, given the dramatically different evolutionary rates that usually 
divide mammalian hosts from their viral pathogens? The answer to this conundrum lies 
largely in the complex and multi-faceted nature of the immune system. Novel mutations 
in viral genomes that allow escape from one arm of the immune system will only be 
viable if they do not make the virus susceptible to other immune strategies. Viral 
evolution is further limited by interactions with proviral host proteins. As obligate 
parasites, viruses survive by hijacking host proteins (called cofactors) for processes such 
as cellular entry and nuclear trafficking (Figure 1-1A). For instance, cellular entry of HIV 
requires the human cell surface receptor CD4. A co-receptor is also required for entry, 
which for most HIV strains is the chemokine receptor CCR5 (Figure 1-1A)(21). In large-
scale screens, HIV and influenza have each been shown to require several hundred 
cofactors for replication in humans cells (see (22, 23) and references therein). It should be 
noted that allelic versions of cofactors that lack compatibility with viruses are just as 
effective at blocking infection as potent immunity alleles, and possibly more so. For 
example, some humans encode a variant allele of CCR5, CCR5∆32, where a 32 base pair 
deletion gives rise to a defective receptor that is not expressed on the cell surface (21). 
Those individuals homozygous for this allele are almost completely resistant to HIV 
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infection, and even heterozygous genotypes afford some protection due to reduced 
expression levels of CCR5. Why this allele exists is unknown, but it is highly relevant in 
a population that is now infected with HIV. In this respect, cofactors can also be engaged 
in arms race dynamics with viruses (24-27). In such cases, the host genome experiences 
selection to encode cofactors that are non-optimal for viruses, and viruses are selected to 
efficiently utilize available host cofactors (Figure 1-1B). New viral variants will only be 
viable if they retain all necessary cofactor interactions, and simultaneously avoid fatal 
interactions with immune system proteins.  
Selective pressures exerted by the many host immunity proteins and cofactors in 
combination funnel viruses into a very small mutational space for escape and adaptation. 
This is supported by many examples where viruses repeatedly escape through the same 
amino acid change, not just through mutation from one amino acid to any other. For 
example, in experimental cross-species infections of simian immunodeficiency virus 
(SIV) from sooty mangabeys (SIVsm) into rhesus macaques, viral replication was 
initially weak due to restrictive TRIM5 alleles (28). However, viral escape occurred in 
four different macaques and, in all cases, involved the same single amino acid change 
(R97S) in the capsid protein. In another example, there have been multiple independent 
cross-species transmissions of SIV from chimpanzees (SIVcpz) and possibly gorillas 
(SIVgor) to humans, giving rise to HIV-1 groups M, N and O. A single amino acid 
position in the gag-encoded matrix protein underwent the same mutational substitution 
(M30R) in all of these cross-species transmissions (29). When HIV-1 was passaged back 
through chimpanzees, this mutation reverted. Like these two examples from the HIV 
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field, there are many amino acid positions in the influenza genome that have 
characteristic mutations depending on the source species, suggesting that the web of 
selective constraints in each species repeatedly results in viruses acquiring signature 
adaptive mutations (30). The focused routes of adaptation seen in these examples are a 
reflection of the massive and multi-factorial constraints imposed by the host. This serves 
as an important reminder that viral evolution studies are most meaningful when 
conducted in animal models, as a greater range of viral mutations can be explored in cell 
culture assays than will actually be viable in the infected host.  
 
Arms races play out in populations of hosts, which slows the rate of viral adaptation 
Each step in an evolutionary arms race begins with selection for an advantageous 
mutation in a population, either host or viral (Figure 1-2). Only when adaptive mutations 
go to fixation in either a host or viral population is the arms race permanently moved 
onward. This is probably a relatively rare event, and the fixation of a potent mutation in a 
host or viral gene could theoretically end an arms race forever, driving the other party to 
extinction. Instead, the Red Queen hypothesis (31) predicts that selective pressures 
exerted by hosts and viruses upon one another will often result in oscillating allele 
frequencies in both populations. This is because selective pressure for viruses to counter-
evolve will not be strong until a significant number of potential hosts are of a resistant 
genotype. This provides an important advantage to the host, because it slows the spread 






















Figure 1-2: Arms races play out in populations. The circles represent populations of 
hosts, with the circle sizes representing the relative frequencies of different alleles of a 
single host gene. The spread of a virus (arrows) through this population of hosts is 
illustrated. Overlapping regions represent heterozygous hosts and non-overlapping 
regions represent homozygous hosts. (A) In this schematic, the effect of polymorphism in 
a cofactor gene is illustrated, where the effect on susceptibility would be predicted to be 
semi-dominant (similar to the CCR5Δ32 mutation discussed in the text). Allele A 
encodes a cofactor that can be exploited by the virus, whereas allele B encodes a cofactor 
variant that is resistant to viral exploitation. The virus will be able to replicate in both 
A/A and A/B individuals, although presumably less well in A/B heterozygotes. 
Eventually, allele frequencies in the host population will shift due to the partial protection 
afforded by the A/B genotype. As allele B becomes more common, there will be selective 
pressure on the virus to better utilize the B cofactor (blue arrows). A new resistant allele, 
C, might also emerge or pre-exist in the host population. (B) In this schematic, the effect 
of polymorphism in a restriction factor gene is illustrated, where allelic versions that 
restrict a virus are predicted to have a dominant influence on susceptibility to infection. 
The major allele, A, encodes a restriction factor that is inactive against a circulating virus 
population. Allele B encodes a restriction factor that is effective against this virus. When 
allele B is rare, all carriers are assumed to be heterozygous. Because A/B individuals are 
protected from infection, allele frequencies shift such that allele B is now more common, 
giving rise to B/B homozygotes. The diminished reservoir of A/A homozygotes places 
pressure on the virus to ‘escape’ (blue arrows) restriction by the B restriction factor. A 













The case of CCR5, the HIV cellular co-receptor mentioned above (Figure 1-1A), 
illustrates this concept. Most SIV strains also use CCR5 as a co-receptor, but some sooty 
mangabeys and red-capped mangabeys encode defective alleles of CCR5 (32, 33). 
Despite the fact that these alleles are relatively common, the SIV strains that infect these 
two species (SIVsmm and SIVrcm) replicate perfectly well, even in individuals that are 
homozygous for defective CCR5. This is because in both cases these viruses have 
evolved to use additional co-receptors. This is the type of escape that can be expected in 
the face of common resistance alleles. In humans, the defective CCR5∆32 allele is quite 
common in some parts of the world, with about 18% of Caucasian individuals being 
heterozygous and 1% being homozygous (21). Similar to sooty and red-capped 
mangabeys, a few CCR5∆32 homozygous humans have also been reported to be infected 
with HIV, again through mutations of the HIV surface protein that allow use of an 
additional co-receptor (CXCR4 in this case) (21). This viral escape through co-receptor 
switching also happens in many late-stage HIV-1 patients who are wild-type for CCR5, 
and in patients treated with the CCR5-inhibiting drug Maraviroc (34). In both cases this 
is presumably because the preferred target cells become more scarce or unavailable. Due 
to the HIV/AIDS epidemic, there continues to be a rise in the frequency of hypomorphic 
alleles of CCR5 in Africa (35), suggesting that HIV might continue to evolve the ability 
to use new co-receptors as highly susceptible hosts diminish.  
The scenario just described is but one part of a larger picture. In fact, probably 
hundreds of host loci additively contribute to viral susceptibility. There are many human 
genes, acting in diverse cellular pathways, in which genetically-encoded polymorphic 
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variants can influence the outcome of viral exposure or infection (36, 37). Primates 
encode entire families of several key proteins involved in virus recognition, such as the 
APOBEC3, TRIM, MHC, killer cell immunoglobulin-like receptor (KIR), and interferon-
inducible transmembrane (IFITM) protein families (9, 14, 38, 39). Further, each of these 
loci might have many co-circulating alleles in a population; the human HLA-B locus of 
the MHC has over 800 reported alleles (7). Diploid hosts can carry two different alleles at 
each locus, each with distinct viral targets. For dominant immunity factors, this means 
twice the specificity and therefore increased resistance to infection. Heterozygote 
advantage has been directly demonstrated at MHC loci in both humans and macaques 
(40, 41). Different alleles of TRIM5 found in primate populations have also been shown 
to have different viral specificities, possibly leading to a scenario where balancing 
selection operates to maintain multiple alleles in populations (28, 42). With all of these 
considerations, it is unlikely that any two individuals in any mammalian population have 
the exact same genetic immunity profile. A key point is that, when viruses evolve to 
escape resistant host genotypes in the context of a host population, this will provide them 
access to only a limited number of new hosts due to the mosaic of host genotypes 
involved. The broad genetic diversity between immune system components of different 
individuals should dramatically slow the spread of viral escape variants through host 







Figure 1-3: Primate restriction factor genes are rapidly evolving. The distribution 
shows dN/dS values previously determined for 13,454 human-chimpanzee orthologous 
gene pairs (43). Adaptive, gain-of-function mutations commonly arise from point 
mutations that change an amino acid in the encoded protein. When genes are 
experiencing sequential rounds of positive selection for new adaptations, as in the arms 
race scenario, they will retain a higher proportion of non-synonymous mutations (dN) 
than synonymous mutations (dS) in the domains critical for governing the physical 
interaction. Domains under positive selection will thus accumulate a characteristic 
signature of dN/dS > 1. dN/dS values for three primate retroviral restriction factor genes 
are indicated on this distribution. As expected, restriction factor genes such as TRIM5 and 
APOBEC3G have some of the highest dN/dS values in the human genome (17, 38). 
Although it is known that codons within tetherin are evolving under positive selection 
(18-20), a full length gene analysis reveals a much lower dN/dS value (dN/dS ~ 0.3). 
Tetherin is either under less intense selective pressure for adaptation than APOBEC3G 
and TRIM5, or is more constrained by its other cellular roles. Both tetherin and TRIM5α 
are known to function in host roles other than retroviral restriction (44-46). Additional 
evolutionary constraint comes from the other host proteins with which restriction factors 
must interact to execute restriction (13, 47).  
 
Single point mutations can lead to major adaptations during evolutionary battles 
Because host genes engaged in evolutionary arms races are under strong selective 
pressure to change and adapt, they often evolve at a faster rate than other genes. In fact,               
immunity genes are some of the most rapidly evolving mammalian genes, acquiring 
unexpectedly high numbers of non-synonymous nucleotide substitutions (3, 48, 49). The 
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genes of all three of the retroviral restriction factors diagrammed in Figure 1-1 have 
accumulated such mutations more rapidly than the bulk of human genes (Figure 1-3). 
Importantly, this pattern indicates that single amino acid substitutions in a protein can be 
adaptive in the context of an arms race (17, 50, 51). This is critical to the success of the 
host because simple point mutations are the most common and abundant form of genetic 
variation upon which natural selection can act. 
The power of point mutations can be well demonstrated with examples from the 
functional characterization of these same three retroviral restriction factors. Single amino 
acid changes in TRIM5α can be highly adaptive, as some allow recognition of different 
mammalian retroviral capsid types (52-56). Conversely, single amino acid changes in 
retroviral capsid proteins can also be adaptive by decreasing susceptibility to TRIM5α 
(28, 57-60). Another restriction factor, tetherin, is a cell surface, membrane-bound 
protein that prohibits budding of retroviruses as well as filoviruses, herpesviruses, and 
arenaviruses (Figure 1-1A)(13). Viruses encode countermeasures to tetherin, including 
the SIV antagonist Nef and the HIV-1 antagonist Vpu, and single point mutations in 
tetherin can modulate sensitivity to these viral antagonists (18-20). The APOBEC3G 
protein is a restriction factor with activity against a broad range of viruses, but is 
neutralized by the HIV/SIV accessory protein Vif (Figure 1-1A)(47). A single amino acid 
change in APOBEC3G can make it insensitive to Vif (61-63), and single amino acid 
changes in Vif can alter specificity for APOBEC3G (64). Thus, exquisitely small 
biochemical changes, at the level of a single amino acid, can enhance or reduce affinity 
between players in an evolutionary arms race.  
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In some cases, changes more dramatic than point mutations occur in the context of 
arms races, and these often end one arms race and start another. For instance, in two 
different primate lineages TRIM5 has fused with the gene encoding cyclophilin A to 
produce a TRIM-Cyp restriction factor with a novel retroviral recognition domain, 
significantly changing the terms of the arms race between TRIM5α and capsid in those 
species (16). In humans, tetherin has acquired a deletion in the binding site for its 
historical SIV antagonist, Nef, freeing tetherin from that arms race until HIV-1 evolved a 
novel way to neutralize human tetherin using the viral protein Vpu (19, 20, 65). Adaptive 
point mutations in the ligand-binding surface of primate CCR5 that influence HIV and 
SIV binding are not common. Instead, as previously discussed, CCR5 seems to fight the 
arms race through protein downregulation at the cell surface, with frame-shifted null 
alleles having arisen independently in humans and two additional SIV-infected primate 
species (32, 33, 66). Although highly effective, major adaptive changes such as these are 
expected to occur less often than adaptive point mutations, simply because they involve 
rarer genetic events.  
 
Rock-paper-scissors: are arms races cyclic?  
Our studies and those by other groups reveal that host restriction factors may be 
resampling a small number of biochemical forms repeatedly as arms races play out over 
evolutionary time. For instance, a single amino acid mutation in human TRIM5α 
(R332P) can largely restore to this protein the ability to recognize and restrict HIV, and is 
therefore an important determinant of retroviral specificity (54, 55). Interestingly, three 
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amino acids, arginine (R), proline (P), and glutamine (Q), have been repeatedly sampled 
by natural selection at position 332 over tens of millions of years of primate evolution 
(Figure 1-4A) (28). The R-, P-, and Q-bearing forms of TRIM5α each target different 
suites of retroviruses (53-60). Amazingly, R, P, and Q are each encoded by different 
alleles co-circulating in sooty mangabey populations, whereas P and Q are each encoded 
by different alleles found in rhesus macaque populations (Figure 1-4A) (42, 67). This 
pattern might reflect ancient polymorphism that has survived all or some of simian 
primate speciation, rather than recurrent mutation to the same few amino acids (42). 
Long-term maintenance of such polymorphism could occur if there were balancing 
selection acting on these alleles (42, 67).  However, polymorphism has rarely been 
shown to survive even a single speciation event. Regardless of how this striking pattern 
























Figure 1-4: The cyclic arms race: a game of rock-paper-scissors? (A) Molecular 
evidence for the rock-paper-scissors model. For each restriction factor, a key residue 
known to alter specificity for retroviral targets is illustrated, and the amino acid (aa) 
encoded at that position is reported for a panel of primate sequences available on 
Genbank. In two cases, SNPs have been noted at these positions, so multiple amino acids 
are listed. Amino acid coordinates refer to the human protein except in tetherin (*), where 
amino acid 17 is the chimpanzee coordinate, since amino acids 14-18 are deleted in the 
human sequence. Abbreviations: nd, not determined; del, deletion; W, tryptophan; L, 
leucine; C, cysteine; R, arginine; Q, glutamine; P, proline; K, lysine; D, aspartic acid. (B) 
The illustration shows the physical interaction between a host restriction factor protein 
(square) and a virus protein (circle). In the rock-paper-scissors model, both the host and 
the virus have only a small number of biochemical variants with which to compete (3 in 
this example), because of the many constraints placed on each. These variants are 
symbolized by different colors. When colors are matched, the host restriction factor 
successfully inhibits viral infection. However, escape by the virus is also possible. The 
host population will then respond through selection for an adaptive mutation that re-
establishes interaction. The virus might re-sample previous states (gray circle) that will 






















It is unknown why TRIM5α has resampled three amino acids (R/P/Q) at position 
332 over evolutionary time. Only three amino acids at this position would be necessary if 
there are just three amino acids possible at the cognate position(s) in capsid. If true, this 
would represent a highly constrained arms race, one that is perhaps consistent with the 
many constraints detailed above. The consistent cycling over evolutionary time between 
three amino acids (R/P/Q) is perhaps indicative of a rock-paper-scissors game where the 
choice of weapons on both sides is limited, and therefore must be recycled (Figure 1-4B). 
The evolutionary histories of other retroviral restriction factors, APOBEC3G and 
tetherin, also reveal resampling of a small set of amino acids at key positions that 
critically govern viral specificity (Figure 1-4A). This is interesting, given the vastly 
different viral repertoires and modes of action of each of these three restriction factors. 
Small insertions and deletions in the regions of these critical residues have also been 
observed (17, 19, 68), but these more dramatic mutations may sometimes change the 
interaction surface in a way that still fits into the cyclic pattern of recycled biochemical 
forms, or may introduce a new one.   
In reality, physical interactions involve three-dimensional protein surfaces, not 
single amino acid sites, so changes at single sites must be considered in the context of the 
rest of the protein. This can be demonstrated with examples from TRIM5α biology, 
where R332 in the context of the human TRIM5α protein does not restrict HIV, but R332 
in the context of sooty mangabey TRIM5α does (42, 54, 69). It is known that other amino 
acids in the vicinity of position 332 also contribute to target specificity (52, 54-56, 67). 
Several codon positions in TRIM5 show elevated rates of non-synonymous substitution 
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and high levels of polymorphism (28), so arms races with retroviruses probably play out 
at multiple specificity-determining residues simultaneously. If multiple residues on a 
binding surface each engage in their own rock-paper-scissors chase, this will create a 
finite number of unique protein surfaces with unique interaction specificities. This has 
been demonstrated with primate protein kinase R (PKR), where amino acid combinations 
at three critical residues determine interaction with the poxvirus antagonist K3L (51). 
Importantly, this study and others demonstrate that the rules of engagement between two 
interacting proteins, even at a complex interaction surface, can be determined. Although 
the rock-paper-scissors model is almost certainly over-simplified, it may at least help 
begin to define constraints on viral evolution as discussed in more detail below. 
Our knowledge of how viruses have responded over time to these cycling 
evolutionary forms of restriction factors remains weak. Alignments of viral genomes are 
usually limited to samples that have been collected within the last several decades, a scale 
that precludes analyzing mutational change through an evolutionary arms race. 
Importantly, the fact that viral genomes dating back tens of millions of years have now 
been found to be frozen in their historical form in the genomes of slowly-evolving 
animals may, for the first time, allow us the opportunity to look at viral adaptation over 
evolutionary scales. Nonetheless, some relevant data does currently exist. Rapid 
resampling of amino acids at certain residue positions has been observed in the HIV 
genome. This has been shown to reflect escape from MHC presentation in one host, and 
then due to the fitness cost of this escape mutation, reversion in another host (70). 
Importantly, this does support the idea that there are cognate viral forms that correspond 
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to different host immunity alleles. It was recently found that TRIM5α also restricts 
herpes simplex virus, but that this effect is highly virus strain-specific (71). This is again 
consistent with viral populations having cognate polymorphisms that exhibit escape from 
certain host alleles. Strain-specific interactions with host cells are commonly observed in 
the influenza field (72). Studies that utilize diverse clinical and laboratory isolates of a 
single virus are powerful and can reveal functional polymorphisms within viral 
populations, some of which may reflect individual adaptations to different host 
polymorphisms.  
To reiterate, the rock-paper-scissors model describes a scenario where viral 
adaptation to a particular host genotype is highly constrained due to the delicate interplay 
of thousands of genetic determinants. Because of the limited number of genetic forms 
available, we have proposed a modified arms race model where both parties (host and 
virus) recycle a small number of alleles in a rock-paper-scissors chase. It remains 
unknown whether such dynamics will describe other systems. Thanks to high-throughput 
techniques, rapid progress is being made in understanding the host genetics of viral 
infection. New immunity genes and cofactors are still being discovered on a regular 
basis. The IFITM proteins, which restrict cellular entry of diverse viruses such as 
Dengue, West Nile, SARS, HIV, and Influenza A, were discovered only in 2009 (39, 73, 
74). Signatures of positive selection have been documented in various host cofactor and 
immunity genes, suggesting that arms race dynamics will describe many other host-virus 
interactions (27, 75, 76). It remains to be seen how generally amino acid re-sampling, 
potentially reflective of rock-paper-scissors dynamics, occurs in these scenarios.  
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Predicting viral evolution, will it ever be possible? 
It is tempting to speculate that the level of constraint observed may make 
forecasting of virus evolution possible. Important goals are to predict the evolution of 
viruses as they spread through populations, the transmission of viruses from one species 
to another, and the development of drug resistance. Due to the difficulty of these 
problems, the number of papers where prospective prediction of viral evolution has even 
been attempted remains small (77, 78). Many interesting evolutionary scenarios 
fundamentally require viruses to adapt to new host genotypic landscapes. The entire 
endeavor would be doomed if viral escape were truly unconstrained with no ‘rules’ to be 
found. However, the rock-paper-scissors model says that limited opportunities for escape 
are possible, at least if we assume that only point mutations will be utilized. Major and 
more rare genetic events utilized for escape, such as recombination or reassortment 
between viruses of different species, or the acquisition of novel viral genes, gene 
domains, or deletions within genes, will likely be impossible to predict. This may 
preclude prediction of evolution in viruses that experience these phenomena frequently, 
such as influenza.  
Ultimately, forecasting viral evolution will require 1) a model of the selective 
constraints at play in any particular genotypic environment, and 2) knowledge of how the 
virus will respond to each of these constraints. Understanding the selective constraints 
imposed by different host genotypes will be difficult (see Outstanding Questions). This 
will require a comprehensive list of immunity and cofactor genes relevant to a particular 
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virus, a catalogue of the major alleles of each, and an understanding of which genes are 
the most potent barriers to, or facilitators of, infection. Next, different host alleles of each 
gene will each need to be characterized for their viral specificity. Viral escape from 
restrictive alleles will also need to be characterized, either empirically or using 
computational models, of the protein-protein interaction interfaces between host and viral 
proteins. Finally, all of this information has to be combined. Once such models exist, if a 
new genotypic environment presents to a virus one major genetic incompatibility in a 
known cofactor or immunity factor, and viral response to that block has been well 
characterized, prediction of viral evolution will be possible. Multiple genetic blocks to 
infection in a particular genetic background will require multiple corresponding 
adaptations of the virus, making prediction of viral evolution more complex but perhaps 
not impossible.  
 
CONCLUSIONS 
Evolutionary thinking in the HIV field has lead to many significant biological insights. 
For example, any given retrovirus is expected to be very well adapted to its natural host, 
and able to evade all aspects of that host’s immune system. The opportunities for 
discovering novel mechanisms of resistance are limited in such systems. However, 
retrovirologists have clearly demonstrated that cross-species infection assays can lead to 
a rich description of host and virus genetics. By studying heterologous pairings of viruses 
and hosts, pairs that have not stayed ‘in step’ through arms race evolution, large genetic 
phenotypes of both immunity and virulence have been revealed. Such approaches are, at 
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their core, based on an appreciation for the antiquity of mammalian retroviruses and the 
fact that mammals have co-evolved with similar viruses for tens of millions of years. 
Now that we realize that many other virus families are ancient and ubiquitous in nature, 
such approaches should be applied in those fields. Reciprocally, such studies are likely to 
continue to refine the evolutionary theory of host-virus interactions. 
 
OUTSTANDING QUESTIONS 
• What is the global repertoire of host antiviral and proviral genes that interact with 
each virus? 
• Which host loci present the most potent genetic barriers to cross-species and 
individual-to-individual virus transmission?  
• How many functionally different alleles circulate at each proviral and antiviral 
locus in host species, and how are they geographically localized? 
• Once restrictive cofactor and immunity alleles are known, how do different viral 
isolates escape them?   
• Once relevant host genes have been described, and viral escape to each defined, 
can models be derived that predict viral evolution in a new host? 
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Chapter 2* 
The effect of species representation on the detection of positive selction 
in primate gene datasets 
 HIV arose from a family of viruses that has infected non-human primates for 
millions of years. During this time, both host- and virus-encoded genes have been 
continually selected to modify their interactions with one another. This has resulted in the 
rapid evolution of the specific codons that govern the physical interactions between host 
and virus proteins. Virologists have discovered that these evolutionary signatures, 
acquired in nature, can provide a shortcut in the functional dissection of these host-virus 
interactions in the laboratory. However, the use of evolution studies in this way is 
complicated by the fact that many non-human primate species are endangered, and 
biomaterials are often difficult to acquire. Here, we assess how the species representation 
in primate gene datasets affects the detection of positive natural selection. Our results 
demonstrate how targeted primate sequencing projects could greatly enhance research in 
immunology, virology, and beyond. 
 
 
                                                
* Ross McBee, Shea Rozmiarek, Dr. Paul Rowley, and Dr. Sara L. Sawyer all contributed 
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accepted for publication and is in press at Molecular Biology and Evolution. Permission 




The evolution of human genes can be studied in multiple ways (79). One 
approach uses comparisons of gene orthologs from humans and nonhuman primates to 
analyze selection over long evolutionary timescales. The main metric used is dN/dS, 
which summarizes the rates of non-synonymous (dN) and synonymous (dS) DNA 
substitutions in gene sequence (80-82). Codons where dN/dS > 1 have experienced 
natural selection in favor of non-synonymous mutations. Viruses and their hosts co-
evolve over long periods of time and, as a result, the dN/dS > 1 signature can often be 
detected in gene regions corresponding to physical interaction interfaces between host 
and virus proteins. The identification of codons with dN/dS > 1 in primate genes has 
recently become important in guiding genetic studies in the HIV field, having been 
particularly powerful in dissecting the physical interactions of several human immunity 
proteins with HIV (17-20, 83-86). The identification of this evolutionary signature has 
been recognized as a short-cut in the laborious functional dissection of host-virus 
interactions, and is now being used to characterize the interplay between host proteins 
and other types of pathogens as well (25, 51, 75, 87-91).  
The main limitation to using this analysis is the acquisition of appropriate primate 
sequence datasets. There are currently nine available simian primate genome projects 
available through the UCSC genome browser (http://www.genome.ucsc.edu/), but the 
acquisition of additional primate sequences is complicated by the fact that many 
nonhuman primate species are endangered, and the purchase of immortalized cell lines 
derived from these species can require a federally-issued permit. Because the analysis of 
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dN/dS has become so useful in guiding the genetic study of human genes that interact 
with viruses, we wished to investigate how many primate sequences are required to 
reliably detect positive selection.   
 
MATERIALS AND METHODS 
Primate sequence datasets 
  All sequence alignments were previously generated by our lab (27, 92).  
 
PAML analysis  
Each gene alignment was fit to two codon models, M7 and M8, as implemented in 
PAML (93). A likelihood ratio test was then performed, using 2 degrees of freedom, to 
assess whether M8 (permitting some codons to evolve under positive selection) gives a 
significantly better fit to the data than M7 (positive selection not allowed). The Bayes 
Empirical Bayes approach was then used to calculate posterior probability that each 
codon is properly assigned to the dN/dS > 1 site class (94). This entire protocol was 
performed for each of the 11 datasets, for each of the subtrees analyzed.   
 
Generation of random trees 
The analysis shown in panels D-F of Figure 2-2 required the generation of 
random trees. Ten random trees of each of the 7 tree sizes (“number of species” on X 
axis) were generated for a total of 70 unique trees for each gene. To generate the random 
trees, each species in each of three primate clades (color coded in Figure 2-1A) was 
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assigned an integer and random.org was used to generate 10 unique sets of non-repeating 
integers. For the first 4 of these sets of trees, 1, 2, 3, and then 4 species were chosen at 
random from each of the 3 primate clades resulting in trees containing a total of 3, 6, 9, 
and 12 species. However, because sequences were available from only 4 New World 
monkeys, tree sets past the 12-species size only introduced two new species at each step, 
one from each of the two other clades.  
 
RESULTS 
To test the sensitivity of positive selection analyses when using different primate 
datasets, we re-analyzed datasets that our group has previously generated for 11 different 
genes (XLF, XRCC4, MAP4, NBS1, CtIP, WNK1, POLλ, NUP153, RANBP2, IBTK, and 
NUP98/96) (27, 92). These 11 datasets each consist of 20 orthologous sequences from a 
matched set of primate species (Figure 2-1A). In the studies where these datasets were 
generated, genes were chosen for sequencing based on higher-than-normal levels of 
protein divergence, or because they are known to encode proteins important for viral 
lifecycles. Therefore, this is not a random set of genes, but rather a set that is skewed 




Figure 2-1: Primate datasets representing different levels of divergence. (A) The 
master tree of 20 species from which subsequent "pruned" trees were derived, as well as a 
matrix showing which primates were included in those pruned trees. Simian primates are 
broken into three major groups: hominoids/apes (blue), Old World monkeys (black) and 
New World monkeys (red). (B) The overall divergence in each dataset (shown in tree 
length) as the number of species increases. Tree length is the sum of all branch lengths on 
a tree. A line is fit to the data for each gene (R2 values reported in the legend), excluding 
the three species tree because the tree length is so low for this set.  
 
We then generated 10 pruned trees representing subsets of these 20 species 
(Figure 2-1A). The first four trees were made to reflect the history of primate genome 
sequencing projects. For instance, the first tree that we analyzed was a 3-species tree of 
human, chimpanzee, and rhesus macaque, representing the first three primate genomes 
sequenced (43, 49). The 4-species tree also included marmoset, the fourth primate to have 
its genome sequenced. We then added the fifth sequenced primate species, Sumatran 
orangutan (95), creating a 5-species tree, and then white-cheeked gibbon and gorilla (96), 
creating a 7-species tree. We specifically chose this strategy to evaluate the power of 
early positive selection studies that only had access to a limited number of primate 
genomes (49, 95, 97-99). Beyond this, 10-, 12-, 14-, 15-, 16-, and 18- species subtrees 
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were made (Figure 2-1A). The species included in these trees were chosen so that “tree 
length” scales approximately linearly with the number of species included (Figure 2-1B). 
Tree length is the sum of the branch lengths along the tree or, in other words, the average 
number of nucleotide substitutions per site in an alignment. For any given tree, we find 
higher tree length in some of our datasets than others (Figure 2-1B). For instance, the 
DNA repair gene XLF has the highest level of sequence divergence, and the nuclear pore 
gene NUP98/96 has the lowest level of divergence. This set of trees was then used to test 
the effects of species representation on the detection of positive selection. 
Because the PAML software suite is now commonly used in virology research, 
we focused on the detection of positive selection using codon models implemented in 
PAML’s codeml program (93, 100). To detect selection, each alignment was fit to the 
codon models M7 (null model, codon values of dN/dS fit to a beta distribution bounded 
between 0 < dN/dS < 1) and M8 (positive selection model, similar to M7 but with one 
extra site class assigned at dN/dS > 1). A likelihood ratio test was then used to determine 
whether the null model (M7) could be rejected in favor of the model of positive selection 
(M8). We performed likelihood ratio tests between M7 and M8 for all 11 gene datasets, 
using each of the 11 possible trees. These genes fell into three classes. First, six genes 
converged on significant rejection of the null model (p < 0.05) as more species were 
added (Figure 2-2A). One of these, XRCC4, reached significance after only 4 species, and 
stayed significant as more species were added. On the other extreme, MAP4 did not reach 
significance until the 20 species dataset. We conclude that more species allow an 




Figure 2-2: The impact of dataset composition on PAML's ability to detect positive 
selection. (A-C) Each point represents a single model comparison performed. The x-axis 
denotes the primate tree that was used, as defined in Figure 2-1A, and the y-axis is the 
calculated p-value of the M7-M8 likelihood ratio test. The dashed line indicates a 
significant p-value (p < 0.05) where the null model is rejected. Panel A shows those 
genes that converge on a significant p-value as more primate species are added. Panel B 
shows those genes that do not. Panel C shows genes that lack a clear convergence 
towards a stable p-value as more species are added. (D-F)  These graphs each represent 
data for a single gene from panels A-C. In this case, 10 alternate species sets were 
randomly chosen for each number of species shown on the X-axis. Each of these random 
trees was used to evaluate M7 and M8, and the p-value is calculated for each model 
comparison. The Y-axis is shown on a linear (top) and log (bottom) scale. 
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sensitive than others. A second set of 2 genes (WNK1 and XLF) did not reach the p < 0.05 
significance threshold using any of the trees tested (Figure 2-2B). Further, for these genes 
there is no clear trend towards significance, suggesting that the null hypothesis would 
never be rejected even if more sequences were added. Finally, for a third set of 3 genes, 
the null hypothesis is rejected (or very nearly so in the case of NBS1) with smaller 
datasets, but then the likelihood ratio test loses significance as more species are added 
(Figure 2-2C). These genes might be experiencing positive selection specifically in the 
hominoid clade. The smaller datasets are hominoid-rich because several of the first 
species sequenced were primates closely related to humans (e.g. chimpanzee and 
orangutan). In fact, we have previously substantiated hominoid-specific positive selection 
for one of these three genes, NBS1 (92). Large scale screens for positive selection using 
fixed species sets will likely miss these patterns, and special tests will need to be run to 
test alternate hypotheses like clade-specific positive selection. In summary, except for 
genes with clade-specific effects, the 20 species dataset that we show here is adequate for 
detecting selection in all of the genes tested. For genes that do not reach significance by 
the time 20 species are included, there is no trend indicating that the addition of more 
sequences will lead to the rejection of the null hypothesis. 
In the analyses just discussed, there is stochastic noise in the patterns observed. 
Based on this, we wished to test how likely it would be to get a false signature of positive 
selection. We next examined more closely the effects of primate species choice on the 
evolution of one gene from each of the three classes of evolution that were just described 
(RANBP2, WNK1, and IBTK). Likelihood ratio test results for 3-, 6-, 9-, 12-, 14-, 16-, and 
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18- species trees were again examined, but this time randomly chosen species from the 
20-species collection were used to create 10 trees of each of these sizes. Those trees and 
the corresponding sequences were then fit to M7 and M8, and the p-value of the 
likelihood ratio test is shown (Figure 2-2D-F). With small, three species trees, a broad 
range of p-values, ranging from 0 < p < 1, were observed. In other words, the results were 
highly stochastic and depended on the specific three species chosen for analysis. As more 
species were added to the tree, the variance of these results diminished and converged on 
a true value. This trend continues well below the statistical cutoff of p = 0.05, as seen 
when using a log scale (Figure 2-2D-F bottom). For instance, for RANBP2, all 10 
randomly generated 12-species trees have p < 0.05, and this is true for all trees larger than 
12 species as well (Figure 2-2D). Thus, it is possible to get a false signature of positive 
selection due to stochastic effects, but that the likelihood of this decreases as more 
species are included.  
If the null model (M7) is rejected in favor of the model of positive selection (M8), 
the individual codons assigned to the dN/dS > 1 bin can be used to guide genetic studies 
(17-20, 83-85, 101). The logic is that non-synonymous mutations in these codons impact 
function, otherwise selection would not be acting on these sites. For the 6 genes that pass 
the likelihood ratio test (Figure 2-2A) we examined how increasingly rich datasets affect 
the fraction of codons assigned to the dN/dS > 1 class in M8. In general, this value 
stabilizes by the these 20 simian primate species were included (Figure 2-3A). The proper 
assignment of each codon to this class can also be evaluated using a posterior probability 
(94). If a codon has a posterior probability of P > 0.95, there is a 95% chance that this 
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codon is correctly assigned to the dN/dS > 1 class. We then looked at the fraction of sites 
in each dataset assigned to the dN/dS > 1 class with a posterior probability > 0.95 (Figure 
2-3B). These values also stabilize after inclusion of these 20 simian primate species. The 
specific codons identified are illustrated for two of these genes, RANBP2 (Figure 2-3C) 
and Polλ (Figure 2-3D). Interestingly, it appears that many sites identified with as few as 
4-5 sequences, even when the likelihood ratio test has low statistical support (Figure 2-
2A), are often increasingly supported as more sequences are added. This surprising 
finding suggests that it may be worth functionally testing codons identified even if only a 
few sequences are available for analysis, and even before the likelihood ratio test has 
reached the rigorous p < 0.05 value.  
 
DISCUSSION 
In conclusion, positive selection can be adequately characterized in primate genes 
with a 20-species dataset composed of 8 hominoids, 8 Old World monkeys, and 4 New 
World monkeys (Figure 2-1A). Tree length, a measure of overall divergence in an 
alignment, can also be used as a guide, and 20-species datasets have tree lengths between 
approximately 0.3 and 0.65 (Figure 2-1B). This study should serve both evolutionary 
biologists and virologists who are interested in the molecular evolution of genes during 
the course of simian primate speciation. It also underscores the need for more sequenced 
primates genomes, which would alleviate the burden on individual researchers to obtain 
these precious primate biomaterials. 
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Figure 2-3: The impact of dataset composition on the identification of codons 
targeted by positive selection. (A) The fraction of the codons in each gene that were 
placed in the ω > 1 bin in M8, using datasets composed of increasing numbers of species. 
(B) The fraction of codons in the ω > 1 bin in M8 with a posterior probability of P ≥ 0.95. 
(C and D) Domain diagrams for RANBP2 and Polλ with the locations of codons, shown 
as dashes, placed in the ω > 1 bin in the M8 model with a posterior probability > 0.5. 
Codons with a posterior probability of P ≥ 0.95 are highlighted in black, and those with 
posterior probability of P ≥ 0.99 in red. Each row represents an analysis performed with a 
different number of species, with asterisks indicating datasets for which the null model 








HIV-1 host factors identified through evolutionary analysis 
 HIV-1 requires the functions of many human proteins to replicate in human cells. 
Because these proteins constitute viable targets for antiviral drugs, there has been intense 
interest in identifying and characterizing these proteins. Genome-wide screens have 
generated large numbers of new, putative HIV-1 host factors, and the next challenge is to 
prioritize these candidates for in-depth study. Towards this goal, we made use of an 
evolutionary signature, caused by recurrent positive selection, which is commonly found 
in host genes encoding virus-interacting proteins. Here, five genes from these screens that 
bear the signatures of positive selection were identified. Some of these genes (CD4, 
NUP153, RANBP2/NUP358) are well characterized with respect to the HIV-1 lifecycle, 
whereas others (ANKRD30A/NY-BR-1 and MAP4) remain relatively uncharacterized. We 
find that ANKRD30A, which has never been functionally studied in the context of the 
HIV-1 life cycle, interacts through its C-terminal domain with HIV-1 soon after the virus 
enters cells. These data provide a rationale for why ANKRD30A was identified in only a 
subset of high-throughput screens for HIV-1 host factors. This addresses an outstanding 
issue in the interpretation of the large, genome-wide datasets being generated in virology 
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research: the often low overlap between them. We propose that evolutionary analysis can 
be a powerful addition to the systems biology-based models of human-virus interactions 
that are now required. 
INTRODUCTION 
HIV-1 exploits a vast network of human proteins to replicate within human cells. 
These human proteins, referred to here as HIV-1 host factors, are involved in processes 
such as transcription, translation, and transport of the virus (102-105). Experimentally, 
the depletion or disabling of HIV-1 host factors decreases viral replication. For this 
reason, these host proteins constitute novel and potentially highly effective antiviral drug 
targets. The FDA has recently approved the first anti-HIV drug targeting such a protein, 
Maraviroc, which is a small molecule antagonist of the HIV-1 co-receptor CCR5. For this 
reason, there is intense interest in human proteins that promote the replication of viruses 
that cause human disease, including HIV-1, influenza, West Nile virus, Dengue virus, 
and others (reviewed in (23, 76, 106-111)). 
A current assessment of the literature would suggest that HIV-1 requires 
hundreds, or potentially more than a thousand, human proteins to facilitate its replication 
inside of the cell. In 2008, a survey of HIV-1 host interactions reported in the HIV-1 
literature led to the creation of the “HIV-1, Human Protein Interaction Database” hosted 
by NCBI (112, 113). In that survey, 1,448 human proteins were identified that are either 
bound, inhibited, upregulated, or modified by HIV-1. As there are only 15 distinct HIV-1 
proteins, this equates to 96 direct or indirect interactions, on average, for every viral 
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protein. Since that time, high-throughput screens for HIV-1 host factors have been 
conducted. In several genetic screens, RNA interference was used to systematically 
deplete human gene transcripts, and then the effects of depletion on HIV-1 replication 
were evaluated (reviewed in (114)(22)). Collectively, these screens uncovered 
approximately a thousand genes that lead to reduced HIV-1 replication when their 
expression is decreased (115-118). Another proteomics-based study recently employed 
affinity purification and mass spectrometry to uncover 435 human proteins that interact 
with HIV-1 proteins (119). Although these high-throughput technologies have 
undoubtedly led to new insights, one surprise has been the low overlap between the 
different screens, and between the screens and the interactions previously reported in the 
literature (22, 120). Similar scenarios have played out in other fields of virology where 
high-throughput studies are being employed (106)(121). Despite many important new 
host factor genes being identified, the task now at hand is to triage these gene lists for 
further, more in depth mechanistic studies. 
To achieve this goal, we took advantage of a unique evolutionary signature that 
has been faithfully found in all known HIV-1 restriction factors (17-20, 38, 84, 85, 122, 
123). This evolutionary signature results from the millions-of-years long struggle for 
survival between retroviruses and the primates that they infect (124-129). In contrast to 
host factors, restriction factors block the replication of HIV-1 upon recognition of and 
interaction with specific viral targets (7, 11, 104, 130). Retroviruses, in turn, encode 
antagonist proteins that specifically recognize and inhibit some restriction factor proteins 
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(131). The evolutionary battles between restriction factors and viruses play out at 
physical interaction interfaces between host and virus proteins. Both parties (host and 
virus) are continuously selected for mutations that modulate this interaction to give each 
the upper hand over the other. For instance, the TRIM5α restriction factor has 
experienced continuous selection to better recognize its target, the retroviral capsid (17), 
whereas capsid continuously evolves to escape interaction with TRIM5α (28)(132). This 
continual evolutionary struggle is referred to as an evolutionary “arms race” and, because 
it occurs at the level of protein-protein interactions, results in the rapid evolution of each 
of the interacting host and viral proteins (127, 133). This signature of rapid evolution is 
so typical of restriction factors that it has even be used to predict novel restriction factors 
(38, 133-136), as well as the virus-binding domains of restriction factors (17, 126, 127, 
133).  
Although the application of these evolutionary analyses to the study of HIV-1 
restriction factors is now common practice, we hypothesized that HIV-1 host factors 
evolve under positive selection due to their long-term evolutionary engagement with viral 
proteins. In this scenario, virus genomes would be selected for mutations that improve 
physical interaction between virus proteins and beneficial host factors. In turn, host 
genomes would be selected for mutations in these host factors that reduce interactions 
with viruses. However, it is not known whether HIV-1 host factors will have the 
evolutionary flexibility to engage in arms race dynamics the way that restriction factors 
do. Unlike restriction factors, which are typically dedicated proteins of the immune 
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system, host factors that facilitate viral replication tend to play important roles in cellular 
physiology and so would be expected to have significantly more evolutionary constraints 
acting upon them. Thus, while these proteins might easily be able to accrue mutations 
that would allow them to avoid being hijacked by viral pathogens, the question is whether 
they will be able to do so without major collateral damage to the cell through loss or 
alteration of their housekeeping functions. Several recent reports indicate that virus host 
factors also experience positive selection and arms race dynamics (25, 89, 90, 92, 137-
139). This idea was tested further by harnessing the predictive power of this evolutionary 
signature to help highlight interesting new HIV-1 host factors uncovered in high-
throughput screens.  
Patterns of molecular evolution were analyzed in all of the human genes that have 
been identified in two or more independent RNA interference screens for HIV-1 host 
factors (115-118). This analysis required the generation of 160 primate gene sequences. 
We find that HIV-1 host factor genes are, overall, more conserved than restriction factor 
genes, as would be predicted by the higher level of evolutionary constraint acting on 
them. Nonetheless, these genes can experience positive selection at certain residue 
positions, just as restriction factors do. Positive selection was detected in three human 
genes with well-established roles in promoting the HIV-1 lifecycle (CD4, NUP153, 
RANBP2) and two less characterized genes (ANKRD30A and MAP4). The identification 
of these well-characterized host factors supports the idea that positive selection analysis 
can be a powerful addition to large-scale screening efforts, and indicates that the 
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remaining two genes, MAP4 and ANKRD30A, are worthy of closer examination. We 
verify ANKRD30A as an HIV-1 host factor, showing that this protein interacts with HIV-
1 through its C-terminal domain at a stage between virus entry and nuclear import. 
Finally, a potential rationale for why ANKRD30A has been identified in some high-
throughput screens for HIV-1 host factors but not others is presented, directly addressing 
why candidate proteins found in high-throughput genetic and proteomic screens often 
show limited overlap. 
 
MATERIALS AND METHODS 
Primate biomaterials 
Primary and immortalized primate cell lines from primate species were grown in standard 
media supplemented with 15% fetal bovine serum at 37oC and in 5% CO2. Macaque, owl 
monkey, and squirrel monkey samples included in the population study were acquired 
from either the Michale E. Keeling Center for Comparative Medicine and Research 
(Bastrop, Texas), or from the New England Primate Research Center (Southborough, 
MA). For these individuals, 2.5 mL of whole blood was collected in PaxGene Blood 
RNA Tubes (BD, #762165). Alternately, B-cell lines were expanded in suspension 
culture, in RPMI, 20% FBS, Pen/Strep, L-glutamine, HEPES, and AZT.  Genomic DNA 
and RNA from primate blood and cell lines was isolated using the PaxGene miRNA kit 
(Qiagen, #763134) and/or the Qiagen All Prep DNA/RNA mini kit (Qiagen, #80204).  
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Primate gene sequences 
Human Refseq sequences were obtained from the NCBI nucleotide database. 
Chimpanzee, orangutan, rhesus macaque, and marmoset gene sequences were obtained 
from the UCSC genome database (http://genome.ucsc.edu/) using the BLAT alignment 
tool. Genes were sequenced from additional primate species, and from chimpanzee, 
orangutan, rhesus and marmoset in instances where the genome-project sequences were 
of poor quality. PCR or RT-PCR was performed from total RNA, gDNA, or cDNA with 
SuperScript III One-Step RT-PCR system with Platinum Taq (Invitrogen, #12574-018), 
PCR SuperMix High Fidelity (Invitrogen, #10790-020), or Phusion High Fidelity PCR 
Master Mix (NEB, #F-531S). Primate gene sequences have been deposited in GenBank 
(accession numbers KJ531711-KJ531825).  
 
Human polymorphism analysis  
 Human SNPs were identified in datasets deposited by the 1000 Genomes Project 
(http://browser.1000genomes.org, release 13) and NCBI’s dbSNP database 
(http://www.ncbi.nlm.nih.gov/SNP).  
 
Sliding window analysis  
 Sliding-window dN/dS calculations for each alignment were performed with the 
SLIDERKK program (140). Human-orangutan, human-rhesus and rhesus-marmoset 
alignments were analyzed with standard window sizes (92) of 450bp, 306bp and 153bp, 
respectively, to reflect the increasing level of divergence in these species pairs (window 
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size must be a multiple of nine in this program). To generate confidence values for 
windows with dN/dS > 1, the K-estimator program (141) was utilized to generate a null 
distribution of dN/dS values through Monte Carlo simulation in the gene region of 
interest. 
 
PAML analysis  
 Codon models were tested with codeml in the PAML 4.1 software package (93). 
To detect selection, multiple alignments were fit to the NSsites models M8a (neutral 
model, codon values of dN/dS fit to a beta distribution plus an extra codon class fixed at 
dN/dS = 1) and M8 (positive selection model, similar to M8a but with the extra class 
allowed to be dN/dS >1). A likelihood ratio test was performed to assess whether 
permitting codons to evolve under positive selection gives a significantly better fit to the 
data (model comparison M8a vs. M8). In situations where the null model could be 
rejected (p < 0.05), posterior probabilities were assigned to individual codons belonging 
to the class of codons with dN/dS > 1. For the whole-gene dN/dS values indicated on the 
genome-wide distribution of human/chimpanzee/rhesus gene trios, dN/dS values were 
calculated using the M0 model in PAML. 
 
ANKRD30A and MAP4 cloning  
 The ANKRD30A gene fragment was synthesized and cloned into the plasmid 
pUC57 (synthesis and cloning by GenScript). The MAP4 gene fragment was amplified 
from human cDNA (Clontech, #636643) and TA-cloned into pCR4 (Invitrogen, #K4575-
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01). For both of these genes, an N-terminal 3xFLAG tag was added using a PCR reaction 
and these tagged constructs were TA-cloned into the gateway entry plasmid pCR8 
(Invitrogen, #K2500-20). An LR Clonase II reaction (Invitrogen, #11791-100) was used 
to move these constructs into a Gateway-converted pLPCX retroviral vector (Clontech, # 
631511).  
 
Generation of stable cell lines  
 To produce cell lines that stably express MAP4 and ANKRD30A fragments, 
retroviral vectors were used to transduce CRFK cells (ATCC). 293T cells were seeded at 
a concentration of 1x106 cells/well in a 6-well dish. After 24 hours each well was 
transfected with 2 µg of pLPCX construct (empty or encoding the gene fragment of 
interest), 1 µg pCS2-mGP encoding MLV gag-pol (142), and 0.2 µg pC-VSV-G at a final 
1:3 ratio of DNA to Fugene (µg DNA : ml Fugene6). Supernatants were collected after 
48 hours, passed through a 0.2 µm filter, and used to infect CRFK cells grown in DMEM 
supplemented with 10% fetal bovine serum, 100 IU/ml penicillin, 100 µg/ml 
streptomycin, and 2 mM L-glutamine. After 24 hours, media containing 8 mg/ml 
puromycin was added to select for transduced cells. Expression of ANKRD30A and 
MAP4 constructs was detected by Western blot.  
 
Western blot analysis  
 Puromycin-resistant cell lines were grown to confluency in a 6-well dish, 
collected using a cell scraper, and lysed in a buffer containing 150 mM NaCl, 50 mM 
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Tris-HCl (pH 7.4), 1% NP-40, and Complete protease inhibitor (Roche, #11836170001). 
After quantitation of protein concentration using a Bradford assay, 30 µg (ANKRD30A) 
or 1 µg (MAP4) of whole cell extract was resolved using a 10% polyacrylamide gel and 
transferred to a nitrocellulose membrane. FLAG-tagged constructs were detected using a 
1:2000 dilution of mouse anti-FLAG antibody 3B9 (Syd Labs, #PA000274-M20008L). A 
1:10,000 dilution of donkey anti-mouse horseradish peroxidase-conjugated antibody 
(Thermo Scientific, #32430) was used as a secondary probe. β-actin was also detected as 
a loading control using a 1:1000 dilution of mouse anti β-actin (Santa Cruz, #sc-47778). 
Blots were developed using the ECL Plus detection reagent (GE Healthcare, #RPN2132).  
 
Microscopy preparation and confocal imaging  
 CRFK cells stably expressing FLAG-tagged fragments of MAP4 or ANKRD30A, 
or transduced with an empty vector, were seeded into a 4-well permanox chamber slide 
(LabTek, #70400) at a concentration of 100,000 cells/well. Cells were fixed with 4% 
paraformaldehyde in PBS for 10 minutes, permeabilized with 0.5% Triton-X in PBS for 
15 minutes, blocked with 3% bovine serum albumin (Sigma-Aldrich, #A7906-50G) in 
PBS for an hour, stained with a 1:500 dilution of anti-FLAG antibody (Syd Labs, 
#PA000274-M20008L), and then visualized using a 1:1000 dilution of Alexa Fluor 594 
antibody (Molecular Probes, #A-11005). Cells were mounted using Vectashield 
mounting media containing DAPI stain (Vector Laboratories, #H-1200). All incubations 
were done at room temperature and followed by three washes using 3% bovine serum 
albumin in PBS. Confocal microscopy was performed using a Zeiss LSM 710 confocal 
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microscope with a 40x objective. All images were collected with identical laser and 
exposure times. Confocal slices of 1 mm were taken in the nuclear volume. Images were 
analyzed using the ImageJ version 1.43u software package (143). 
 
Retroviral integration assays  
 Viruses for single-cycle infection assays were packaged in 293T cells by co-
transfection of plasmids encoding viral proteins and VSV-G, along with a transfer vector, 
as follows: HIV-1 (pMDLg/pRRE, pRSV-Rev, pMD2.G, pRRLSIN.cPPT.PGK-
GFP.WPRE; all available from Addgene), FIV (pFP93 (144), pC-VSV-G, pGIN-
SIN:GFP (144)), NB-MLV (pCS2-mGP, pC-VSV-G, pLXCG (142)). After 48 hours, 
supernatant containing viruses was harvested, filtered, and frozen. For infection assays, 
CRFK stable cells lines were plated at a concentration of 5x104 cells/well in a 24-well 
plate and infected with HIV-1, FIV, or NB-MLV the following day. Two days post-
infection, cells were analyzed by flow cytometry for expression of GFP using the BD 
Bioscience Fortessa cell analyzer. Dose curves were performed in triplicate, and results 
were confirmed with independent experiments. 
 
Expression analysis of ANKRD30A in human tissues and laboratory cell lines 
 Primers were designed to amplify a 750bp fragment that spans the last two exons 
of ANKRD30A. PCR reactions were performed with PCR SuperMix High Fidelity 
(Invitrogen, #10790-020) along with primers NRM602 (forward: 5’-
TTAGGGAAGAATTAGGAAGAATC-3’) and NRM604 (reverse: 5’-
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CATTTGACACTGTGTTTCACGTTG-3’). The Human Total RNA Master Panel II 
(Clontech, #636643) was converted to cDNA using the SuperScript III First-Strand 
Synthesis System (Invitrogen, #18080-051) and used as a template in PCR reactions. The 
Human MTC cDNA Panel II (Clontech, #636743) was also utilized. HeLa, 293T, Jurkat, 
and breast carcinoma (HCC1937) cells were grown in DMEM and RNA was harvested 
using an All Prep DNA/RNA mini kit (Qiagen, #80204). Each of these cell lines was also 
treated with IFN- β (Betaseron) at a concentration of 1000 units/ml for 24 hours prior to 
isolation of RNA. ANKRD30A transcripts detected were verified via sequencing.  
 
RESULTS 
Five putative HIV-1 host factors have evolved under positive selection 
 In this study, we concentrated on the 40 human genes that have been identified in 
two or more of the large-scale RNA interference screens for HIV-1 host factors (Figure 
3-1A) (22, 117). Positive selection can be detected by analyzing the “dN/dS” ratio, which 
summarizes the rate at which non-synonymous (amino-acid altering; dN) and 
synonymous (not altering the encoded amino acid; dS) mutations have accumulated in a 
gene over evolutionary time. Repeated rounds of positive natural selection for non-
synonymous mutations result in a characteristic signature of dN/dS > 1 because non-
synonymous mutations tend to be more deleterious than synonymous mutations. First,  
dN/dS in HIV-1 host factor and restriction factor genes were compared. Figure 3-1B 
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Figure 3-1: Evolutionary analysis of genes identified in at least two RNA 
interference screens for HIV-1 host factors. (A) Each circle represents a whole-
genome RNA interference screen previously conducted to identify human genes 
important for HIV-1 replication (115-118). Within each overlap region is listed the 
number of human genes identified in multiple screens. Only three human genes (RELA, 
MED7, MED6) were identified in three screens, and no genes were identified in all four 
screens. (B) A histogram shows whole-gene dN/dS values previously calculated for 
10,376 orthologous gene trios from the human, chimpanzee, and rhesus genomes (49). 
On the x-axis is shown the average dN/dS calculated over the length of each gene for this 
three-species tree. On the y-axis is the number of human-chimp-rhesus gene trios with 
this average dN/dS value. On this distribution are overlayed the dN/dS values for similar 
trios hand-curated for known HIV-1 restriction factors (red asterisks), and for the 40 
putative host factors analyzed in this study (gray asterisks). The restriction factors are 
(from left to right on the distribution): SAMHD1, Tetherin, ZAP, TRIM22, TRIM5, 
APOBEC3H, APOBEC3DE, APOBEC3G. (C) Example sliding window analyses for 
CD4 and CXCR4. The x-axis is in base pairs and represents the length of each gene.  
dN/dS was calculated in sliding windows moving along the length of the gene. The three 
pairwise species comparisons made are color-coded (blue, human vs orangutan; red, 
human vs rhesus; green, rhesus vs marmoset). For each comparison, the gene region with 
the maximum dN/dS value was tested for statistical significance, and regions where 
dN/dS is significantly greater than 1 (p < 0.001 and p < 0.004) are indicated. (D) The 
maximum dN/dS value observed in each pairwise sliding window analysis is 

















As expected, most primate genes have dN/dS << 1. Overlayed on this distribution are the 
values of the 40 host factor genes analyzed in this study (gray stars). For comparison, 
dN/dS values for known restriction factor genes are also shown (red stars). These data 
show that genes encoding host factors are, in general, more conserved than genes 
encoding restriction factors, consistent with previous reports (99) and with their role as 
housekeeping genes. 
In host genes subject to arms races with viruses, patterns of dN/dS > 1 would not 
be expected to be evenly distributed throughout the entire length of a gene, but rather to 
be specifically concentrated in gene regions correlating to the protein-protein interaction 
surface with the viral antagonist (127). Rather than analyzing dN/dS on a whole-gene 
basis, gene regions that are experiencing positive selection were determined. For each of 
the 40 genes being analyzed, sequences from three species with available genome 
projects were used to construct three pairwise gene alignments (human vs orangutan, 
human vs rhesus, and rhesus vs marmoset). For each of these alignments, dN/dS was 
calculated in sliding windows along the length of each gene (38, 92, 138). Examples of 
the sliding window results are shown for two of the 40 genes analyzed, CD4 and CXCR4, 
encoding two receptors for HIV-1 entry (Figure 3-1C). Typical of most genes in primate 
genomes, dN/dS << 1 along the entire length of CXCR4 in all three pairwise 
comparisons. On the other hand, peaks of dN/dS > 1 are observed in all three pairwise 
comparisons in CD4, two of which are significantly greater than 1 (p < 0.001 and p < 
0.004; Figure 3-1C). The maximum dN/dS value found in each pairwise comparison is 
summarized in Figure 3-1D, where it can be seen that many genes have peaks of dN/dS > 
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1. The peaks mostly fall towards the beginning of the gene, the region encoding the D1 
domain that interacts with HIV-1 (145). Sliding window analysis has an inherent multiple 
testing problem that is difficult to correct because of the non-independence of tests 
(windows overlap) (146). As an ad hoc method for eliminating some false positive 
signatures, we sought genes with regions of dN/dS significantly > 1 (p < 0.05) in at least 
two out of three different pairwise primate comparisons made. We find that 8 out of 40 
genes analyzed meet these criteria (highlighted in gray in Figure 3-1D). Thus, we have 
identified preliminary signals of positive selection in eight candidate genes: ANKRD30A, 
CD4, IBTK, MAP4, NUP98/96, NUP153, RANBP2, and WNK1. 
Now that we have potentially identified domains under positive selection, we 
wished to use a more sophisticated statistical test for positive selection, and to analyze 
dN/dS on a codon-by-codon basis. There are good methods for doing this, but such 
analyses require deep sequence sets for each gene to be analyzed (147). We next 
generated large primate datasets for each of these 8 candidate genes. Each gene was 
sequenced from 20 hominoid, Old World monkey, and New World monkey species 
(species shown with asterisks in Figure 3-2). For 5 of the 20 species, it was possible to 
acquire some gene sequences from available genome projects, and for the other 15 
species cell lines were acquired and cDNA libraries constructed. Details of primate cell  
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Figure 3-2: Genetic divergence and diversity in two candidate HIV-1 host factors. 
The amino acids at positions under positive selection are highly variable between species. 
Four positions are shown, one in ANKRD30A and three in MAP4. Numbers refer to 
amino acid coordinates. The colored boxes represent unique amino acids sampled at that 
position. The 20 species used in the positive selection analysis are indicated with an 
asterisk. All codons under positive selection in ANKRD30A and MAP4 (not just these 
four) were re-sequenced from individuals representing small population sets of different 
non-human primate species (indicated with a triangle at the end of the branch on the 
primate cladogram). For humans, SNPs were identified in human SNP databases. Non-
synonymous SNPs identified are indicated by 2 squares next to each other. A hyphen 
indicates lack of information, because ANKDR30A could not be sequenced from these 
species as described in the text.  
 
lines, conditions for cell culture, mRNA extraction, cDNA library construction, PCR, and 
sequencing are given in the Materials and Methods section. High-quality Sanger 
sequencing was used. In all, 160 gene sequences for the 8 genes of interest were 
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generated. Two of these genes, ANKRD30A and RANBP2, were difficult to amplify from 
the available primate tissues, so sequencing was focused on a portion of these genes 
corresponding to the location of dN/dS > 1 peaks in the sliding window analysis, as 
indicated in Table 3-1. In the case of ANKRD30A, we were unable to amplify this gene 
from samples acquired for 7 species, so the final dataset for this gene consisted of only 13 
species. In the case of CD4, sequences from 5 additional primate species, beyond the core 
set of 20 species, were available on Genbank. For each gene, the number of sequences in 
the final dataset, and the region of the gene analyzed, is summarized in Table 3-1. 
The multiple sequence alignment generated for each gene was then analyzed for 
positive selection with PAML (93). Alignments were fit to a null model (Model M8a) 
where all codon positions are constrained to evolve with dN/dS ≤ 1, and a positive 
selection model (Model M8) where a dN/dS > 1 category of codons is allowed. A 
likelihood ratio test was then used to compare the positive selection model to the null 
model. The null model is rejected (p<0.05) in favor of the positive selection model in five 
of the eight genes analyzed: ANKRD30A, CD4, MAP4, NUP153, and RANBP2 (Table 3-
1). The null model could not be rejected in the case of IBTK (p=0.34), NUP98/96 
(p=0.46), and WNK1 (p=0.79). For each of the 5 genes that passed this statistical test, the 
individual codons in the dN/dS > 1 class were identified (Table 3-1), and the residues 
corresponding to these codons are diagrammed in Figure 3-3. Figure 3-2 illustrates the 




Table 3-1: PAML analysis of primate genes 
Gene a Number of 
species a 
2Δl b p-value b Positive 
selection? 
dN/dS c % sites c Codons with dN/dS>1 d  




13 36 p<0.001 yes 3.5 34% A985, D986*, Q1015**, 
I1022*, V1027, N1032, 
T1037, C1049**, 








25 15 p<0.001 yes 2.2 18% T15, T17*, Q20*, S23*, 
N32, I34, N39*, N52*, 




20 0.9 p=0.340 no na na na 
MAP4 
aa 10-1152 




20 0.5 p=0.464 no na na na 
NUP153 
aa 1-1475 
20 8.9 p<0.003 yes 6.4 0.5% I794, V1189** 
RANBP2 
aa 2002-3224 
20 15 p<0.001 yes 3.7 2.2% H2418**, A2724*, 
M2786*, M2813*, 




20 0.07 p=0.795 no na na na 
 
a Each dataset consists of gene orthologs from 20 primate species, with the exception of 
ANKRD30A due to inability to amplify this gene from 7 species, or CD4 due to 5 
additional primate sequences that were available in Genbank. The gene regions analyzed 
are indicated (by encoded amino acids, aa). Two of these genes, ANKRD30A and 
RANBP2, were difficult to amplify from the primate tissues that were available, so 
sequencing focused on the portion of these genes corresponding to the location of dN/dS 
> 1 peaks in the sliding window analysis.  
b Twice the difference in the natural logs of the likelihoods (2Δl) of the two models (M8a-
M8) being compared. The p-value indicates the confidence with which the null model 
(M8a) can be rejected in favor of the model of positive selection (M8).  
c dN/dS value of the dN/dS>1 class of codons in M8, and the percent of codons falling in 
that class.  
d Codons assigned to the dN/dS>1 class in M8 with a posterior probability of P>0.90 by 
Bayes empirical Bayes analysis. Codon coordinates and the encoded amino acid 
correspond to the human protein. 
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Figure 3-3: HIV-1 host factors exhibit signatures of positive selection. Domain 
diagrams are shown for the proteins encoded by each of the five genes evolving under 
positive selection. Residue positions experiencing positive selection are marked by red or 
black tick marks. Gene regions that were not sequenced are indicated by a transparent 
gray box. Dashed boxes indicate fragments used in infection assays in Figure 3-4. 
Diagrams are internally scaled.  
 
dynamic nature over evolutionary time. In several instances we see “recycling” of amino 
acids at these positions, which has been observed before at positively selected sites (127). 
These five genes are involved in various processes, with variable amounts known 
about their role in the HIV-1 lifecycle. CD4 is the main receptor for HIV-1 entry into 
cells (148) and has been previously documented as evolving under positive selection (99, 
139). NUP153 and RANBP2, both associated with the nuclear pore (149), are known to 
be important for the trafficking of the HIV-1 pre-integration complex into the nucleus 
(101, 150-152). The positive selection of RANBP2 has been previously noted in 
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mammals beyond primates (101). The identification of well-characterized host factors 
supports the idea that positive selection analysis can be a powerful addition to large-scale 
screening efforts. Two less characterized genes were also identified in our study: 
ANKRD30A and MAP4. While this work was in progress, the first report of the role of the 
microtubule-associated protein MAP4 in HIV-1 biology was published (153). Prior to 
this, little was known about the function of ANKRD30A other than the fact that it is 
upregulated in breast carcinomas (154). Nonetheless, ANKRD30A has the highest dN/dS 
value for any HIV-1 cofactor in this study, both by the metric shown in Figure 3-1B, and 
in the PAML analysis of individual codons (2Δl values in Table 3-1). No role for this 
gene in HIV-1 biology has yet been reported. 
 
Characterization of ANKRD30A and MAP4 
The novel candidate host factors ANKRD30A and MAP4 were investigated 
further. A dominant negative assay similar to assays used to characterize the interaction 
of HIV-1 with the host factors NUP153, LEDGF, and CPSF6 was used (152, 155, 156). 
In this assay, expression of a protein fragment constituting the known or putative HIV-
interaction domain of a host factor interferes with viral infection. This is because the 
fragment acts as a decoy that competes with the endogenous, full-length form of the same 
protein for interaction with virus proteins or complexes. This assay is particularly well-
suited to this study, because positive selection is predicted to accumulate in portions of 
host factor genes corresponding to the virus-interacting domain of the encoded protein 
(127). Plasmids encoding truncated fragments of human ANKRD30A (amino acids 970-
 57 
1341) and MAP4 (amino acids 486-693) were generated that correspond to the regions 
where positively selected residues are found (expressed protein fragments are boxed in 
Figure 3-3). These FLAG-tagged constructs were stably expressed in CRFK cells (Figure 
3-4A). Full-length MAP4 and ANKRD30A are both known to localize to the cytoplasm 
(153, 154, 157). The ANKRD30A fragment also localized to the cytoplasm, whereas the 
MAP4 fragment is distributed throughout the cell (Figure 3-4B). These cells were 
infected with retroviral vectors derived from HIV-1, feline immunodeficiency virus 
(FIV), and murine leukemia virus (MLV), all of which were pseudotyped with the 
vesicular stomatitis virus (VSV) G glycoprotein. Viral infection was measured by the 
expression of a green fluorescent protein (GFP) reporter gene. The expression of the 
ANKRD30A fragment reduced levels of HIV-1 and FIV infection by as much as 50%, 
but did not affect the integration of MLV (Figure 3-4E). The expression of the MAP4 
fragment had no effect (Figure 3-4C-D), but mis-localization of the MAP4 fragment 
makes it difficult to draw any conclusions for this fragment. Nonetheless, this serves as a 
control for the specific effects of the ANKRD30A fragment on the inhibition of HIV-1. 
ANKRD30A was previously identified in two independent RNA interference 
screens as important for HIV-1 replication, both of which used live HIV-1 and the 
infection of human cells (115, 118). Both of these screens also found this protein to be 
important for a step in the early part of the viral replication cycle, upstream of 





















Figure 3-4: Characterization of ANKRD30A as a novel HIV-1 host factor. (A) 
Western blot analysis of CRFK stable cell lines expressing FLAG-tagged fragments of 
ANKRD30A (amino acids 970-1341) or MAP4 (amino acids 486-693), or transduced 
with an empty vector (pLPCX). An actin antibody serves as a loading control. (B) 
Confocal microscopy was performed for each of the three cell lines. Cells were stained 
with a primary FLAG-specific antibody and with DAPI, and then visualized using a 
secondary Alexa Fluor 594 antibody. Images shown are representative of each stable cell 
line. (C-E) Single-cycle infection assay using VSV-G pseudotyped retroviruses. For each 
cell line, dose curves were generated in triplicate and standard deviations are indicated 
with error bars. Significant differences relative to the empty vector control were 
calculated using a two-tailed Student’s t-test. (*) P<0.01 (**) P<0.001 (F) A human 
tissue panel was probed for ANKDR30A expression using a primer set that spans an 
intron. As a positive control, the CRFK cells stably expressing the dominant negative 
ANKRD30A fragment were included. Human DNA was also used as a control, to show 
the product size obtained from genomic template (with the intron). Because ANKRD30A 
was originally identified as a gene associated with breast cancers, its expression was also 















These data place the timing of interaction between HIV-1 and ANKRD30A in a slightly 
narrower window, between cellular entry and nuclear entry. It also suggests that this 
interaction is direct, and that the final third of the ANKRD30A protein constitutes the 
virus interaction domain. The most exposed HIV-1 protein at this stage of the viral 
lifecycle is capsid. To investigate a possible direct interaction between capsid and this 
fragment of ANKRD30A, this fragment of ANKRD30A was fused to the TRIM portion 
of the owl monkey TRIM-Cyp restriction factor (see (101)(158) for a description of this 
assay). Viral restriction indicative of an interaction between capsid and TRIM-
ANKRD30A was not observed, but very low expression of these TRIM fusion proteins 
was noted, suggesting that they may be misfolded or unstable (data not shown). 
ANKRD30A is expressed in white blood cells (GenBank record BF171216.1), and these 
data show expression in brain, heart, muscle, testis, and uterus (Figure 3-4F). More 
extensive work will be needed to characterize the interaction of ANKRD30A with HIV-1 
and to investigate a possible role of ANKRD30B in HIV-1 biology. This could be quite 
important because, in addition to having the strongest signature of positive selection in 
this study, ANKRD30A is one of the few candidate HIV-1 host factors that has been 
categorized as a “druggable” target, based on properties that is shares with proteins that 
have been already successfully targeted by drugs (22, 159). 
In addition to species-specific genetic differences, single nucleotide 
polymorphisms (SNPs) circulating within primate species can dramatically affect 
interactions between host restriction factor proteins and retroviruses (28, 122, 160, 161). 
For instance, SNPs found in the TRIM5 restriction factor locus of rhesus macaques can 
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dramatically affect the ability of the encoded TRIM5α protein to restrict different HIV-1 
and simian immunodeficiency virus (SIV) strains (16). Codons targeted by positive 
selection in MAP4 and ANKRD30A (Table 3-1 and Figure 3-3) were sequenced from 
small populations of select primate species. This population survey focused on three owl 
monkey species (Azara’s, Nancy Ma’s, and Spix’s owl monkeys), three squirrel monkey 
species/sub-species (common, Peruvian, and Bolivian squirrel monkeys), and two 
macaque species (crab-eating, also known as cynomolgus, and rhesus macaques). We 
also utilized human SNP databases to look for non-synonymous human SNPs that 
coincide with codons under positive selection. MAP4 bears human SNPs at three out of 
four sites of positive selection, but no polymorphisms at these sites in the macaque, 
squirrel monkey, or owl monkey populations that we investigated (Figure 3-2). In 
ANKRD30A, SNPs were found at one site of positive selection (residue 1037) in both 
human and rhesus macaque populations. ANDRD30A from owl monkeys was unable to 
be sequenced. Unlike all other genes analyzed, the inability to sequence ANKRD30A 
from some species was a consistent problem in this study, suggesting that this gene is 
being lost, duplicated, or rearranged in different species. More extensive work will be 
needed to characterize the interaction of MAP4 and ANKRD30A with HIV-1, and to 
determine the significance of species-specific and population-level genetic divergence in 
these genes.  
 
Inconsistent identification of ANKRD30A in different genetic screens 
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Interestingly, ANKRD30A was identified as critical for HIV-1 replication in some 
but not all genome-wide RNA interference screens. It was identified in two screens 
conducted in HeLa cells (115, 118), but not in similar screens performed in 293T or 
Jurkat cells (116, 117). ANKRD30A was also not identified in a proteomic screen for 
HIV-interacting proteins that was conducted in both 293 and Jurkat cells (162). To 
investigate this discrepancy, the expression of ANKRD30A in HeLa, 293T, and Jurkat 
cells was tested. Interestingly, ANKRD30A was not expressed in any of these cell lines 
(Figure 3-5A), making it hard to understand why this gene would have been identified in 
any screens. The transfection of short interfering RNAs (siRNAs), which was performed 
in several of these screens (Figure 3-5B), is known to induce the interferon response 
(163), and siRNAs may be detected by pattern recognition receptors in the cytoplasm. 
We considered the possibility that ANKRD30A expression was induced under some 
experimental conditions by siRNA transfection and interferon induction, and then 
subsequently knocked down when on-target siRNAs were used. To explore this idea, we 
treated HeLa, 293T, and Jurkat cells with interferon-β and found that expression of 
ANKRD30A is readily detected in HeLa and Jurkat cells, but not in 293T cells (Figure 3-
5A).  
These expression patterns may explain why ANKRD30A was found in some 
genome-wide screens and not others (summarized in Fig. 3-5B). It was identified only in 
screens that combined HeLa cells with siRNA transfection (115, 118). Jurkat cells are not 
easily transfectable, so transduction was always used with these cells. In transduction, the  
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Figure 3-5: ANKRD30A expression under conditions used in high-throughput 
genetic screens. (A) Expression of ANKRD30A was assessed in various laboratory cell 
lines. Cells were grown both without and with stimulation by interferon-β, and mRNA 
was harvested. Expressed and spliced transcripts were detected by RT-PCR. Primers 
were also designed to amplify spliced transcripts of NUP153, and were used as a control 
for the amount of input material in each reaction. (B) A summary of genome-wide 
screens for HIV-1 host factors, along with relevant details of the methods used. 
 
 
retroviral capsid core would be predicted to shield nucleic acids from detection by pattern 
recognition receptors. This is a demonstration of how genome-wide screens may be 
sensitive to the particular cell type used, and why different studies may not agree because 
of differences in the experimental design.  
 
DISCUSSION 
Here five human genes that both promote HIV-1 replication and contain 
signatures of positive selection were identified. Although the positive selection of 
restriction factor genes is well documented, it is becoming clear that arms races may also 
be shaping host genes that facilitate pathogen life cycles, with preliminary reports coming 
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from cell surface receptors (25, 89, 90, 137) and DNA repair machinery (92, 138). In the 
current study, 5 out of 40 housekeeping genes investigated (13%) were found to have 
experienced strong positive selection. We conclude that HIV-1 host factor genes can be 
caught in evolutionary arms races just like restriction factor genes. However, in this case, 
collateral damage to cellular housekeeping functions must be carefully controlled as the 
evolutionary battle with viruses plays out. The identification of three well-known HIV-1 
host factors in our screen supports the idea that intersecting gene lists from HIV-1 host 
factor screens with evolutionary analysis for positive selection will provide a meaningful 
way to prioritize certain candidate host factors over others.  
ANKRD30A was identified as a novel HIV-1 host factor of interest. This gene 
has the strongest signature of positive selection observed in this study. A truncated form 
of ANKRD30A inhibited HIV-1 and FIV, but not MLV, in single-cycle infection assays. 
The protein region corresponding to this dominant-negative fragment contains many 
residues targeted by positive selection (Figure 3-3), as well as SNPs in both human and 
primate populations (Figure 3-2). Together, these data are consistent with the C-terminal 
portion of ANKRD30A making direct physical contact with an unknown HIV-1 protein 
or complex. This gene is expressed in CD4+ Jurkat T-cells, the target tissue for HIV-1 
replication, at least under conditions of interferon stimulation. The interferon induction of 
this gene is intriguing, as one would not expect a host factor to be upregulated during an 
immune response. However, this gene is also expressed in a handful of normal tissues 
(Figure 3-4F). ANKRD30A has been identified as copy number variable in the human 
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population (164), and gene dosage of an HIV-1 host factor could contribute to variable 
susceptibility of disease progression. 
With the advent of high-throughput genetic and proteomic screening in the field 
of HIV-1 research, there is now an opportunity to utilize techniques from the field of 
systems biology so that the results of multiple high-throughput studies may be integrated 
(165). The field of systems biology provides a roadmap for finding “signal in the noise” 
generated by these screens, predominantly by looking for associations that come up 
repeatedly in independent types of studies and assays. It is important that all types of 
screens continue to be performed, as each has its strengths and weaknesses (106). Yeast 
two-hybrid screens capture direct human-HIV physical interactions, pull-down/mass-
spectrometry based screens capture interactions that occur in the context of larger protein 
complexes, and genetic screens capture genes with even indirect effects on viral 
replication. Genome-wide association studies yield different information altogether, in 
this case revealing information only on genes where polymorphism between humans 
results in differential susceptibilities (76, 166, 167). Positive selection analysis is yet 
another type of screen that can and should be added into this systems biology approach, 
also having its own strengths and weaknesses. A particular strength is that this analysis 
tends to identify genes that encode proteins that interact with HIV-1 directly (127).  
Several limitations of positive selection analysis must also be noted. First, the 
positive selection of human and primate genes can be driven by processes other than 
host-virus arms races. For instance, genes involved in sexual selection can experience 
positive selection (168). In the case of the present study, we began not with a random set 
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of genes, but with a set that had scored in assays for HIV-1 replication, making 
retroviruses the most likely drivers of this evolutionary signature. Second, the 
evolutionary signature in a gene can be a composite of multiple selective forces, 
potentially involving host-virus arms races taking place with more than one virus family 
(137). Another limitation is that some host genes involved in retroviral lifecycles will not 
experience positive selection. Indeed, CXCR4, LEDGF and CPSF6 are examples of 
human genes that are well-known to be involved in HIV-1 replication, and which encode 
proteins that directly interact with retroviruses, but that are extremely conserved in 
protein sequence (158, 169). From the sliding window analysis of dN/dS (Figure 3-1D), 
another gene recently characterized important to the HIV-1 lifecycle, TNPO3 (170, 171), 
also appears to be highly conserved. These genes apparently lack the evolutionary 
flexibility to engage in evolutionary arms races. In some cases, genes are so essential that 
no mutation exists that could offer an advantage in the face of viral challenge without 
serious collateral damage to the normal cellular function of this gene. Other host genes 
will be able to produce mutations that dissociate host functions from viral interactions, 
but these mutations may act in a recessive fashion with regard to viral susceptibility. 
Such mutations will not experience selection in the context of heterozygous hosts, 
making it unlikely that they will become common enough for homozygotes to arise 
(where selection would start acting). One major difference between the evolution of 
restriction factors and host factors is that mutant alleles of restriction factors act in a 
dominant or semi-dominant fashion, whereas alleles of host factors are predicted to act in 
recessive or semi-dominant fashion (127). 
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In conclusion, positive selection analysis can be used to strengthen high-
throughput and systematic studies of host-virus interactions. Although this analysis has 
certain limitations, its strength and value increases when combined with other types of 
virological data, as demonstrated here. 
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Chapter 4 
Identification of the first nonhuman primate CD4 receptor 
compatible with primary HIV-1 isolates 
 Because HIV-1 does not replicate in most mammals, studies of viral pathogenesis 
employ modified viruses known as SHIVs. SHIVs encode an envelope protein (Env) that 
can use macaque CD4 as an entry receptor. However, these Envs are not representative of 
the major circulating variants of HIV-1. Therefore, the major antigen on HIV-1 relevant 
to vaccine studies, Env, is altered in the course of creating the animal model used to study 
vaccines. Animal models for SHIV strains bearing clinically-relevant Envs are lacking. 
Here, CD4 genetic diversity within primate populations was sampled. Spix’s owl monkey 
(Aotus vociferans) individuals were found to carry CD4 alleles compatible with HIV-1 
Envs isolated from early human infections, and representing all of the major HIV-1 group 
M clades (A, B, C, and D). Based on these results, a strategy for building improved HIV-
1 model organisms is propsed. If permissive alleles at key loci like CD4, CCR5, 
restriction factor genes, and MHC could be identified within a single primate species, 





 Humans, chimpanzees and white-handed gibbons are the only mammals that are 
known to support HIV-1 replication, but the latter two primates are endangered and only 
rarely develop immunodeficiencies upon infection (172). Cells from other nonhuman 
primate species are resistant to HIV-1 infection even in laboratory cell culture, in most 
cases due to restriction factors that they encode (11, 173). However, entry into the cell is 
also a major barrier to HIV-1 infection in many nonhuman primate species. For example, 
HIV-1 variants derived directly from humans at early stages of infection, which are most 
relevant to the HIV-1 pandemic, have only been shown to be compatible with human 
CD4 (174), whereas lab-adapted or chronic-stage isolates of HIV-1 can use the CD4 
receptor encoded by multiple nonhuman primate species (175, 176). In the laboratory, 
mutations can be introduced into virtually any cellular receptor or restriction factor to 
make it compatible with HIV-1 replication, but using these modified genes to create 
transgenic laboratory animals, particularly monkeys, has been a consistent roadblock in 
translating these findings. 
 In the absence of an animal model for HIV-1, the main strategy thus far has been 
to modify the virus itself, thereby making it capable of replicating in some macaque 
species and even inducing an AIDS-like disease (172, 177). This has given rise to a 
number of SHIV strains (simian/human immunodeficiency virus hybrids) that replicate 
well in macaques, but only after serial passage and adaptation in this species. The process 
of adapting SHIVs to replicate in macaques leads to changes in the viral envelope 
glycoprotein (Env) (178), as well as the ability of HIV-1-specific antibodies to recognize 
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Env (Boyd, Peterson, Haggarty, Jordan, Hogan, Goo, Hoxie and Overbaugh; submitted). 
Because Env is the major antigen relevant for vaccine studies, this potentially 
compromises the macaque model for some applications and could contribute to the 
failure of vaccine studies to translate into humans. In addition, there are currently no 
SHIVs encoding Envs derived from HIV-1 variants isolated soon after sexual 
transmission, which is the major mode by which HIV-1 is spread. Such SHIVs do not 
replicate in nonhuman primates, at least in part due to incompatibilities with the CD4 
receptor, an issue that has only recently been appreciated (174, 179). Instead, most 
SHIVs bear Env from lab-adapted HIV-1 strains, typically isolated during chronic stages 
of infection. Finally, the majority of SHIVs represent subtype B Env sequences, and few 
are representative of subtypes A, C, and D, which are the most prevalent types in sub-
Saharan Africa.  
 There remains an urgent need to identify a nonhuman primate species that will 
support the replication of SHIVs bearing Env from clinically-relevant human isolates. In 
this pursuit, the population genetics of nonhuman primate species has largely been 
untapped. Like in humans, significant genetic polymorphism exists in nonhuman primate 
populations. Here, we explore the possibility that natural variation already exists within 
primate species that could be harnessed for the development of an animal model. In this 
study, small populations were analyzed, representing 11 different nonhuman primate 
species, and individual animals were evaluated for CD4 polymorphisms. Multiple CD4 
alleles were identified in one New World monkey species, the Spix’s owl monkey (Aotus 
vociferans), which encode CD4s that support entry mediated by Envs from all of the 
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major clades of HIV-1 group M. This very limited survey of primate populations is a 
powerful demonstration of how large-scale bioprospecting in nonhuman primate 
populations could reveal naturally-occurring alleles compatible with HIV-1 infection. If 
permissive alleles at key loci like CD4, CCR5, restriction factor genes, and MHC could 
be identified within a single primate species, they could be combined into a single 
animal. Such an approach would require no special transgenic methods, but rather simple 
breeding techniques dating back thousands of years. 
 
MATERIALS AND METHODS 
Primate samples 
 Nonhuman primate samples were acquired from the M.D. Anderson Cancer 
Center’s Michale E. Keeling Center for Comparative Medicine and Research (KCCMR) 
in Bastrop, TX, or from the New England Primate Research Center in Southborough, 
MA. For each individual, 2.5 mL of blood was collected in PaxGene Blood RNA Tubes 
(BD, #762165). Alternately, B-cell lines were expanded in suspension culture in RPMI, 
20% FBS, Pen/Strep, L-glutamine, HEPES, and AZT. Genomic DNA and RNA from 
blood and cell lines were isolated using the PaxGene miRNA kit (Qiagen, #763134) 
and/or the Qiagen All Prep DNA/RNA mini kit (Qiagen, #80204). cDNA libraries were 
generated using oligo(dT) primers with isolated primate RNA and the Superscript III 
First-strand Synthesis System (Invitrogen, #18080-051). PCR was performed from 
gDNA or cDNA with PCR SuperMix High Fidelity (Invitrogen, #10790-020) or Phusion 
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High Fidelity PCR Master Mix (NEB, #F-531S). All newly characterized SNPs were 
verified with independent PCR and sequencing reactions.  
 
Expression constructs. 
 Human CD4 was amplified from RNA isolated from Jurkat T cells. Owl monkey 
CD4 was amplified from RNA isolated from blood samples as described above. Each 
CD4 was sub-cloned into the pCR8 Gateway entry vector using TA cloning (Invitrogen, 
#K2500-20). An LR Clonase II reaction (Invitrogen, #11791-100) was used to move 
these constructs into a Gateway-converted pLPCX retroviral packaging vector (Clontech, 
# 631511). The expression plasmid encoding rhesus macaque CD4 was described 
previously (180).  
 
Envelope clones 
 The following envelope clones from early HIV-1 infections were used: Q461e2 
(181), QH343.21 (182), WITO4160.33 and TRO.11 (183), ZM53M.PB12 and 
ZM197M.PB7 (184), QA013.70I and QB857.110I (182). As a control, two subtype B 
HIV-1 env clones (BaL.01 and SF162) representing variants known to infect macaque 
cells (174) were also used. GFP reporter pseudoviruses were generated in HEK293T cells 
by cotransfecting 667 ng of Q23Δenv-GFP (179) and 333 ng of the HIV-1 env clone of 
interest using Fugene 6 (Roche) transfection reagent at a ratio of 3 µl Fugene 6 to 1 µg 
DNA following the manufacturer’s protocol. 
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Generation of stable cell lines 
 HEK293T and Cf2Th/syn CCR5 (185) cells were cultured in Dulbecco’s 
modified Eagle’s medium (Invitrogen) with 10% FBS (Gibco), 2 mM L-Glutamine 
(Gibco), and 1% antibiotic (Gibco) (complete medium) at 37°C and 5% CO2. Cf2Th/syn 
CCR5 cells, which are canine thymocytes engineered to express human CCR5, were 
further supplemented with 400 µg/ml of Geneticin (Gibco) to maintain CCR5 expression. 
For generation of CD4-expressing cell lines, retroviral virus-like particles (VLPs) were 
generated in HEK293T cells by cotransfecting pLPCX (retroviral vector encoding the 
CD4 of interest), pJK3 (MLV-based packaging plasmid), and pMD.G (VSV-G envelope 
plasmid) at a ratio of 1:1:0.5 using Fugene 6 (Roche) transfection reagent following the 
manufacturer’s protocol. Forty-eight hours post-transfection, the supernatant containing 
VLPs were collected, filtered through 0.22 mm filters, and concentrated using Amicon 
Ultracel 100K filters (Millipore). The concentrated VLPs (~200 µl) were used 
immediately to transduce Cf2Th/syn CCR5 cells that had been plated 24 h prior at a 
density of 105 cells/well in a 6-well plate in 2 mL of drug-free complete medium. The 
cells were transduced in the presence of 10 µg/ml of DEAE-dextran by spinoculation at 
1200 g for 90 min. The following day, cells were split and transferred into new T75 
flasks in 10 ml of drug-free complete medium and cultured for 48 h. The cells were then 
passaged and maintained in complete medium supplemented with 400 µg/ml of Geneticin 
(to maintain CCR5 expression) and 2 µg/ml of Puromycin (to select for CD4 expression). 
The transduced cells with high levels of CD4 expression were obtained by sorting the 
cells on FACSAria II cell sorter using an allophycocyanin-conjugated CD4 monoclonal 
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antibody (BD Biosciences, #551980) as described previously (174). Cf2Th/syn CCR5 
cells stably expressing Rhesus CD4 have been described previously (174).  
 
CD4 infectivity assay 
 Cf2Th/syn CCR5 cells stably expressing CD4 (2.5 x 104 cells/well in a 12-well 
plate in 1 ml of drug-free complete medium) were seeded 24 h prior to infection. The 
cells were infected with HIV-1 pseudoviruses in duplicate wells at an MOI of 0.5 in the 
presence of 10 µg/ml of DEAE-dextran by spinoculation at 1200 g for 90 min. After 72 
h, the cells were washed once with 200 µl 1x PBS, harvested using 200 µl of 0.05% 
Trypsin-EDTA (Gibco), and fixed in 200 µl of 2% paraformaldehyde. The fixed cells 
were washed twice with 500 µl FACS buffer (1x PBS buffer containing 1% FBS and 1 
mM EDTA). The cells were resuspended in 400 µl of FACS buffer, filtered through a 35 
µm pore size nylon mesh cap (BD Falcon) and analyzed for GFP expression on a BD 




 An alignment of primate CD4 D1 domain was analyzed using the codeml 
program contained in PAML 4 (100). The free-ratio model was used to estimate dN/dS 




Polymorphism in the primate CD4 gene  
 To detect single nucleotide polymorphisms (SNPs), CD4 from small populations 
of select nonhuman primate species (bold type in Figure 4-1) were sequenced. Although 
in practice macaques have been used as the main animal model, there has also been 
interest in developing New World monkeys as a model system (176, 186). For this 
reason, this population survey focused on two macaque species (cynomolgus and rhesus 
macaques) and five different species of New World monkeys: three owl monkey species 
(Azara’s, Nancy Ma’s, and Spix’s owl monkeys) and two squirrel monkey species 
(common squirrel monkeys, and the related Peruvian and Bolivian squirrel monkey sub-
species). For this study, whole blood or B-cell lines were obtained from primates housed 
at two different primate research centers. The number of individual monkeys sampled 
from each species ranges between 3 and 35, as indicated in Figure 4-1. Human SNP 
databases and previous reports on CD4 diversity in chimpanzees, three different species 
of African green monkeys (grivets, tantalus monkeys, and sabaeus monkeys), and squirrel 
monkeys (187-189) were also used. 
CD4 interacts with HIV-1 Env through its D1 protein domain (145). Even in the 
relatively small populations surveyed, 6 of the 12 primate species exhibited  
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Figure 4-1: Non-synonymous SNPs in the portion of CD4 encoding the D1 domain. 
An amino acid alignment of the D1 domain from species included in the population 
study. Non-synonymous SNPs identified are indicated with slashes, where the two 
alternately encoded amino acids are given on either side. Dotted lines separate the major 
clades of simian primates (Hom. = hominoids, OWMs = Old World monkeys, NWMs = 
New World monkeys). The number of individuals analyzed from each species is shown 
in parentheses adjacent to the species name. Amino acid positions highlighted in yellow 
were previously identified to be evolving under positive selection (27). Numbering along 
the top is relative to the mature CD4 protein, after cleavage of the 25 amino acid N-
terminal signal peptide. Species shown in bold indicate populations that were sequenced 
in this study. Arrows indicate three sites that have been shown to affect HIV-1 entry.  
 
non-synonymous polymorphism in this domain (slashed positions in Figure 4-1). A total 
of 17 sites in the D1 domain contain non-synonymous SNPs. Species-specific (as 
opposed to intra-specific) variation at three sites in the D1 domain, N39, P48, and R59, 
has been shown to alter interactions with HIV-1 (arrows in Figure 4-1) (174, 189). For 
instance, a single amino acid difference at position 39 of CD4 between human 
(asparagine) and pig-tailed macaque (Macaca nemestrina, isoleucine) accounts for the 
species-specific differences in the ability of these CD4s to function as receptors for HIV-
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1 (174). Of these three positions, only N39 is under positive selection (27) and is 
therefore highly variable between species. At this position, various nonhuman primate 
species encode asparagine (N), isoleucine (I), lysine (K), or valine (V) (Figure 4-1). This 
position is also polymorphic in the Spix’s owl monkey species, where certain alleles 
encode the amino acid found at position 39 in humans (asparagine; N) and other alleles 
encode the amino acid found in macaque species (isoleucine; I) (Figure 4-1). On the basis 
of these findings, we hypothesized that there is functional variation in the CD4 proteins 
encoded by different Spix’s owl monkey individuals. 
 
Spix’s owl monkey CD4 alleles are compatible with entry by HIV-1 isolates from 
early human infections 
 To test the ability of Spix’s owl monkey CD4 to support HIV-1 infection, we 
cloned all four CD4 alleles from two individuals that encode non-synonymous SNPs at 
residue 39, or a neighboring site under positive selection, residue 32 (both boxed in 
Figure 4-1). These alleles encode proteins that are identical at every other amino acid 
position with one exception: the Spix 2 and Spix 3 (Figure 4-2A) alleles encode identical 
proteins but differ by a T275A SNP outside of the D1 domain (not shown in alignment). 
Cell lines stably expressing these CD4 alleles were generated in Cf2Th/syn CCR5 cells, 
which express human CCR5. Cells expressing human or rhesus CD4 were also generated 
as controls. Similar expression levels of CD4 were observed across these cell lines 




Figure 4-2: Spix’s owl monkey CD4 alleles encode receptors permissive for entry by 









Figure 4-2: Spix’s owl monkey CD4 alleles encode receptors permissive for entry by 
primary HIV-1 isolates. (A) Amino acid alignment of the D1 domain from six CD4 
receptors tested for virus entry. Sites that are polymorphic in Spix’s owl monkeys are 
highlighted in yellow. (B) Expression levels of CD4s stably introduced into Cf2Th/syn 
CCR5 cells as measured by flow cytometry using an APC-conjugated CD4-specific 
antibody. (C) Cell lines expressing different CD4 alleles (denoted along x-axis) were 
infected with the indicated Env-pseudotyped virions. Env variants are labeled such that 
the first letter represents the subtype, followed by the strain name. Infection is indicated 
as percent GFP-positive cells measured by flow cytometry 72 hours post infection. All  
pseudotyped virions were generated using the subtype A-derived Q23DEnvGFP proviral 
clone. Error bars represent the standard deviation of the mean from three independent 

















Virions bearing Envs from two lab-adapted subtype B variants (BaL and SF162; 
(174)) gained entry through all CD4s tested, including those encoded by the 4 Spix’s owl 
monkey alleles (Figure 4-2C). The env genes from subtype B viruses isolated from early-
stage human infections, including one that was not passaged prior to cloning 
(WITO4160.33) and one that was cloned after low passage (TRO.11) (183) were tested. 
As observed previously (174), human CD4, but not rhesus macaque CD4, supports entry 
of these viruses (Figure 4-2C). This illustrates the key obstacle that CD4 presents in 
macaques, requiring that adapted Envs are used. Surprisingly, three out of the four Spix’s 
owl monkey CD4 receptors tested were permissive to HIV-1 pseudotyped with these 
Envs, at a level similar to human CD4 (Figure 4-2C). The three Spix’s owl monkey CD4 
receptors that support infection (Spix 2, 3, and 4) all have an asparagine (N) at position 
39, whereas Spix 1 encodes an isoleucine (I) at this position (Figure 4-2A). This amino 
acid mutation is solely responsible for this phenotype, because Spix 1 and Spix 3 encode 
identical proteins except at position 39.  
 
Spix’s owl monkey CD4 alleles are permissive to major HIV-1 subtypes 
 To further investigate the permissiveness of these Spix’s owl monkey CD4 alleles 
for HIV-1 entry, the CD4-expressing cell lines were challenged with a panel of viruses 
pseudotyped with Envs from the major clades of HIV-1 group M circulating globally  
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Figure 4-3: Spix’s owl monkey CD4 receptors are permissive for entry by the major 
clades of HIV-1 group M. Cf2Th/syn CCR5 cells expressing various CD4 alleles 
(denoted along x-axis) were infected with the indicated Env-pseudotyped virions. Env 
variants are labeled such that the first letter represents the subtype, followed by the strain 
name. Infection is measured by flow cytometry as percentage GFP-positive cells 72 hours 
post infection. All pseudotyped virions were generated in the Q23DEnvGFP background. 
Error bars represent the standard deviation of the mean from three independent 
experiments conducted in duplicate.   
 
(Figure 4-3). This panel includes R5-tropic Envs from two subtype A variants (Q461e2, 
QH343.21), two subype C variants (ZM53M.PB12 and ZM197M.PB7), and two subtype 
D variants (QA013.70I and QB857.110I). All of these Envs are derived from HIV-1 
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isolated in early phases after sexual transmission and, importantly, are representative of 
the most prevalent circulating variants of HIV-1.  
Human CD4 facilitates entry by all of these viruses (Figure 4-3). In contrast, the 
rhesus macaque CD4 receptor does not facilitate entry by any of them, again dramatically 
illustrating the major hurdle in generating SHIVs that are both replication-competent in 
macaques and relevant for human vaccine design. The three Spix’s owl monkey CD4 
alleles that encode an asparagine (N) at position 39 (Spix 2, 3, and 4) encode receptors 
that facilitate entry by 5 of the 6 Envs tested. These alleles support entry by at least one 
Env from each subtype tested (A, B, C, or D). Therefore, the CD4 encoded in the 
genomes of some Spix’s owl monkeys are broadly permissive to entry by HIV-1 group M 
subtypes. In this limited survey of three individual Spix’s owl monkeys, two of the 
individuals are homozygous for permissive alleles. 
Interestingly, not all subtype C Envs can enter through these Spix’s owl monkey 
CD4s (Figure 4-3). Subtype C Env ZM197M.PB7 is unable to use any Spix’s owl 
monkey CD4, whereas subtype C Env ZM53M.PB12 readily enters through CD4 
encoded by three of the Spix’s owl monkey alleles. This result illustrates how genetic 
diversity in both the host and the virus can impact whether the CD4 receptor can mediate 
entry. 
 
A host-virus evolutionary arms race involving primate CD4 
 Why does the ability of CD4 to act as an HIV-1 receptor vary so much between 
and within species? To answer this question, we considered the evolutionary pressures 
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shaping the CD4 gene. We and others previously demonstrated that CD4 is evolving 
under positive natural selection in primates (27, 139). When hosts and viruses co-evolve 
over long periods of time, both will experience positive selection for new allelic forms of 
genes that regulate their interaction with one another (126, 127). For instance, primate 
genomes will be selected for new allelic forms of CD4 that limit retroviral entry.  
Retroviruses will, in turn, be selected for new allelic forms of env that permit entry using 
new forms of CD4. This dynamic results in the accelerated fixation of mutations at the 
binding interface between host and virus proteins (CD4 and Env in this example). 
Residues in CD4 that have been targeted by positive selection (red spheres) were mapped 
onto the co-crystal structures of the CD4 D1 domain in complex with both of its binding 
partners: MHC-II and Env (gp120) (Figure 4-4A-B). Although these CD4 residues appear 
to fall in a binding interface that is shared between both of these interaction partners, 
closer inspection reveals that positively selected residues track more closely with Env 
gp120 binding than with MHC-II binding (Figure 4-4C). Therefore, CD4 is predicted to 
be constant across species in its interaction with MHC-II, but variable between species in 
its interaction with HIV-1 and related viruses.  
Furthermore, codons that have evolved under positive selection are often 
polymorphic within species (25, 42, 92, 122, 127, 190, 191). Many of the SNPs that were 
identified in CD4 (gray boxes in Figure 4-4C) cluster around codons under positive 
selection, and there are 6 positions where SNPs exactly overlap with sites under selection 
(T15, N32, I34, N39, N52, and A55). This suggests that significant variation in CD4 
function will exist between individuals of the same species.  
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Figure 4-4: Evolution of the CD4 D1 domain. (A) A schematic of the interaction 
between CD4 and MHC-II, alongside its co-crystal (PDB ID:1JL4) (192) where the sites 
under positive selection in CD4 (27) are represented by red spheres. APC = antigen 
presenting cell. (B) Schematic of the interaction between CD4 and HIV-1 gp120, 
alongside its co-crystal (PDB ID:1RZJ) (193) where the sites under positive selection in 
CD4 (27) are represented by red spheres. (C) A table showing amino acids in the CD4 
D1 domains that contact gp120 (blue) or MHC-II (orange), are under positive selection 
(red; (27)), or are polymorphic for non-synonymous mutations in primate populations 
included in the present study (gray). Asterisks along the bottom denote residue positions 
that are completely conserved in the 31 primate species shown in panel D. Table format 
modified from (139). (D) Evolutionary analysis of the D1 domain of CD4 showing the 
number of non-synonymous and synonymous mutations (in parentheses; N:S) predicted 
to have occurred along each branch of a 31 species primate phylogeny (194). Branches 
with red text have dN/dS >1, and this ratio is shown before the parentheses. This ratio 
cannot be calculated in cases where dS=0. Primate species shown in bold text are known 
















But why does variation in CD4 function exist in New World monkeys, which 
have never been found to harbor lentiviruses? The newly generated CD4 sequences, 
along with existing sequences, were used to reconstruct the ancestral CD4 sequence that 
existed at each node of a 31 species primate phylogeny using PAML (100) (Figure 4-4D). 
On each branch of the tree, the ratios in parentheses represent the numbers of non-
synonymous and synonymous substitutions (N:S) predicted to have occurred in the D1 
domain. To detect selection, these values must be normalized to the number of 
opportunities that existed for each type of mutation in the DNA sequence of CD4 
(converting these raw counts to the rates dN and dS). The D1 domain experienced 
selection in favor of non-synonymous mutations (dN/dS > 1) along many branches of the 
tree (shown in red type). Some of the most extreme dN/dS values are found in the New 
World monkey clade. This observation, along with the presence of the potent TRIM5-
CypA restriction factor in the Aotus genus of New World monkeys (196-198), suggests 
that this primate clade may have been antagonized by lentiviruses in their evolutionary 
past. The resulting host-virus arms race drove key residue positions in CD4 to become 
highly diverse both within and between species.  
DISCUSSION  
Here, we have identified the first nonhuman primate species that encodes a CD4 
receptor compatible with Envs from primary, unadapted isolates of HIV-1. These 
permissive CD4 alleles already exist in the genomes of living animals and, unlike 
transgenes made in the lab, can be manipulated through breeding techniques that do not 
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require transgenic approaches. A host-virus arms race appears to exist between CD4 and 
lentiviral env, and this has driven the positive selection of CD4 over evolutionary time 
leaving behind substantial sequence and functional variation in the CD4 alleles encoded 
by different individuals of the same species. As such, we have demonstrated how 
individual monkeys can vary in their ability to support HIV-1 replication, and that gross 
conclusions made about the inability of certain species to support HIV-1 replication need 
to be revisited with population genetics in mind. This study serves as a powerful proof of 
principle that valuable nonhuman primate models may have been overlooked simply 
because individuals with the correct combination of alleles in their genetic background 
have not been identified.  
Besides Spix’s owl monkey, the other two owl monkey species that were 
examined, Nancy Ma’s and Azara’s owl monkeys, encode CD4 alleles with D1 domains 
that are identical to that of permissive Spix’s owl monkey CD4 alleles (Figure 4-1), and 
therefore are likely to also support entry by circulating HIV-1 Envs. This suggests that 
there is still much to be discovered about the genetic capabilities of potential HIV-1 
animal models. 
Systematic exploration of genetic variation at the HIV-1 receptor and restriction 
factor loci in primate populations is now warranted. The literature suggests that there is 
rich genetic variation to be unearthed. SNPs at restriction factor loci have been shown to 
dramatically affect the outcome of infection experiments (28, 122, 160, 199-201). Less is 
known about polymorphism at host loci that encode the HIV-1 receptors, including CD4 
and CCR5. If future studies are successful at finding and combining permissive 
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restriction factor and receptor alleles into a single animal, additional genetic loci like the 
major histocompatibility complex (MHC) and Toll-like receptors will also have to be 
considered (202-205).  
New World monkeys, like the Spix’s owl monkey, are found in Central and South 
America and Mexico. They are generally small in size, have short gestation periods, and 
many are already being used as models for human diseases (206). New World monkeys 
became a subject of interest as potential models for HIV-1 pathogenesis when it was 
observed that their cellular blocks to infection are minimal. For instance, cells from 
various species of squirrel monkeys, marmosets, and tamarins are infected at high levels 
by VSV-G -pseudotyped HIV-1 vectors, suggesting that no restriction factor blocks exist 
after virus entry up to the stage of genome integration (207). Subsequent to this 
observation, primary cells from common marmosets (Callithrix jacchus) and squirrel 
monkeys (Saimiri sciureus) were found to support every phase of HIV-1 replication 
(reverse transcription, integration, transcription, translation, assembly, and budding) 
except for the entry of HIV-1 into cells (189).  
The conclusion that cellular entry is the only barrier to HIV-1 replication in New 
World monkey cells has mostly held true. The one exception has been owl monkeys, 
which have been found to harbor three restriction factors active against HIV-1. The use  
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Figure 4-5: Aotus vociferans (Spix’s owl monkey) express TRIM5-CypA. cDNA from 
three Aotus vociferans individuals along with other New World monkeys was used as a 
template in a PCR reaction to amplify full-length TRIM5-CypA. Primers were designed 
to amplify a 1,424 bp product that represents full-length TRIM5-CypA. Amplicons were 
confirmed via sequencing using PCR primers. 
 
of owl monkeys, including Spix’s owl monkey, as a model organism is not precluded by 
any of these, as it is possible to bypass these restrictions through modifications of HIV-1 
that are independent of Env. First, all species of owl monkeys, including Spix’s owl 
monkey (Figure 4-5), encode the TRIM5-CypA restriction factor (196, 197, 208). It is 
possible to bypass this restriction with a single amino acid mutation in HIV-1 capsid 
protein (G89V) (196, 197). The SIVmac capsid, which is used in all SHIV strains, also is 
not susceptible to owl monkey TRIM5-CypA (209). Second, some species of owl 
monkeys, including the Spix’s owl monkey, have functional versions of the tetherin 
restriction factor that is not overcome by HIV-1 Vpu (176). Third, some species of owl 
monkeys express levels of APOBEC3G high enough to interfere with HIV-1 replication, 
but HIV-1 Vif can partially overcome this block (176).   
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 SHIVs modified to replicate in Spix’s owl monkey may allow experiments to be 
performed with viruses bearing clinically-relevant Envs derived from HIV-1. An even 
better scenario would be if functional receptor alleles could be identified in other New 
World monkey species that do not have these restriction factor blocks. In this case, an 
animal might even be identified that would harbor infection of unmodified HIV-1. 
Bioprospecting into the genomes of nonhuman primates housed in primate centers, 
particularly New World monkeys, could lead to the discovery of more desirable 
genotypes for HIV-1 research. Favorable alleles could then be combined through simple 












The cyclophilin domain of RANBP2 exhibits species-specific 
interactions with lentiviral capsids 
 
 RANBP2/Nup358 is the largest component of the nuclear pore complex and the 
major constituent of the pore’s cytoplasmic filaments. Human immunodeficiency virus 
type 1 (HIV-1) utilizes RANBP2 during the nuclear import of the pre-integration 
complex. Although the exact role of RANBP2 during this process is not fully understood, 
it is clear that the lentiviral capsid protein interacts with the cyclophilin domain of 
RANBP2 (RANCyp). We have previously documented an excess accumulation of 
amino-acid altering mutations and positive selection in RANCyp during the divergence 
of simian primate species. Here, we investigate how the genetic divergence in primate 
RANCyp affects interactions with diverse lentiviral capsids using a TRIM-fusion assay. 
The results show that the region in capsid that mediates interactions with a more well-
characterized cyclophilin molecule, CypA, is also the same region that mediates 
interactions with RANCyp. Using chimeric capsid proteins we investigate how naturally 
occurring evolution in capsid between different primate lentiviruses has responded to 
divergence in RANCyp, and reveal that a recent cross-species transmissions of simian 
immunodeficiency virus (SIV) from chimpanzees into gorillas coincided with changes in 
capsid that allowed the exploitation of gorilla RANCyp. Ancestral reconstructions of 
RANCyp were then used to highlight important amino acid changes that have occurred 
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during the speciation of the great apes. These observations are in line with a scenario 




 Lentiviruses, like HIV-1, are unlike other families of retroviruses in that they are 
capable of infecting non-dividing cells. Although the lentiviral mechanism of infecting 
non-dividing cells is not fully understood, the major determinant is the capsid protein 
(142, 210). Replacing the capsid protein in a retrovirus that can only infect dividing cells 
with HIV-1 capsid confers the ability to infect non-dividing cells. However, there still 
remains some uncertainty as to how the capsid protein interacts with host proteins to 
allow access of the pre-integration complex into the nucleus. Recent whole-genome 
screens for host proteins required for HIV-1 infection revealed that several members of 
the nuclear pore complex, a massive multisubunit complex, which is composed of several 
copies of 30 nuceloporins embedded in the nuclear membrane and is responsible for 
selective nuclear import and export (211, 212), are exploited by lentiviruses to gain 
access to the nucleus (114-118, 213). Subsequently, various studies have confirmed the 
role of several nucleoporins in the nuclear import of the HIV-1 pre-integration complex 
(150, 214-216).  
 In particular, RANBP2 has generated interest as a key player in lentiviral nuclear 
import. RANBP2, also known as Nup358, is the major constituent of the nuclear pore’s 
cytoplasmic filaments (217, 218). There are eight copies of RANBP2 at every nuclear 
 93 
pore that mirror the octagonal symmetry of the pore itself (149, 219). It is a giant protein 
composed of 3225 amino acids and multiple protein domains, including a leucine-rich 
region, eight zinc-finger motifs, four Ran-binding domains, a C-terminal cyclophilin 
domain, and multiple FG-repeat domains that mediate cargo import and export through 
the nuclear pore (217, 218). RANBP2 was first implicated in HIV-1 replication when it 
was shown to regulate the shuttling of HIV-1 Rev protein between the cytoplasm and 
nucleus (220, 221). This protein also affects HIV-1 replication in two independent whole-
genome siRNA screens (115, 116). Subsequently, a more detailed analysis confirmed a 
role for RANBP2 in the import of the HIV-1 pre-integration complex into the nucleus 
during the early phases of the viral life cycle (222). However, whether or not RANBP2 is 
an essential host factor for HIV-1 remains debatable. This is due in part to the 
redundancy in nuclear import pathways used for HIV-1 replication (223). One 
observation that has resolved this issue is that although HIV-1 can use redundant 
pathways for import, these alternative pathways lead to suboptimal integration sites for 
the provirus (223). Therefore, even if HIV-1 uses an alternative pathway to enter the 
nucleus, this is not a sufficient condition for productive infection. Another confounding 
factor is that not all lentiviruses are affected by RANBP2 knockdown (101, 224), which 
brings into question the significance of RANBP2 in the nuclear import of lentiviral pre-
integration complexes.   
 We have documented signatures of positive selection in primate RANBP2 (27). 
These signatures have previously been shown to identify regions of host proteins that are 
critical for modulating interactions with primate lentiviruses (11, 126-128). The presence 
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of this signature in RANBP2 is in support of its critical role in the nuclear import of 
lentiviruses. More specifically, we identified the cyclophilin domain of RANBP2 
(RANCyp) to contain several amino acid residues with a heightened rate of evolution. In 
fact, it was recently shown that RANCyp directly interacts with HIV-1 capsid to mediate 
the nuclear entry of the pre-integration complex (101, 150), and the co-crystal structure 
of this interaction reveals that the amino acids in RANCyp that were identified to be 
evolving under positive selection are either at or near the interaction region (225). In this 
study, we aim to understand how genetic divergence in primate RANCyp affects 
interactions with lentiviral capsids.  
 The RANCyp domain of RANBP2 is homologous to another very important 
protein in HIV-1 biology, cyclophlin A (CypA) (226-231). HIV-1 capsid, along with 
some other lentiviral capsids, interact with CypA to stabilize the capsid core during 
cellular entry (232, 233). Comparing the co-crystals of CypA-capsid and RANCyp-capsid 
shows a high level of similarity, which suggests a conservation of function (225, 234). 
However, why stability of the capsid core would be necessary at the nuclear pore in 
unclear, because it is generally accepted that the core must partially disassemble for the 
pre-integration complex to gain access to the nucleus. One explanation is that although 
the prolyl isomerase activity of CypA mediates stability of the capsid core, the same 
prolyl isomerase activity of RANCyp may promote the disassembly of the capsid core at 
the nuclear pore complex (214). Adding to the complexity of cyclophilin interactions that 
lentiviruses must juggle is the presence of TRIM-CypA fusion molecules in some primate 
species (196, 235, 236). These molecules are antiviral in nature and have resulted from 
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the natural fusion of TRIM5 and CypA genes. Whereas CypA and RANCyp promote the 
replication of lentiviruses, TRIM-CypA is a potent inhibitor of lentiviral replication and 
therefore drastically affects how lentiviruses can maneuver the mutational landscape 
when adapting to new species (28, 237, 238). Because all of these interactions depend on 
capsid and occur early in the viral life cycle, we became interested in further 
characterizing the role of RANCyp during nuclear import and how primate lentiviruses 
maintain interactions with RANCyp while preserving the interaction state with other 
cyclophilin domains.  
 In the current study, how various primate RANCyp alleles interact with diverse 
lentiviral capsids was investigated. We began by comparing and contrasting the 
evolutionary modes of CypA and RANCyp to gain insight into how these two molecules 
have been shaped during the divergence of primates. Using a TRIM-fusion assay in 
combination with capsid mutants, we functionally characterized the genetic divergence of 
primate RANCyps, identified the region in capsid that is critical for interaction with 
RANCyp, revealed amino acids in RANCyp that mediate interactions with capsid, and 
showed that a natural cross-species transmission of a primate lentivirus coincided with 
adaptation to utilize the RANCyp in the new host species. Together, these results lend 
credence to the role of RANBP2 during the HIV-1 life cycle and are consistent with a 
scenario where some cross-species transmissions of primate lentiviruses may require the 




MATERIALS AND METHODS 
Primate biomaterials used 
 Primary and immortalized primate cell lines from primate species were grown in 
standard media supplemented with 15% fetal bovine serum at 37oC and in 5% CO2.  
 
Primate RANBP2 and CypA gene sequences  
 Human Refseq sequences for RANBP2 and CypA were obtained from the NCBI 
nucleotide database. Chimpanzee, orangutan, rhesus macaque, and marmoset gene 
sequences were obtained from the UCSC genome database (http://genome.ucsc.edu/) 
using the BLAT alignment tool. Genes were sequenced from 22 additional primate 
species, and from chimpanzee, orangutan, rhesus and marmoset in instances where the 
genome-project sequences were of poor quality. PCR or RT-PCR was performed from 
total RNA, gDNA, or cDNA with SuperScript III One-Step RT-PCR system with 
Platinum Taq (Invitrogen, #12574-018), PCR SuperMix High Fidelity (Invitrogen, 
#10790-020), or Phusion High Fidelity PCR Master Mix (NEB, #F-531S). Primers were 
designed in conserved regions of the 5’ or 3’ UTR in order to amplify full open reading 
frames.  
 
PAML analysis  
 Codon models were tested with codeml in the PAML 4.1 software package (93). 
To detect selection, multiple alignments were fit to the NSsites models M8a (neutral 
model, codon values of dN/dS fit to a beta distribution plus an extra codon class fixed at 
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dN/dS = 1) and M8 (positive selection model, similar to M8a but with the extra class 
allowed to be dN/dS >1). A likelihood ratio test was performed to assess whether 
permitting codons to evolve under positive selection gives a significantly better fit to the 
data (model comparison M8a vs. M8). In situations where the null model could be 
rejected (p < 0.05), posterior probabilities were assigned to individual codons belonging 
to the class of codons with dN/dS > 1. Residues under positive selection were mapped 
onto existing crystal structures using MacPyMol (v.0.99; http://pymol.sourceforge.net/). 
A branch model was used to calculate the most likely locations of non-synonymous and 
synonymous changes (N:S in Figure 5-1) along each lineage in the primate phylogeny 
used in this study.  
 
TRIM-CypA and TRIM-RANCyp expression constructs  
 HA-tagged owl monkey TRIM-CypA in the pLPCX expression vector was a kind 
gift from Michael Emerman. TRIM-RANCyps were constructed by generating fragments 
with 20-25bp overlapping regions of owl monkey TRIM-CypA and RANCyp. 
Overlapping fragments were spliced together using a PCR reaction and each fragment as 
a template with outside flanking primers. Constructs were TA-cloned into pCR4 
(Invitrogen, #K4575-01). An N-terminal HA tag was added using a PCR reaction and 
these tagged constructs were TA-cloned into the Gateway entry plasmid pCR8 
(Invitrogen, #K2500-20). An LR Clonase II reaction (Invitrogen, #11791-100) was used 
to move these constructs into a Gateway-converted pLPCX retroviral vector (Clontech, # 
631511). Ancestral TRIM-RANCyp alleles were generated using PfuTurbo DNA 
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polymerase (Stratagene, #600250). Parental pLPCX plasmids were used as a template 
along with primers containing the mutations of interest.  
 
Generation of stable cell lines  
 To generate cell lines that stably express owl monkey TRIM-CypA and TRIM-
RANCyps, retroviral vectors were used to transduce CRFK cells (ATCC). To generate 
the retroviral vectors, 293T cells were seeded at a concentration of 1x106 cells/well in a 
6-well dish. 24 hours later each well was transfected with 2 mg pLPCX construct (empty 
or encoding the gene fragment of interest), 1 µg pCS2-mGP encoding MLV gag-pol 
(142), and 0.2 µg pC-VSV-G at a final 1:3 ratio of DNA to TransIT-293 (µg DNA : ml 
TransIT-293). Supernatants were collected after 48 hours, passed through a 0.2 µm filter, 
and used to infect CRFK cells grown in DMEM supplemented with 10% fetal bovine 
serum, 100 IU/ml penicillin, 100 µg/ml streptomycin, and 2 mM L-glutamine. After 24 
hours, media containing 8 µg/ml puromycin was added to select for transduced cells. 
Expression of TRIM-CypA and TRIM-RANCyp constructs was detected by Western 
blot.  
 
Antibodies and Western blot analysis  
 Cell lines were grown to confluency in a 6-well dish, collected using a cell 
scraper, and lysed in a buffer containing 150 mM NaCl, 50 mM Tris-HCl (pH 7.4), 1% 
NP-40, and Complete protease inhibitor (Roche, #11836170001). After quantitation of 
protein concentration using a Bradford assay, 30 µg of whole cell extract was resolved 
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using a 10% polyacrylamide gel and transferred to a nitrocellulose membrane. HA-tagged 
constructs were detected using a 1:5000 dilution of anti-HA-peroxidase antibody (Roche, 
#12013819001). Maturation of Gag protein was monitored using a 1:1000 dilution of 
anti-p24 (AIDS reagent database, #183-H12-5C). β-actin was also detected for a loading 
control using a 1:1000 dilution of mouse anti-β-actin (Santa Cruz, #sc-47778). A 
1:10,000 dilution of donkey mouse-specific horseradish peroxidase-conjugated antibody 
(Thermo Scientific, #32430) was used as a secondary probe. Blots were developed using 
the ECL Plus detection reagent (GE Healthcare, #RPN2132).  
 
Retroviral integration assays  
 Viruses for single-cycle infection assays were packaged in 293T cells by co-
transfection of plasmids encoding viral proteins and VSV-G, along with a transfer vector, 
as follows: HIV-1 and cyclophilin binding loop mutants (pMDLg/pRRE, pRSV-Rev, 
pMD2.G, pRRLSIN.cPPT.PGK-GFP.WPRE; all available from Addgene), FIV (pFP93 
(144), pC-VSV-G, pGIN-SIN:GFP (144)). After 48 hours, supernatant containing viruses 
was harvested, filtered, and frozen. For infection assays, CRFK stable cells lines were 
plated at a concentration of 7.5x104 cells/well in a 24-well plate and infected with HIV-1, 
cyclophilin binding loop mutants, or FIV the following day. Two days post-infection, 
cells were fixed, washed, resuspended in PBS supplemented with 1% FBS, and analyzed 
by flow cytometry for expression of GFP using the BD Bioscience Fortessa cell analyzer. 




Cyclophilin-binding loop capsid mutants  
 pMDLg/pRRE expressing HIV-1 gag-pol was used as a template for site-directed 
mutagenesis using PfuTurbo DNA polymerase (Stratagene, #600250).  
 
RESULTS 
CypA and RANCyp have contrasting evolutionary histories in primates 
 CypA and RANCyp interact with HIV-1 capsid in a highly similar fashion (Figure 
5-1A) (225, 234). Alignment of homologous regions in CypA-capsid and RANCyp-
capsid co-crystals results in an RMSD = 1.323Å, indicative of a conserved interaction. 
This observation is consistent with the functional conservation of HIV-1 capsid prolyl 
isomerase activity of both CypA and RANCyp, however, it conflicts with the earlier 
report that RANBP2 has evolved under positive selection in the primate lineage (27). To 
further investigate this paradox, we extended the analysis of the RANCyp domain and 
performed a parallel evolutionary analysis of CypA. To do this, we generated 7 additional 
primate RANCyp sequences and 22 primate CypA sequences. This allowed us to 
construct alignments of CypA and RANCyp, each composed of a total of 27 primate 
species (Figure 5-1B).  
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Figure 5-1: Contrasting evolutionary modes of CypA and RANCyp. (A) Co-crystal 
structures of CypA bound to HIV-1 capsid (left, pdb:1AK4) and RANCyp bound to HIV-
1 capsid (right, pdb:4LQW). Amino acid residues under positive selection are shown as 
red spheres. (B) Phylogenetic tree of the primates used in the evolutionary analysis. 
Numbers shown in parenthesis are (number of non-synonymous changes : number of 
synonymous changes) as calculated using an ancestral reconstruction in the codeml 
program of PAML. Lineages with numbers if red have experienced non-synonymous 
changes. (C) Results of a site-based evolutionary analysis using the codeml program of 
PAML. Here, a model that allows positive selection (M8) was compared against a null 
model that does not allow positive selection (M8a). Amino acid numbering is relative to 




















 The evolutionary history of CypA and RANCyp was studied by employing 
maximum likelihood codon models of evolution as provided in the PAML package (239). 
First, we constructed ancestral sequences at each node of the primate phylogeny to track 
where non-synonymous and synonymous DNA mutations have occurred (Figure 5-1B) 
(194). CypA is almost entirely conserved in the primate lineage, with only two non-
synonymous mutations (E84D, A117V) occurring on the lineage leading to New World 
monkeys. Neither of these mutations have been implicated in HIV-1 biology, although 
most research in this context has been performed on the TRIM5-CypA fusion molecule 
(240-243). On the other hand, RANCyp has a dynamic evolutionary history. Non-
synonymous mutations have accumulated on 19 branches throughout the primate 
phylogeny (branches with red labeling in Figure 5-1B), often in excess of synonymous 
mutations. Nearly half of these branches are located in the hominoid clade, where the 
most rapidly diverging branch leading to gorilla is located. Site-based tests were also 
used in PAML to identify individual codon positions that are evolving under positive 
selection (see Methods). There was no evidence of positive selection in CypA, however, 
an intense signal of positive selection was identified in RANCyp that was consistent with 
a previous analysis of this domain (Figure 5-1C) (27). Therefore, CypA and RANCyp 
have contrasting evolutionary histories even though their structures and interactions with 
HIV-1 capsid are nearly identical.  
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Figure 5-2: TRIM-RANCyp fusion proteins differentially restrict divergent 
lentiviruses. (A) Protein schematic of TRIM-fusion constructs that are stably expressed 
in CRFK cells. (B) Protein alignment of the RANCyp alleles that were constructed were 
placed in a phylogenetic context. The region shown encompasses the three amino acid 
positions under positive selection, which are each highlighted in yellow. Amino acid 
numbering is relative to homologous positions in CypA. (C) Single-cycle infection assay 
of CRFK stable cell lines using either HIV-1 or FIV pseudotyped virus containing a GFP 
reporter. Represented as relative infectivity relative to the empty vector control. 
Expression of each fusion construct was observed using Western blotting of whole cell 
lysates.    
 
Divergence in primate RANCyp affects binding to lentiviruses 
 The evolutionary history of primate RANCyp suggests that there may be 
functional divergence in this domain with respect to capsid binding. To test this, a 
RANCyp-capsid interaction assay that has been utilized to study host interactions with 
capsid was used (Figure 5-2) (101, 158, 244, 245). A chimeric protein that consists of the 
human RANCyp domain fused with the core ‘RBCC’ motif of TRIM5α (human TRIM-
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RANCyp) was shown to restrict HIV-1 infection similarly to the owl monkey TRIM-
CypA allele, indicative of a human RANCyp-capsid interaction (101). We recapitulated 
these results and also generated six additional HA-tagged TRIM-RANCyp alleles 
representing various primate RANCyps (Figure 5-2A,B). These particular primate 
species were chosen to encompass the extent of sequence divergence in the region 
containing amino acid residues under positive selection. Stable cell lines expressing these 
TRIM-RANCyp alleles were generated in CRFK cells using a lentiviral vector system.  
 These TRIM-RANCyp cell lines were then challeneged with single-cycle, VSV-G 
pseudotyped, HIV-1 (Figure 5-2C). As expected, human TRIM-RANCyp and owl 
monkey TRIM-CypA interact with and restrict the HIV-1 capsid. The other 6 TRIM-
RANCyp alleles behaved similarly to human TRIM-RANCyp, with the exception of the 
gorilla allele. This allele only restricted HIV-1 about 2-fold, which suggests that gorilla 
RANCyp does not interact with HIV-1 capsid as well as the other primate RANCyps 
tested. To be certain that gorilla TRIM-RANCyp is actually an active molecule and the 
lack of effect on HIV-1 is not simply due to misfolding of the protein, the panel of 
primate TRIM-RANCyp alleles was tested against a feline immunodeficiency virus (FIV) 
construct and confirmed to interact with and restrict FIV capsid (Figure 5-2C). Therefore, 
gorilla TRIM-RANCyp is a fully functional molecule that does not restrict HIV-1, but 
does restrict FIV capsid. Because there are only a total of 5 amino acid differences 
between human and gorilla TRIM-RANCyp, it is clear that the significant difference 
between these alleles in the infection assays is due to a small number of mutations in the 
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RANCyp domain. These data suggest that HIV-1 would be incapable of utilizing the 












Figure 5-3: Cyclophilin binding loop of capsid mediates interaction with RANCyp. 
(A) Crystal structures of hexameric (pdb:3GV2) and monomeric (pdb:1AK4) HIV-1 
capsid forms. Region shown in red is the cyclophilin A binding loop (top). Region of 
gag-pol genomic region where the cyclophilin A binding loop is located (middle). An 
alignment of various lentiviral capsids used to generate mutants. ’CypA binding loop’ is 
highlighted in gray (bottom). (B) Titering of mutant viruses on CRFK reporter cells. (C) 
Western blot of capsid mutants using an anti-p24 antibody to show proper maturation of 
mutant capsids. Gag-pol plasmids were transfected into 293T cells, and whole cell extract 
(WCE) was harvested at 48 hours post transfection. (D) Single-cycle infection assay 
using indicated TRIM-RANCyp stable cells lines and viruses that have the indicated 
‘CypA binding loop’ in the HIV backbone. Representated as relative infectivity relative 
to empty vector control. A Western blot is also shown for the expression of the TRIM-































CypA binding loop in capsid affects RANCyp interactions 
 After establishing that divergence in primate RANCyp can affect binding to 
capsid, we established the genetic determinants of this interaction in capsid sequences. At 
this point, we focused exclusively on the human, chimpanzee, and gorilla RANBP2 
alleles for two reasons. First, a phenotypic difference with the gorilla allele was observed 
in the infection assays. Second, all three of these species have extant lentiviruses 
circulating in their populations and thus presents a convenient system for understanding 
the potential role of RANBP2 during cross-species transmissions (195). In relation to this 
point, chimpanzees harbor SIVcpz, which is currently thought to have been the 
progenitor of HIV-1 in humans and SIVgor in gorillas (246). With these considerations in 
mind, how genetic differences in lentiviral capsids affect binding to RANCyp was 
investigated.  
 We hypothesized that the CypA binding loop in capsid might also be the genetic 
determinant for RANCyp binding. To test this, mutant capsid chimeras were generated by 
replacing this 10 amino acid CypA binding loop in HIV-1 with the homologous region 
from other lentiviruses (Figure 5-3A, CypA binding loop is red in crystal structures). 
These mutants were made via site-directed mutagenesis of the HIV-1 gag-pol expression 
vector from the pseudotyping system. To ensure the viability of these mutants, single-
cycle HIV-1 virus harboring the mutant CypA binding loops was produced and titered on 
CRFK cells (Figure 5-3B). Proper Gag maturation was confirmed by probing 293T 
producer cell lysates with a p24-specific antibody (Figure 5-3C). No significant 
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difference in titers or Gag maturation were observed, therefore these mutant viruses were 
used for downstream analyses.  
 It was previously shown that SIVmac does not utilize RANBP2 for entry into the 
nucleus (101). Therefore, if the CypA binding loop in capsid mediates interactions with 
RANBP2, then the HIV/SIVmac chimeric capsid should not bind RANCyp. Indeed, 
when the human, chimpanzee, and gorilla TRIM-RANCyp harboring cell lines were 
challenged with HIV/SIVmac chimeric virus, the virus was uninhibited (Figure 5-3D). 
This indicates that the 10 amino acid patch in capsid known as the CypA binding loop 
completely determines interactions with TRIM-RANCyp, and also suggests that this 
region of capsid could be critical for interactions with RANCyp in the context of full-
length RANBP2 at the nuclear pore. Further, the assay used here has been shown to 
recapitulate both positive and negative interactions between RANCyp and lentiviral 
capsids.  
 
Natural evolution of capsid correlates to RANCyp utilization 
 We now turn to understand how the dynamic interaction of RANCyp and 
lentiviral capsids has played out in a natural context by studying how this interaction has 
evolved during known cross-species transmissions. There are currently over forty primate 
species that are naturally infected with extant lentiviruses (247, 248). Collectively, these  
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Figure 5-4: Capsid interaction with RANCyp is a potential barrier to cross-species 
transmission of lentiviruses. (A) Schematic of the natural cross-species transmissions of 
lentiviruses that have occurred amongst the species shown. Only the gag coding sequence 
has been taken into account. (B) Single-cycle infection assays of three primate TRIM-
RANCyp cells lines using mutant capsids with the indicated ‘CypA binding loop’ 
inserted into the HIV-1 backbone. Represented as relative infectivity relative to empty 
vector (empty vector data not shown). 
 
SIV strains constitute a large reservoir for cross-species transmissions amongst their 
primate hosts in Africa (249-251). Here, we will focus on two well-documented 
transmissions that have preceded the emergence of HIV-1 (Figure 5-4A). First, SIVcpz in 
chimpanzees emerged as a recombination event of SIV strains from red-capped 
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mangabeys (SIVrcm), greater spot-nosed monkeys (SIVgsn), mustached monkeys 
(SIVmus), and mona monkeys (SIVmon) (252). However, the entire region of the SIVcpz 
gag coding sequence descended from SIVrcm, and so for the purpose of studying the 
RANCyp-capsid interaction, SIVrcm can be considered as the most recent ancestor of 
SIVcpz. Second, SIVgor in gorillas emerged after SIVcpz infected and adapted to gorilla 
populations (246, 253). These two events are diagrammed in Figure 5-4A and will serve 
as the prime motivation for the following experiments.  
 Using the TRIM-RANCyp assay described above we studied how the red-capped 
mangabey, chimpanzee, and gorilla alleles interact with capsid mutants (HIV-1 backbone 
with chimeric CypA binding loops) representing SIVrcm, SIVcpz, SIVgor, and HIV-1. 
More specifically, the TRIM-RANCyp alleles were challenged with three red-capped 
mangabey derived strains (SIVrcmCAM, SIVrcmGAB, SIVrcmNG), three chimpanzee-
derived strains (HIV group M, SIVcpzCAM, SIVcpzTAN), and three gorilla-derived 
strains (HIV group P, SIVgorBQ, SIVgorCP) (Figure 5-4B). All capsid variants are 
recognized and inhibited by the red-capped mangabey TRIM-RANCyp allele. This shows 
that sequence divergence in capsid does not affect its ability to bind red-capped 
mangabey RANCyp. However, chimp and gorilla TRIM-RANCyps each have distinct 
interaction phenotypes with the various capsid mutants. For example, chimpanzee TRIM-
RANCyp interacts only with chimp-derived strains and gorilla TRIM-RANCyp interacts 
with only red-capped mangabey and gorilla derived strains. Two points of interpretation 
can be made. First, all three of these TRIM-RANCyp alleles interact with capsids derived 
from that same host (i.e. red-capped mangabey TRIM-RANCyp interacts with red-capped 
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mangabey derived SIV strains, chimpanzee TRIM-RANCyp interacts with chimpanzee 
derived SIV strains). This is to be expected if SIVrcm, SIVcpz, and SIVgor utilize 
RANBP2 during their life cycles to gain access to the nucleus. Another important point is 
evident only when considering the transmission of SIVcpz from chimpanzees into 
gorillas, which eventually evolved to become SIVgor. In this case, the SIVcpz strains 
were adapted to interact with chimpanzee RANCyp, but not gorilla RANCyp. However, 
after evolving to become SIVgor, the virus gained the ability to interact with gorilla 
RANCyp and lost the ability to interact with chimpanzee RANCyp. Our interpretation is 
that during the course of cross-species transmission, the ability to utilize RANBP2 may 
have been critical enough to warrant adaptation to gain this function. The net result was 
adaptation to utilize the RANBP2 of a new host at the expense of losing this function in 
the previous host.  
 Next we tested how the zoonotic events that lead to the emergence of HIV-1 
might have been affected by divergence in RANCyp. The main group of HIV-1 emerged 
into the human population early in the 20th century (254), and since then several 
independent zoonoses have occurred that have led to the emergence of various HIV-1 
strains (195). All of the known strains of HIV-1 were passed from either chimpanzees or 
gorillas into humans. Therefore, we proceeded to test how the RANCyp-capsid 
interaction was shaped during these events. We found that capsid mutants representing 
SIVcpz and SIVgor sequences were already capable of binding human RANCyp (Figure  
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Figure 5-5: Capsid interaction with RANCyp was conserved during SIV zoonosis. 
(A) Schematic of the zoonotic event that led to the emergence of HIV-1 group M (left). 
Single-cycle infection assay of TRIM-RANCyp cells lines using mutant capsids with the 
indicated ‘CypA binding loop’ inserted into the HIV-1 backbone. Represented as relative 
infectivity relative to empty vector (right). (B) Schematic of the zoonotic event that led to 
the emergence of HIV-1 group P (left). Single-cycle infection assay of TRIM-RANCyp 
cells lines using mutant capsids with the indicated ‘CypA binding loop’ inserted into the 
HIV-1 backbone. Represented as relative infectivity relative to empty vector (right).   
 
5-5). Additionally, this interaction was maintained as SIVcpz and SIVgor evolved into 
HIV group M and HIV group P, respectively. Therefore, adaptation to utilize human 
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RANBP2 was not an obstacle met by SIVcpz and SIVgor strains that crossed the species 
barrier into humans.  
 
Ancestral reconstruction of great ape RANCyp identifies critical residues 
 The human, chimpanzee, and gorilla RANCyp alleles are all very similar, with at 
most five amino acid differences given any pairwise comparison. These differences are 
shown in both a phylogenetic context and an amino acid alignment (Figure 5-6A,B). The 
ancestor of this clade has been reconstructed and has also been included it in the Figure 
5-6B alignment. Each species has accumulated its own unique mutations since 
divergence from the ancestor and are shown in parentheses next to the phylogenetic tree. 
Residues V113, H121, and Q103 have recently been shown to make important contacts in 
the RANCyp-capsid co-crystal (225), and therefore divergence at these sites amongst the 
primate alleles is likely to affect capsid interactions.  
 To test this we generated ancestral TRIM-RANCyp alleles and stably expressed 
them in CRFK cells (Figure 5-6C). Three gorilla-specific mutations (G75R, K82R, and 
Q103E) were used because the effects of the other mutations (F113V, H121L, and 
K149E) can be inferred from previous experiments, as the ancestral RANCyp allele is 
identical to the red-capped mangabey RANCyp allele (Figure 5-2 and 5-4). All possible 
single, double, and triple mutants using the gorilla mutations were generated relative to 
the ancestral allele and tested their interactions with various capsid mutants using the 
TRIM-fusion assay (Figure 5-6D). All representative capsid mutants that were tested 
(HIV-1, SIVcpz, SIVgor, and FIV) bound the ancestral RANCyp allele. Interestingly,  
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Figure 5-6: Ancestral reconstruction of RANCyp reveals critical amino acid 
residues. (A) Amino acid changes along the lineages leading to human, chimpanzee, and 
gorilla RANCyp placed in a phylogenetic context. (B) Alignment of RANCyp alleles 
used to construct the ancestral allele. Amino acid numbering is relative to CypA. (C) 
Western blot showing the expression and labels for the ancestral RANCyp alleles that are 
stably expressed in CRFK cells. (D) Infection of the ancestral RANCyp cell lines using 
mutant capsids with the indicated ‘CypA binding loop’ inserted into the HIV-1 backbone.  
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none of the mutations tested affected binding to FIV capsid, which was invariably 
maintained. Combined with data from Figure 5-1, all the divergence in primate RANCyp 
discussed in this study has no effect on binding FIV capsid. Therefore, the mutations that 
have accumulated in primate RANCyps seem to be in response to primate lentiviral 
capsids. All three of the gorilla-specific mutations had significant effects, although 
sometimes in different contexts. For example, the G75R mutation always results in a loss 
of binding to HIV-1 and SIV, whereas the K82R had an effect on SIVgor capsid binding 
in conjunction with the Q103E mutation. The SIVgor capsid mutant is the only variant 
that is able to bind the triple mutant, which is expected since this virus has adapted to use 
gorilla RANCyp. This is also the only capsid mutant whose binding to RANCyp is 
affected by the isolated Q103E mutation. These patterns of host- and viral-specific 
interactions are suggestive of RANCyp being a barrier to cross-species transmission. 
While the order with which these mutations arose in the gorilla lineage is unknown, it is 
clear that they had the potential to inhibit their utilization by lentiviral capsids.  
 
DISCUSSION 
 The cyclophilin domain of RANBP2 has been shown to be the main determinant 
of the RANBP2-capsid interaction (150). Here, we show that divergence in primate 
RANCyp affects interactions with a diverse set of capsid mutants that are representative 
of extant lentiviruses. Although the patterns of RANBP2 utilization by primate 
lentiviruses has yet to be established, the data presented here suggest a highly dynamic 
process, whereby interactions between RANCyp and capsid have been continuously 
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made and broken over evolutionary time. These observations, in combination with the 
evolutionary analysis that RANCyp has evolved under positive selection, are consistent 
with a scenario where the cylclophilin domain of RANBP2 is engaged in an arms race 
with capsid from primate lentiviruses.  
 In contrast to well-documented cases of arms races between HIV-1 and restriction 
factors (17, 19, 38, 85, 202), RANBP2 is an essential housekeeping gene. While there are 
now several documented cases of housekeeping genes rapidly evolving (24, 27, 138), the 
current study is the first to show that a component of the nuclear pore may be involved in 
an arms race. The nuclear pore and the cellular process of nuclear trafficking are both 
common targets of antagonism and utilization by viruses (255). However, it has been 
unclear how the host might counteract the hijacking of nuclear pore and trafficking 
proteins. Genes that encode proteins that constitute the nuclear pore or are involved in 
nuclear trafficking are generally well conserved in primates (data not shown), whereas 
only RANBP2 and Nup153 have been shown to be evolving under positive selection (27). 
Although the role of divergence in primate Nup153 has yet to be explored, there is some 
overlap between positively selected sites and the regions known to mediate interactions 
with HIV-1 capsid (256).  
 This study reveals a strategy by which a nuclear pore protein, RANBP2, could 
avoid being utilized by lentiviral capsids. Specifically, the accumulation of amino acid-
altering substitutions in RANCyp seems to force adaptation in the cyclophilin binding 
loop of lentiviral capsid. It is important to note that, because RANBP2 utilization by 
lentiviruses has not been broadly explored, it is possible that a given lentivirus might 
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adapt by bypassing the RANBP2 nuclear import pathway all together. This strategy is 
evident with the SIVmac lentivirus, which is cyclophilin-independent and does not bind 
RANCyp (Figure 5-3)(101, 226). Nevertheless, SIVmac does access the nucleus of non-
dividing cells by a mechanism that has yet to be established. Therefore, while RANCyp 
and capsid seem to be involved in genetic conflict, some primate lentiviruses may 
completely step out of this conflict by adapting to use a RANBP2-independent nuclear 
import pathway.  
 The results shown in Figure 5-4 are consistent with lentivral capsids adapting to 
utilize RANCyp of a new species during cross-species transmission events. This would 
be indicative of RANBP2 being a genetic barrier to cross-species transmissions of primate 
lentiviruses in nature. Most host genes that have been documented to be genetic barriers 
to transmission are either restriction factors of the innate immune system (28, 199) or cell 
surface receptors (25, 26, 89, 257). To determine with certainty that RANBP2 is a bona 
fide genetic barrier would require more extensive analysis of in vivo infections of 
primates. Studies in the past have employed retrospective sequence analysis of primate 
center virus samples to show how SIVagm (African green monkey) adapted to rhesus 
macaque TRIM5α and APOBEC3G as it evolved into SIVmac. It will be impossible to 
find a similar dataset to study how SIVcpz adapted to gorilla RANBP2 as it evolved into 
SIVgor due to the heavy conservation restrictions on chimpanzees and gorillas. However, 
a cell-based assay where SIVcpz virus is passged on gorilla cells until it becomes well 
adapated is possible. The resulting viruses could then be sequenced and compared to the 
parental virus to look for adaptive mutations in the cyclophilin binding domain of capsid. 
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Until then, our data is only suggestive of RANBP2 acting as a genetic barrier to cross-
species transmission of primate lentiviruses.  
 To study the interaction between RANCyp and capsid, we utilized a TRIM-fusion 
assay that is becoming common for studying interactions with capsid (101, 158, 256, 
258). By fusing the RANCyp domain downstream of the core domain of TRIM5α, we 
were able to use the restriction activity of this molecule as a proxy for interactions with 
capsid. However, there are several caveats to this method. First, these fusion molecules 
are located in the cytoplasm, which is distinct from the nuclear pore localization of full-
length RANBP2 (259). Second, TRIM5α (and TRIM-fusion proteins) restricts 
retroviruses by forming a large hexameric lattice around the intact capsid core (260), 
whereas eight copies of RANBP2 extend out from the cytoplasmic face of the nuclear 
pore. Therefore, the architecture of the interaction between TRIM-RANCyp and capsid is 
very different than that of full-length RANBP2 and capsid. Third, It has been shown that 
a RANBP2 molecule that does not contain its cyclophilin domain will still bind capsid, 
although not as avidly (150). This suggests that there are regions of RANBP2 outside of 
the cyclophilin domain that are important for binding, and the TRIM-RANCyp assay 
used here, does not explore these regions. Another study even shows that the cyclophilin 
domain of RANBP2 is completely dispensible for HIV-1 replication (216). These 
conflicting reports will need to be reconciled in future studies, and the true role of the 
cyclophilin domain of RANBP2 remains to be fully characterized.  
 Nevertheless, there is evidence that the TRIM-RANCyp assay does faithfully 
predict interactions between full-length RANBP2 and capsid. In Figure 5-2, the assay 
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recapitulated the observation that SIVmac does not utilize human RANBP2 during 
infection. Another group has shown that lentiviral capsids that are sensitive to RANBP2 
knockdown using siRNA are also susceptible to TRIM-RANCyp (224). An important 
observation of this study is that none of the lentiviral capsids that were sensitive to 
TRIM-RANCyp were shown to be insensitive to siRNA knockdown of RANBP2. 
Therefore, although experiments using full-length RANBP2 are certainly warranted, the 
TRIM-RANCyp assay is a convenient and accurate assay to use as a substitute. It is 
especially appealing considering that RANBP2 is over 3000 amino acids in length, which 
makes expression, purification, and biochemical assays using this protein particularly 
challenging.  
 The ability of primate lentiviruses to infect non-dividing cells by traversing the 
nuclear pore has been a long standing mystery. Only recently have molecular details 
come to light, which highlight capsid as a main determinant of nuclear access (210). Even 
more recently, specific nucleoporins, such a RANBP2, Nup214, Nup153, and Nup98, 
have all been shown to be involved in the nuclear import of the pre-integration complex 
of HIV-1 (150). We have now shown that the rapid evolution in the cyclophilin domain 
of RANBP2 affects interactions with lentiviral capsids in a species-specific manner, 





Disruption of human-influenza evolutionary equilibrium reveals a 
novel restriction mechanism 
 Influenza A virus non-structural protein 1 (NS1) antagonizes the host interferon 
response through various mechanisms. One proposed mechanism involves binding the 
ubiquitin ligase TRIM25 and thereby inhibiting the ubiquitination of RIG-I and 
downstream signaling of the type I interferon response. However, the binding of TRIM25 
by NS1s of various influenza strains is not perfectly correlated with inhibition of 
interferon signaling, suggesting that NS1 might bind TRIM25 to inhibit another antiviral 
function of TRIM25. Using a combination of evolutionary and functional analyses, we 
are able to show that TRIM25 binds directly to incoming influenza viral 
ribonucleoproteins in an RNA-dependent manner. This binding restricts influenza 
replication by inhibiting the transcription of viral RNA. The linker 2 domain of TRIM25 
confers this antiviral activity and has been the target of recurrent positive selection during 
primate evolution, indicative of an ancient and ongoing genetic conflict between TRIM25 







Influenza A viruse (IAV) causes annual epidemics that lead to severe respiratory 
disease in humans (261). Worldwide, millions of people are infected and hundreds of 
thousands succumb every year (262). The success of IAV is in no small part due to its 
ability to antagonize the host immune response. Specifically, one of IAV’s eight RNA 
segments encodes non-structural protein 1 (NS1), which suppresses the innate immune 
system by shutting down host protein production and inhibiting the activation of 
interferon through various mechanisms (263, 264). One such mechanism is the binding 
and inhibition of the E3 ubiquitin ligase TRIM25 (264). TRIM25 is a member of the 
TRIM family of innate immunity proteins (135, 259, 265) and promotes the activation of 
the type I interferon response by ubiquitinating RIG-I, either covalently (266) or non-
covalently (267). TRIM25 binding by NS1 inhibits the ubiquitination activity of TRIM25 
and is thought to block the activation of the interferon response (264). However, some 
primary isolates of IAV do not inhibit the interferon response, even though their NS1 
proteins bind TRIM25 (72). The lack of correlation between NS1-TRIM25 binding and 
interferon suppression led to the hypothesis that TRIM25 might have another function 






Figure 6-1: TRIM25 is under positive selection in primates. (A) Cladogram of the 
primate species represented in the TRIM25 evolutionary analysis. (B) Domain diagram of 
TRIM25. The amino acid positions at domain boundaries are shown. Relevant statistics 
for individual amino acid positions are shown for the M8 model in PAML and Relative 
Effects Likelihood (REL). Red lines indicate significance cutoffs. Gray box highlights 
the Linker 2 domain.    
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RESULTS 
 Further evidence of a novel TRIM25 function is provided by the evolutionary 
history of TRIM25. TRIM25 was sequenced from a panel of 20 simian primates and 
found to be evolving rapidly under positive selection (Figure 6-1 and Table 6-1). Most 
amino acid residues experiencing positive are in the linker 2 (L2) domain of TRIM25, 
distinct from the coiled-coil domain that is known to mediate interactions with NS1 (268) 
(Figure 6-1 and Table 6-1). This suggests that amino acids in the L2 domain of TRIM25 
have been rapidly selected for adaptation. Currently, the L2 domain has only been 
implicated in RNA binding, but it was not shown to be sufficient (269). The observation 
that TRIM25 is under positive selection in primates is in agreement with a previous study 
carried out on a more limited dataset (270). The evolutionary signature of positive 
selection in primates can highlight specific regions of proteins that interact with viruses 
and, in some cases, even be used to discover novel functions of previously 
uncharacterized protein domains (87, 126, 127). 
 Studies that use primate alleles to probe host-virus interactions have led to 
molecular insights about how viruses adapt to a host’s innate immune response (51, 87, 
88, 271). More importantly, they have highlighted the necessity to use nonhuman primate 
alleles when studying human viruses (133). Because human viruses have adapted to 
replicate in a human cell, they have developed mechanisms to bypass human antiviral 
factors. Therefore, by challenging a virus with nonhuman primate alleles, evolutionary 




Figure 6-2: Primate TRIM25 alleles restrict influenza A virus protein levels. CRFK 
cells were used to stably express different FLAG-tagged TRIM25 alleles. Each cell line 
was infected at 0.1 MOI with the Udorn H3N2 influenza A virus. Whole-cell protein 
extracts were collected at 12 hours post infection and probed for the presence of the 
indicated proteins. A β−actin blot is shown as a loading control.  
 
 
This strategy was used with TRIM25 to determine if its evolutionary history in 
primates has impacted interactions with IAV. Cell lines that stably express FLAG-tagged 
human, orangutan, agile gibbon, or talapoin TRIM25 were generated, along with an 
empty control cell line (Figure 6-2). Each of these cell lines was then subjected to a 
single-cycle infection using the Udorn H3N2 strain of IAV at 0.1 MOI. At 12 hours post 
infection, whole-cell lysate was obtained and probed for the presence of various influenza 
proteins using a Udorn-specific antibody that recognizes hemagglutinin (HA), 
nucleoprotein (NP), and matrix protein 1 (M1) (Figure 6-2). Primate TRIM25 alleles 
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restrict IAV protein levels to varying degrees. Therefore, genetic divergence in primate 
TRIM25 does affect antiviral activity against IAV.   
 
Figure 6-3: Human and agile gibbon TRIM25 restrict influenza A virus replication. 
CRFK cells stably expressing the indicated TRIM25 allele were infected with Udorn 
H3N2 influenza A virus at 0.02 MOI. Supernatant was collected at the indicated time 
points and titers were measured via plaque assay on an MDCK reporter cell line. Each 
growth curve was performed in triplicate and error bars represent the standard deviation 
of the mean. (B) Whole cell lysates from a single-cycle infection of CRFK cells stably 
expressing the indicated construct were probed for influenza virus proteins. 
 
 Next the antiviral activity of TRIM25 was tested during the full replication cycle 
of IAV. We focus on only the human and agile gibbon TRIM25 cell lines due to their 
large phenotypic differences (Figure 6-3). During a multiple-cycle infection, both the 
human and agile gibbon TRIM25 cell lines restrict IAV replication, although to different 
extents. Human TRIM25 inhibits IAV replication by more than a log, whereas agile 
gibbon TRIM25 inhibits IAV replication by more than two logs. Protein levels at an 
earlier time point also were determined (compare Figure 6-2 with  
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Figure 6-4: Protein alignment of human and gibbon TRIM25.   
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6-3B), and the amount of restriction was further exaggerated and in agreement with 
results from the growth curves. The human and agile gibbon TRIM25 proteins differ at 
only 21 out of 630 amino acid positions (Figure 6-4), suggesting that the increased 
antiviral activity of agile gibbon TRIM25 is conferred by a small number of genetic 
changes. 
To characterize the mechanism by which agile gibbon TRIM25 restricts flu 
replication more potently than human TRIM25, we investigated the extent of interferon 
induction in the TRIM25 stable cell lines and also tested binding to IAV’s NS1 protein. 
To test interferon induction, quantitative reverse transcription PCR was used to probe 
mRNA levels of IFN-β, Mx1, and ISG15 mRNA in non-infected cells and also cells 
infected at 2 MOI, 6 or 12 hours post infection (Figure 6-5A). Negligible differences 
between TRIM25 and control cell lines were observed with respect to interferon 
induction, suggesting that TRIM25 restriction activity is independent of its role in the 
RIG-I signaling pathway. Both human and agile gibbon TRIM25 bind NS1 with similar 
affinity, which shows that the increased antiviral activity of agile gibbon TRIM25 is not 
due to an evasion of NS1 binding (Figure 6-5B). Together, these results indicate that 










Figure 6-5: TRIM25 antiviral activity is not due to by interferon induction or 
binding to NS1. (A) Quantitate reverse transcription PCR was performed in CRFK cell 
lines stably expressing the indicated TRIM25 allele or empty vector. Cells were either 
mock infected or infected with Udorn H3N2 influenza A virus and harvested for total 
RNA at the indicated time points. cDNA was generated using oligo(dT) primers and 
probed using primers designed to detect the indicated feline gene. (B) Co-
immunoprecipitation assay was performed by transiently transfecting the indicated 
construct in 293T cells and 48 hours later infecting with Udorn H3N2 influenza A virus. 




Figure 6-6: TRIM25 inhibits early transcription of both viral genomic RNA and 
mRNA. CRFK cells stably expressing the indicated TRIM25 construct or empty vector 
were infected with Udorn H3N2 influenza A virus at an MOI=2. Total RNA was isolated 
at the indicated time points and used to generate cDNA with either oligo(dT) primers for 
mRNA or viral specific primers for vRNA. The resulting cDNA libraries were then 
subjected to qPCR using primers for HA, NP, or NS1.   
 
To gain further temporal resolution into TRIM25 restriction of IAV, early events 
in the influenza lifecycle were measured. Total RNA from infected cells at various times 
was isolated shortly after a single-cycle infection (4, 5, 6, and 7 hours post infection). 
These samples were then probed for viral genomic RNA and mRNA (Figure 6-6) using 
qPCR with cDNA templates generated using either oligo(dT) for mRNA or viral-specific 
primers for genomic RNA. The early time points probed in this experiment coincide with 
the first detectable transcription events during the IAV life cycle, shortly after the viral 
ribonucleoproteins have entered the nucleus (272). RNA levels of the HA, NP, and NS1 
RNA segments, which represent structural and non-structural genes along with early and 
late genes, were measured in case there were any segment-specific effects. Both vRNA 
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and mRNA expression of all three segments was reduced in cell lines expressing 
TRIM25. In accordance with the growth curves shown previously (Figure 6-3A), agile 
gibbon TRIM25 exhibits greater antiviral activity than human TRIM25. Even at the latest 
time point, only a small amount of vRNA and mRNA are present, verifying the drastic 
differences in protein levels observed in Figure 6-3B. Therefore, TRIM25 restriction 
activity functions at or before the initial transcription of influenza genomic segments.   
TRIM25 is expressed in the cytoplasm where it activates the RIG-I signaling 
pathway (266). The cytoplasmic localization of both human and agile gibbon TRIM25 
was confirmed (data not shown). During the early stages of IAV infection, the only viral 
components that are exposed to the cytoplasm are M1 and the viral ribonucleoprotein 
(vRNP) (261), which is composed of three polymerase subunits (PA, PB1, and PB2) that 
are attached to one end of a double helical NP structure (273). The RNA segments of 
IAV wrap around the helical structure and form a loop at the end of the vRNP opposite to 
the polymerase complex. Because of the recently characterized RNA-binding property of 
TRIM25 (269), its antiviral activity against IAV could be due to vRNP binding mediated 
by RNA.  
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Figure 6-7: Purification of TRIM25 and IAV vRNPs. (A) Coomassie stained SDS-
PAGE gel of FLAG-purified TRIM25. Whole-cell lysates from 293T cells transfected 
with FLAG-TRIM25 were used for a FLAG immunoprecipitation. (B) Coomassie stained 
SDS-PAGE gel of baculovirus expressed, His-tagged TRIM25 purified using size-
exclusion FPLC. (C) Coomassie stained SDS-PAGE gel of purified IAV vRNPs. Red 
boxes in (B,C) represent fractions that were used in biochemical assays.  
   
   
To test if TRIM25 binds IAV vRNPs, we purified human TRIM25 using FLAG 
immunoprecipitation from 293T whole cell extracts (Figure 6-7A) or a baculovirus 
expression system coupled with size-exclusion fast performance liquid chromatography 
(Figure 6-7B). IAV vRNPs were purified using supernatant from IAV infected canine 
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cells. Briefly, virions were pelleted and purified using sucrose cushions, disrupted using a 
detergent treatment to release vRNPs, and the vRNPs were further purified using a 
glycerol gradient (Figure 6-7C). Purified vRNPs and FLAG-TRIM25 were incubated 
together and then fractionated through a glycerol gradient. Fractions were collected and 
probed for the presence of TRIM25 and NP (Figure 6-8A). In the absence of vRNPs, 
TRIM25 remains in the top fractions. However, in the presence of vRNPs, TRIM25 
migrates to lower fractions that coincide with the presence of NP. This indicates that 
TRIM25 is directly binding vRNPs. To test the role of RNA in TRIM25 binding to 
vRNPs, we pretreated vRNPs with RNase prior to incubation with TRIM25. This resulted 
in a loss of co-migration between TRIM25 and vRNPs. Therefore, TRIM25 binding to 
IAV vRNPs is RNA-dependent. To investigate where on the vRNPs TRIM25 is binding, 
we used electron microscopy to visualize TRIM25-vRNP complexes. His-tagged 
TRIM25 was used and conjugated to Ni-NTA-nanogold beads. Unlabeled vRNPs can be 
visualized and were confirmed to be in their native conformation (Figure 6-8B). Both 
human and gibbon TRIM25 bound to vRNPs, although we observe more nanogold 
particles bound to vRNPs when using gibbon TRIM25 (Figure 6-8B). In the case of 
gibbon TRIM25, the entire length of the vRNP appears to be bound. However, the 
majority of bound vRNPs are bound at the ends, suggesting that TRIM25 initially binds 




Figure 6-8: TRIM25 binds IAV vRNPs and inhibits transcription. (A) Western blots 
of glycerol gradient fractions from TRIM25 and vRNPs incubations. Glycerol 
concentration increases from left to right. (B) Electron microscopy images of vRNPs and 
Ni-NTA-nanogold labeled TRIM25. (C) vRNP transcription assay. Purified vRNPs were 
mixed with cellular mRNAs and labeled rNTPs. Products were separated on a urea gel 
and imaged using a phosphoscreen.       
 
To connect TRIM25-vRNP binding to TRIM25 antiviral activity, this binding was 
assessed for effects on vRNP function. Transcription activity of purified vRNPs can be 
monitored by mixing them with cellular mRNAs and ribonucleotide triphosphates. 
Radiolabelled uracil is used so that transcripts can be visualized (Figure 6-8C, far left 
lane). When human or gibbon TRIM25 is pre-incubated with vRNPs, transcription 
activity is significantly reduced (Figure-6-8C). Again, gibbon TRIM25 was observed to 
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have more antiviral activity than human TRIM25, and this effect can be titrated with 
increasing amounts of TRIM25 to a point where viral transcripts are almost undetectable 
(Figure 6-8C, right gel). Therefore, TRIM25 binding to IAV vRNPs blocks transcription 
by the viral polymerase complex. 
 
   
Figure 6-9: The L2 domain of TRIM25 mediates restriction activity against IAV. 
(A) Domain diagram schematic of TRIM25 and TRIM5α chimeras. Domain boundaries 
for TRIM25 and TRIM5α are provided as amino acid coordinates above and below, 
respectively. Each construct is drawn to scale. (B) Western blot of whole-cell lysates 
from feline cells that stably express the indicated FLAG-tagged construct. (C) IAV 
infection of stable cell lines expressing wild-type and chimeric alleles. Cells were 
infected at 0.002 MOI and supernatants were collected at 1, 24, 48, and 72 hours post 
infection. Canine reporter cells were infected to calculate titers using plaque assays. 
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The L2 domain of TRIM25 has rapidly diverged during the course of primate 
evolution (Figure 6-1). To determine the contribution of this domain to IAV restriction, 
L2 chimeras were generated between TRIM25 and a closely related TRIM protein, 
TRIM5α (Figure 6-9A). TRIM proteins are modular and chimeras between different 
TRIMs have been utilized previously to determine domain function (209). Stable cell 
lines expressing TRIM25/TRIM5α chimeras were generated (Figure 6-9B), infected with 
IAV under multiple-cycle growth conditions, and titered on reporter cell lines (Figure 6-
9C). Human and gibbon TRIM25 restrict IAV to similar levels as before (compare Figure 
6-3A and Figure 6-9C), whereas TRIM5α does not restrict IAV. However, when the L2 
domain from human TRIM25 is inserted into TRIM5α (TRIM5α-25L2, orange curve), 
this construct gains the ability to restrict IAV at a level similar to human TRIM25. 
Conversely, insertion of the L2 domain from TRIM5α into TRIM25 (TRIM25-5αL2, 
green curve) confers a near complete loss of restriction. Therefore, the L2 domain of 
TRIM25 is both necessary and sufficient for restriction of IAV.  
 
DISCUSSION 
Using a combination of evolutionary and functional analyses, a novel function of 
TRIM25 has been defined. By binding IAV vRNPs and inhibiting transcription of the 
viral polymerase complex, TRIM25 potently inhibits the replication of IAV. This is not 
the first example of a TRIM protein that antagonizes a viral polymerase (274, 275), 
however, it is the first example of direct binding to vRNPs. This mechanism most likely 
relies on the unique double helical, elongated structure of IAV vRNPs for two reasons. 
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First, no TRIM25 antiviral activity in a IAV mini-genome assay, where all components 
of the vRNPs (PA, PB1, PB2, NP, and vRNA) are present (data not shown). In these 
assays, fully formed vRNPs are not present in the cytoplasm and the state of the 
polymerase complex, due to overexpression, is most likely not representative of a live 
infection. Second, no interaction between TRIM25 and any single protein component of 
vRNPs was detectable in an immunoprecipitation assay where TRIM25 was co-
transfected with PA, PB1, PB2, or NP (data not shown). These negative results support a 
model where TRIM25 binds a structural element of vRNPs that is not present in any 
single componenet of vRNPs.  
This quality of TRIM25 is reminiscent of another TRIM protein, TRIM5α. By 
recognizing fully intact retroviral capsid cores (45), TRIM5α disrupts the retroviral 
lifecycle in the cytoplasm shortly after reverse transcription takes place (276). Unique 
molecular patterns like the retroviral core or the vRNPs of IAV are ideal targets for 
innate immune proteins because their structures must be maintained and are therefore 
evolutionarily conserved. However, in the case of TRIM5α, escape mutations in the 
capsid core have been observed, and these mutations have helped to identify the interface 
that TRIM5α binds (277). Future studies with TRIM25 should be aimed at identifying 
the interface of IAV vRNPs that TRIM25 recognizes.  
This evolutionary analysis identified the L2 domain of TRIM25 as the 
determinant of IAV restriction. Because a primate dataset was used, this result suggests 
that primates have been antagonized by influenza or influenza-like viruses in the past. 
Although infectious IAV has not been isolated from nonhuman primates, some primates 
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make antibodies that are active against human IAV (278, 279). This suggests that 
nonhuman primates are being infected by IAV in the wild, which would mean that 
primate TRIM25 alleles are actively being selected. This scenario is in line with the 
evolutionary signature of positive selection that we have documented in primate 
TRIM25, and suggests that TRIM25 and IAV vRNPs have been engaged in a genetic 
conflict with each other for many millions of years.  
        
MATERIALS AND METHODS 
Primate biomaterials used 
 Primary and immortalized primate cell lines from primate species were grown in 
standard media supplemented with 15% fetal bovine serum at 37oC and in 5% CO2.  
 
Primate TRIM25 gene sequences  
 Human Refseq sequences for TRIM25 were obtained from the NCBI nucleotide 
database. Chimpanzee, orangutan, rhesus macaque, and marmoset gene sequences were 
obtained from the UCSC genome database (http://genome.ucsc.edu/) using the BLAT 
alignment tool. Genes were sequenced from 15 additional primate species, and from 
chimpanzee, orangutan, rhesus and marmoset in instances where the genome-project 
sequences were of poor quality. PCR or RT-PCR was performed from total RNA, gDNA, 
or cDNA with SuperScript III One-Step RT-PCR system with Platinum Taq (Invitrogen, 
#12574-018), PCR SuperMix High Fidelity (Invitrogen, #10790-020), or Phusion High 
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Fidelity PCR Master Mix (NEB, #F-531S). Primers were designed in conserved regions 
of the 5’ or 3’ UTR to amplify full open reading frames.  
 
PAML and REL analysis  
 Codon models were tested with codeml in the PAML 4.1 software package (93). 
To detect selection, multiple alignments were fit to the NSsites models M8a (neutral 
model, codon values of dN/dS fit to a beta distribution plus an extra codon class fixed at 
dN/dS = 1) and M8 (positive selection model, similar to M8a but with the extra class 
allowed to be dN/dS >1). A likelihood ratio test was performed to assess whether 
permitting codons to evolve under positive selection gives a significantly better fit to the 
data (model comparison M8a vs. M8). In situations where the null model could be 
rejected (p < 0.05), posterior probabilities were assigned to individual codons belonging 
to the class of codons with dN/dS > 1. REL analysis was performed using the 
datamonkey.org webserver (280). In this model, three classes each of dN and dS are 
estimated and a bayes factor for dN > dS (dN/dS > 1) is calculated.  
 
TRIM25, TRIM5α , and TRIM25/TRIM5α  chimera expression constructs 
 Primate TRIM25 constructs were amplified from primate cDNA. 
TRIM25/TRIM5α chimeras were constructed by generating fragments with 20-25bp 
overlapping regions of TRIM25 and TRIM5α. Overlapping fragments were spliced 
together using PCR with each fragment as a template and outside flanking primers. 
Constructs were TA-cloned into pCR4 (Invitrogen, #K4575-01). An N-terminal FLAG 
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tag was added by PCR and these tagged constructs were TA-cloned into the Gateway 
entry plasmid pCR8 (Invitrogen, #K2500-20). An LR Clonase II reaction (Invitrogen, 
#11791-100) was used to transfer these constructs into a Gateway-converted pLPCX 
retroviral vector (Clontech, # 631511).  
 
Generation of stable cell lines  
 To generate cell lines that stably express primate TRIM25 and TRIM25/TRIM5α 
chimeras, retroviral vectors were used to transduce CRFK cells (ATCC). To generate the 
retroviral vectors, 293T cells were seeded at a concentration of 1x106 cells/well in a 6-
well dish. After 24 hours, each well was transfected with 2 µg pLPCX construct (empty 
or encoding the gene fragment of interest), 1 µg pCS2-mGP encoding MLV gag-pol 
(142), and 0.2 µg pC-VSV-G at a final 1:3 ratio of DNA to TransIT-293 (mg DNA : ml 
TransIT-293). Supernatants were collected after 48 hours, passed through a 0.2 µm filter, 
and used to infect CRFK cells grown in DMEM supplemented with 10% fetal bovine 
serum, 100 IU/ml penicillin, 100 µg/ml streptomycin, and 2 mM L-glutamine. After 24 
hours, media containing 8 µg/ml puromycin was added to select for transduced cells. 
Expression of TRIM25 and TRIM5α alleles constructs was detected by Western blot.  
 
Antibodies and Western blot analysis  
 Cell lines were grown to confluency in a 6-well dish, collected using a cell 
scraper, and lysed in a buffer containing 150 mM NaCl, 50 mM Tris-HCl (pH 7.4), 1% 
NP-40, and Complete protease inhibitor (Roche, #11836170001). After quantitation of 
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protein concentration using a Bradford assay, 30 µg of whole cell extract was resolved 
using a 10% polyacrylamide gel and transferred to a nitrocellulose membrane. Udorn-
specific antibody was a kind gift from Robert Lamb. NS1-specific antibody was 
generated by injecting rabbits with purified GST-NS1 from Udorn virus. FLAG-tagged 
constructs were detected using a 1:2000 dilution of anti-FLAG antibody (Roche, 
SydLabs, #PA000274-P-210). β-actin was also analyzed as a loading control using a 
1:1000 dilution of mouse anti-β-actin (Santa Cruz, #sc-47778). A 1:10,000 dilution of 
donkey mouse-specific horseradish peroxidase-conjugated antibody (Thermo Scientific, 
#32430), donkey rabbit-specific horseradish peroxidase-conjugated antibody (Thermo 
Scientific, #32460), or donkey goat-specific horseradish peroxidase-conjugated antibody 
(Santa Cruz, #2020) was used as a secondary probe. Blots were developed using the ECL 
Plus detection reagent (GE Healthcare, #RPN2132).  
 
Influenza A virus infection 
Single-cycle and multiple cycle influenza A virus infections (A/Udorn/H3N2) 
were performed at a MOI=2. CRFK cells were seeded in a 6-well dish at 8x105 cells/well. 
After plating for 24 hours, cells were washed with PBS and then incubated in infection 
media (DMEM supplemented with Pen/Strep, L-Glut, and 1% BSA) for one hour at 
37°C. Cells were washed once more in PBS and incubated in influenza growth media 
(DMEM supplemented with Pen/Strep and L-Glut; multiple-cycle samples also included 
1.0 µg/ml N-acetylated trypsin). For single-cycle infections, cell lysates were harvested at 
8 hours post infection using RIPA buffer supplemented with complete protease inhibitor 
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(Roche) and PMSF (Invitrogen). For multiple-cycle infections, each cell line was seeded 
in triplicate and infected with a unique dilution of influenza A virus. Supernatants were 
collected at 1, 12, 24, 48, and 72 hours post infection and titered by a plaque assay on 
MDCK reporter cells. Infections for plaque assays were performed as described above, 




 293T cells were seeded at 1x106 cells/well in a 6-well dish. After 24 hours, cells 
were transfected with 2 µg of pLPCX-TRIM25 or empty vector using TransIT-293 
(Mirius Bio, #MIR2704) at a 1:3 µg DNA:reagent ratio. After 48 hours of transfection, 
cells were infected at 2 MOI with Udorn influenza A virus. At 9 hours post infection, 
cells were lysed in 250 µl co-IP buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 5 mM 
EDTA, 2.5 mM MgCl2, 1% NP-40, 10% glycerol). Whole-cell lysate (30 µl) was saved 
for inputs and the remainder was diluted 1:1 with Tris-HCl/NaCl buffer and pre-cleared 
using Protein G Dynabeads (Life Technologies, #10003D). Beads were added to WCE 
and rotated at 4° for one hour. Beads were then removed and 1.5 µl of FLAG-specific 
antibody was added to the supernatant and rotated overnight at 4°. The next day, beads 
were washed three times for ten minutes in IP wash buffer (50 mM Tris-HCl pH 7.4, 150 
mM NaCl, 0.25% NP-40) at 4°, and then eluted in 30 µl FLAG elution buffer (50 mM 
Tris-HCL pH 7.4, 150 mM NaCl, 0.012% Triton-X, 10% glycerol, 0.2 mM EDTA, 500 
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ng/mL 3xFLAG peptide (Sigma Aldrich, #F4799)). Eluates were separated using SDS-
PAGE electrophoresis and visualized using a Western blot protocol.   
  
Quantitative reverse transcription PCR 
 Templates for qRT-PCR were generated by infecting target cells with Udorn 
influenza A virus at MOI=2 and collecting RNA at 4, 5, 6, and 7 hours post infection 
using the RNeasy Mini Kit (Qiagen, #74104). RNA (500 ng) was then used to generate 
cDNA using either oligo(dT) or virus-specific primers with Superscript III First-Strand 
Synthesis System (Invitrogen, #18080-051). cDNA was diluted 1:25 and used as a 
template in qPCR with Power SYBR Green PCR Master Mix (Applied Biosystems, 
#4367659) and virus- or host-specific primers (see Figures 6-6 and 6-7). Cycling for 
qPCR was performed in Life Technologies’ Vii-A7 Real-Time PCR System. All samples 
were normalized to GAPDH levels.       
 
Purification of TRIM25  
 FLAG-tagged TRIM25 was purified as described in the immunoprecipitation 
protocol. For His purification, TRIM25 open reading frame was inserted into pFastBac-
HTa (Invitrogen, #10712-024) vector downstream of a 6xHis tag using EcoRI and XhoI 
restriction sites. This plasmid was then transformed into DH10Bac cells (Invitrogen, 
#10359-016) to induce recombination of His-TRIM25 into a Bacmid. Bacmids were 
isolated and transfected into insect cells to generate baculovirus that harbors His-
TRIM25. Sixty 15cm plates of insect cells were then infected with TRIM25-harboring 
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baculovirus, and cells were collected 48 hours later. Cells were lysed in TRIM buffer (50 
mM NaH2PO4 pH 8.0, 300 mM NaCl, 50 mM ZnSO4, 10% glycerol, 100 mM 2-
βMercaptoethanol), dounced and sonicated, and centrifuged to pellet cell debris. One mL 
of 50% Ni-NTA slurry per 4 mL of cleared lysate was added and rotated at 4° for 1-2 
hours. Beads were collected and washed (50 mM Tris-HCl, 150 mM NaCl, 20 mM 
imidazole, 0.5% NP-40) three times. Beads were eluted using wash buffer with 250 mM 
imidazole. Eluates were subjected to fast performance liquid chromatography using a 
Superdex 200 3.2/300 size exclusion column (GE Healthcare, #29-0362-32). Fractions 
with UV peaks at the appropriate size for TRIM25 were used in downstream analyses.  
   
Purification of IAV vRNPs and binding experiments 
 Supernatant from Udorn-infected MDCK cells was clarified by centrifugation at 
2600xg for 10 minutes at 4°. The clarified supernatant was then layered over 5 mL of 
20% sucrose in buffer A (100 mM NaCl, 10 mM Tris-HCl pH 7.4, 2 mM EDTA). The 
virus was pelleted by ultracentrifugation at 104,000 xg for 45 minutes at 4° in a SW28 
rotor. The virus pellet at the bottom was then resuspended in buffer A. Further viral 
purification was achieved by adding the resuspended pellet to a linear sucrose gradient 
(30-50% w/w) in buffer A and separated at 112,600xg for 3 hours at 4° in a SW41 Ti 
rotor. The banded virus was collected and then disrupted to release vRNPs using 
disruption buffer (5 mM MgCl2, 100 mM KCl, 1.5 mM dithiothreitol, 5% glycerol, 10 
mM Tris-HCl pH 8.0, 1% Triton-X 100, 10mg/mL lysolecithin). To purify the vRNPs, a 
discontinuous glycerol gradient (1 mL 70%, 0.75 mL 50%, 0.375 mL 40%, 1.8 mL 33%, 
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all v/v) is prepared in an ultraclear centrifuge tube (Beckman, 13mm x 51mm). The 
sample was then centrifuged at 217,000 xg for 3 hours and 45 minutes at 4° in a SW55 Ti 
rotor. Fractions were then taken from the gradient and analyzed for the preseence of 
nucleoprotein (NP). Fractions containing mainly NP were pooled and used for 
downstream analyses.  
 For TRIM25-vRNP binding, vRNP samples were dialysed with TRIM25 wash 
buffer and then incubated with His-TRIM25 at 4° for 1-2 hours. This sample was then 
loaded onto a discontinuous glycerol gradient and ultracentrifuged as described above. 
Fractions were probed for the presence of NP or TRIM25.  
 
Electron microscopy 
 Purified vRNP and TRIM25 samples were mixed at 1:1 NP-to-Trim25 mass ratio 
and incubated for 1h at 4℃. The mixture (5 µl) was then added onto glow-discharged 
FCF400-Cu grid (Electron Microscopy Sciences). After 1 min, extra liquid on the sample 
grid was removed by gently blotting the edge of the grid on a filter paper. The grid was 
then placed upside-down on a droplet of 5 nm Ni-NTA-Nanogold (Nanoprobes) diluted 
5-fold with 20 mM Tris-HCl pH 7.5, 150 mM NaCl and 5 mM imidazole, and incubated 
for 30 minutes at room temperature. Afterwards, the grid was washed twice with 5 mM 
imidazole and rinsed twice with water before staining with freshly prepared 0.75% uranyl 
formate solution for 90 seconds. After air-drying overnight, the grids were examined 
using JEOL 1230 High Contrast Transmission Electron Microscope at 80kV. 
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In vitro transcription of IAV vRNPs 
 Transcription using purified vRNPs was conducted as described previously (281). 
Briefly, purified vRNPs were incubated with or without TRIM25 (see above) and then 
cellular mRNAs were added to provide cap-snatching substrate for vRNPs. Labeled 
ribonucleoside triphosphates were used to polymerize transcription and visualize 
transcription products. Transcription reactions were resolved on urea-PAGE gels and 















Concluding remarks and future direction 
The practice of applying the evolutionary arms race concept to molecular host-
virus interactions in primates is still in its infancy. Even amongst mammals, only a few 
well-documented cases exist. It has only recently been appreciated that the evolutionary 
signature of positive selection can help to elucidate novel antiviral function, the rules of 
engagement for host-virus interactions, and genetic barriers to cross-species transmission 
of viruses. In the following chapter I will elaborate on how my own studies have 
advanced those topics and propose how evolutionary thinking can continue to benefit the 
study of host-virus interactions. There are also several unexpected applications of host-
virus arms races that will be the core of my future studies. From hunting for new model 
systems to designing potent restriction factors from scratch, these new directions will 
continue to build on their foundation—a signature of positive Darwinian selection 









Host-virus arms races are everywhere, but you must look closely  
Viruses have exerted evolutionary pressure on their hosts throughout the history 
of life on earth. Specifically, viruses have affected mammalian genomes by forcing 
innovative immune strategies and even by depositing themselves in their host’s DNA 
(124, 125, 282). Also, hosts will sometimes repurpose viral genes for their own good 
(283). These observations provide evidence that most mammalian virus families have 
ancient origins dating back millions, in some cases hundreds of millions, of years (284, 
285). As viruses and hosts interact with each other over these long spans of time, relics of 
these battles are left in the genomic content of each organism involved. In the previous 
chapters I have described several cases where I have uncovered these relics using 
statistical analyses that detect the genetic signature of positive selection. These genomic 
signatures, in the context of genes involved in virus replication, are indicative of a host-
virus arms race and can be used to elucidate details of ancient interactions.  
The most well-characterized host-virus arms races come from the HIV-1 field. 
Since the discovery of the restriction factor TRIM5α (286), and the subsequent 
characterization of its evolutionary history in primates (17, 55), innate immunity proteins 
have been prime candidates for genetic conflict with viruses. Although there have been 
four other HIV-1 restriction factors that have been shown to have a dynamic evolutionary 
past (19, 38, 84, 85, 287), evolutionary characterization of restriction factors against other 
viruses is lacking. Aside from retroviruses, there are only concrete examples for 
poxviruses (51, 271), thogotoviruses (87), and hepaciviruses (88). With so many more 
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diverse families of mammalian viruses, it is likely that many more host-virus arms races 
will be revealed in the near future.  
In Chapter 6, I characterize the restriction activity of TRIM25 against influenza A 
virus and show that the Linker 2 domain of TRIM25 mediates this restriction. I also show 
that the linker 2 domain has been the target of positive selection during primate 
evolution. Although the exact molecular interface that TRIM25 binds is yet to be 
determined, the interaction between TRIM25 and flu has likely been highly dynamic over 
evolutionary time. This would be the first example of a host-virus arms race between flu 
and an innate immunity protein. However, there are most likely many more to be 
uncovered because several other proteins have been shown to have restriction activity 
against influenza (39, 288, 289). Future studies should aim at characterizing the 
evolutionary history of the genes that encode these antiviral factors. More generally, 
restriction factors against any other virus are prime candidates for genes involved in host-
virus arms races.  
Aside from restriction factors, many other host proteins that interact with viruses 
could potentially be engaged in host-virus arms races. In Chapter 3, I show how some 
genes that promote HIV-1 replication can also evolve under positive selection (27). What 
is interesting about these cases is that these genes tend to have critical housekeeping 
functions, such as microtubule assembly, nuclear pore trafficking, or DNA repair (24). 
Nevertheless, they have found a way to maintain housekeeping function while 
simultaneously engaging in a host-virus arms race with a virus. This can sometimes be 
achieved because the region of the gene that is critical for housekeeping function is 
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distinct from the molecular interface that interacts with viruses (26). Therefore, 
absolutely any host-virus interaction should be considered as a candidate for a host-virus 
arms race. The possibilities are staggering, given that a virus such as HIV-1 interacts with 
over a thousand proteins (76, 115-118). Similarly, genome-wide siRNA screens for other 
viruses are revealing massive amounts of host proteins that are involved in viral life 
cycles (291-293). Most host genes that interact with viruses will be evolutionarily 
constrained due to their housekeeping function, however, a subset will have the flexibility 
to engage in an arms race, and I have provided a screening method for identifying such 
genes in Chapter 3. 
My studies have focused on primate genes, however, there are instances where 
other animal clades are more appropriate for evolutionary analysis. For example, 
arenaviruses are endemic in the rodent clade and occasionally zoonosis occurs that leads 
to hemorrhagic fever in humans (294). Because this virus spends most of its time in 
rodents, evolutionary signatures of positive selection that relate to arenavirus infection 
can be found in a dataset consisting of rodent genes but not primate genes (26). A similar 
story has played out with respect to SARS-CoV in bats (25). Therefore, to properly 
conduct an investigation into a potential host-virus arms race, one must not only have a 
candidate gene in mind, but also a candidate animal clade that relates to the ecology of 
the virus in question. In this respect, evolutionary signatures of positive selection can be 
used as evidence that a particular animal clade is serving as a reservoir for a virus (25). 
This is one of the biggest surprises that has stemmed from such analyses, and is currently 
being used to search for the Ebola reservoir.  
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Evidence is now emerging that provides a connection between genes involved in 
host-virus arms races and genetic barriers to cross-species transmission of viruses. The 
amount of work that is required to show this definitively is staggering, nevertheless, it has 
now been shown for TRIM5α and APOBEC3G (28, 199). This group was able to 
retrospectively analyze samples taken from a primate center during a cross-species 
transmission event of simian immunodeficiency virus and show that the evolution of the 
virus coincided exactly with evasion of TRIM5α and APOBEC3G genotypes. In Chapter 
5, I show that interactions between RANBP2, a molecule involved in nucleocytoplasmic 
trafficking, and lentiviral capsids is species-specific and correlates to cross-species 
transmission events. This is the foundation of a case for RANBP2 being a barrier to 
cross-species transmissions of primate lentiviruses. Further evidence will come from 
studying how lentiviruses adapt to new RANBP2 alleles. If in vivo data is ever available 
for this interaction (my studies highlight gorilla and chimpanzee interactions, and both of 
these species are highly endangered) it would provide the greatest evidence. Until then, I 
can only speculate that RANBP2, a gatekeeper to nuclear access, is engaged in a host-
virus arms race with lentiviral capsids that mediates cross-species transmissions of 
primate lentiviruses in nature.  
Virology groups that typically do not employ evolutionary analyses are now using 
them as a standard to identify functional domains in host proteins that interact with 
viruses (101, 158, 287, 295), and this is perhaps the greatest evidence of their value. With 
the number of host-virus interactions growing exponentially as more genome-wide data 
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becomes available (296, 297), evolutionary thinking is likely to spread into every corner 
of virology research.    
 
Bioprospecting for the future 
In Chapter 4, I show how an amino acid residue in CD4 that is evolving under 
positive selection, and is polymorphic within Spix’s owl monkeys, mediates entry of 
HIV-1. These owl monkey CD4 alleles are then shown to be permissive to primary 
isolates of HIV-1, a characteristic that is lacking in current model systems of HIV-1. I am 
now in the process of isolating CD4+ T-cells from this owl monkey species to test their 
permissivness for the entire HIV-1 lifecycle. If they are fully permissive, this species 
would be a viable candidate for an HIV-1 model system. This study highlights the 
significance of unchartered territory in model systems biology—genetic polymorphisms 
in nonhuman primate species (298-300). 
It is well accepted that polymorphisms in human populations can affect the 
outcome of virus infections and diseases (37, 301, 302). However, the exploration of this 
concept in model organisms is lacking. Genetic loci that affect the outcome of viral 
infections are constantly being characterized, but rarely do these loci get genotyped in 
relevant model systems. As opposed to viewing this as a problem for existing model 
systems, I see it as an opportunity to discover individuals with unique genotypes in 
species that might have been prematurely discounted as model organisms.  
Consider the case of the HIV-1 model organism. Currently, the major model 
organism for HIV-1 infection is the rhesus macaque (172, 303). Putting all socioeconmic 
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issues aside, this species is a poor model system because rhesus macaques do not encode 
a permissive receptor for HIV-1 (174), and they encode several restriction factors that are 
active against HIV-1 (172). To solve this issue, chimeric viruses have been generated that 
encode parts of HIV-1 and parts of simian immunodeficiency virus, the primate relative 
of HIV-1. However, these chimeric viruses are genetically distant enough from HIV-1 
that vaccines raised against them are not relevant to primary isolates of HIV-1. This has 
been an incredible barrier to generating a viable vaccine against HIV-1, and even the 
pathogenesis of these chimeric viruses in rhesus macaques do not emulate the 
pathogenesis of HIV-1 in humans. And so it is perfectly plausible to pose the question, 
“Have we found the right model organism?”  
  If we search long enough for a primate individual with the perfect genotype, we 
just might find it. This effort of bioprospecting involves genotyping populations of 
primate species, or any other species relevant to a particular virus, at loci that mediate 
virus infection. My search for permissive CD4 alleles in small populations of primates 
has already turned up positive, and if this search is expanded to include more individuals 
and more species, even more desirable alleles may be revealed. The beauty of this 
technique is that these naturally occurring alleles can be mixed and matched using 
standardized breeding techniques, and do not require any sort of genetic therapy.  
The success of bioprospecting lies in an understanding of the critical host-virus 
interactions that take place during any given virus infection. Numerous genetic loci can 
be tested for HIV-1 because this is the most studied virus in the history of virology, and 
there are probably even more critical loci that we have yet to discover. To generalize 
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bioprospecting for other viruses, it will be necessary to generate a detailed map of host-
virus interactions and understand how these interactions mediate infection in a candidate 
model organism.   
 
Modularity of TRIMs: how a protein family is evolving before our eyes 
 The tripartite motif containing (TRIM) family of proteins contains over 70 
members with diverse functions (304-309). All TRIM proteins have a core domain 
composed of a RING E3 ligase, one or two B-Boxes that mediate protein-protein 
interactions, and a coiled-coil domain that is critical for multimerization and functionality 
of TRIMs (265). The C-terminus of TRIM proteins is variable, although many contain a 
B30.2 domain, including TRIM25 and TRIM5α. This protein family is unique to 
metazoans and is highly variable in almost every genera in which it has been examined 
(16, 135, 310-312). It is even copy number variable within humans, such that certain 
individuals actually encode over 100 TRIM genes (135).   
Perhaps the most interesting case of a TRIM gene is the TRIM5-CypA fusion. 
This gene has been independently generated in several primate species and is the 
consequence of a LINE1-mediated insertion of the CypA open reading frame into the C-
terminus of the TRIM5 locus (196, 197, 235, 236). TRIM5-CypA is one of the most 
potent restriction factors against HIV-1, and its mechanism highlights a beautiful 
evolutionary trick. HIV-1 actually interacts with monomeric CypA to perform its life 
cycle, and under normal conditions CypA promotes HIV-1 replication. However, when 
TRIM5-CypA interacts with HIV-1, the core domain of TRIM5 inhibits virus replication 
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(244). Thus, the fusion of an antiviral TRIM5 with a protein needed by HIV-1, CypA, 
generated a highly potent restriction factor that functions by tricking HIV-1 into 
recruiting monomeric CypA. This experiment conducted by nature highlights the 
modular and flexible nature of TRIMs. And so there are pieces of TRIMs that are 
involved in recognition of viruses, and other pieces that are involved in the actual 
restriction activity, whether that be degradation of the target or inhibition of a critical 
process, such as transcription of influenza vRNPs in the case of TRIM25 (see Chapter 6).  
In my future studies I would like to further characterize the modularity of TRIM 
proteins. Although nature has given us an excellent example in TRIM5-CypA, I believe 
that this is only the beginning. Further molecular tinkering could reveal more highly 
potent restriction factors. By mixing and matching domains from TRIM proteins, I hope 
to generate a molecule with broad specificity against many different virus families. 
Already, in Chapter 6, I modified the antiretroviral TRIM5α protein to be restrictive 
against influenza A virus. And, critically, the domain that mediates antiretroviral activity 
is distinct from that which mediates restriction against influenza A virus. This is further 
evidence of TRIM modularity, and it also shows that increased specificity can be 
achieved. There are a handful of other examples where TRIM domains have been 
swapped, mainly to achieve better expression for purification purposes, or to study 
interactions with lentiviral capsids (101, 158, 209, 245, 256, 258, 260). 
Using the TRIM5-CypA fusion example as a guide, I will take advantage of the 
growing body of host-virus interactions to generate synthetic TRIM fusions that harbor 
pieces of proteins that a given virus needs for its life cycle. There will be physical 
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considerations that I will have to take into account, namely, the size of the target 
molecule and the mode of inhibition for a particular TRIM protein. These rules will need 
to be better characterized and, in doing so, I will build a molecular TRIM toolkit that can 
be used to build an antiviral TRIM protein from scratch.  
 
Conclusions 
In this era of high-throughput data and genomics, a challenge we face as scientists 
is to incorporate large amounts of data from divergent fields into hypothesis driven 
research. The goal of these efforts is typically to discover novel functions of proteins, or 
to understand which genes mediate a particular process or disease. However, the use of 
evolution as our guide can provide a shortcut, whereby signatures of positive selection 
can highlight regions of a protein that are mediating a critical process, such as viral 
infection. An added benefit is that we learn how these regions have changed over time, 
which provides a list of mutations that allow us to fine tune function.  
The most exciting part of this field is that it is still brand new. There is no telling 
where the field of viral molecular evolution might take us. Studying viruses has always 
led to important biological discoveries, whether they be esoteric or medically relevant. 
And now, as we strengthen our evolutionary lens, ancient tales of viruses past are sharply 
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